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ABSTRACT 
Modern cancer treatment therapies such as surgery, chemotherapy and 
immunotherapy are deemed relatively unsuccessful due to their ineffectiveness, safety 
issues and costliness. As not all cancer patients respond positively to current anticancer 
agents, mortality rates of cancer are on a continuous rise including melanoma and 
prostate cancer.  
Natural product-based traditional medicine, often overshadowed by modern 
medicine, has returned to be a holistic approach for health care in many societies. This 
“back to basic” approach is due to its long history of usage in disease treatment and the 
pharmacological/nutritional value of these products which are believed to be able to 
halt/delay cancer progression.  
In this study, the anticancer properties of four Phyllanthus (P.amarus, P.niruri, 
P.urinaria and P.watsonii) were studied against on human melanoma, MeWo and 
prostate adenocarcinoma, PC-3 cells. The main aims of this study were to identify the 
anti-proliferation, anti-metastasis, anti-angiogenesis properties, apoptosis induction and 
mechanisms of inhibition of Phyllanthus plant extracts on these cancer cells. 
Phyllanthus extracts have significantly inhibited the growth of MeWo and PC-3 
cells at IC50 values at the range of 155.0-260.0 µg/ml and 54.2-153.3 µg/ml for aqueous 
and methanolic extracts, respectively. This growth inhibition was due to cell cycle arrest 
at G1-phase in PC-3 and S-phase in MeWo cells, concurrent with the accumulation of 
apoptotic cells at Sub-G1. Induction of apoptosis was further implicated with the 
activation of caspase-3/7, presence of TUNEL positive cells and DNA fragmentations 
as well as increased pro-apoptotic Bax proteins activity in treated cancer cells. Low 
level of LDH was detected in treated MeWo and PC-3 cells as the result of damage to 
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the cytoplasmic membrane, indicative of late apoptosis or necrosis. In contrast, 
Phyllanthus exerted low cytotoxicity in human normal cell lines (CCD-1127Sk, RWPE-
1 and HUVECs). 
The anti-metastatic and anti-angiogenic effects of Phyllanthus extracts were 
observed when Phyllanthus extracts inhibited several essential steps during metastasis 
and angiogenesis; (i) adhesion, (ii) migration, (iii) invasion, (iv) transendothelial 
migration and (v) microcapillary-like tube formations. These observations were most 
likely due to reduction in activities of matrix metalloproteinase-2, -7 and -9 in treated 
cells as was noted.   
These observed anticancer properties ofPhyllanthus extracts are believed to be 
due to the plants inhibitory effects on multiple signalling pathways; MAPKs, Wnt, 
Myc/Max, Hypoxia and NFκB, via alteration on their intracellular signalling activities 
including pan-Ras, c-Raf, Akt, Elk1, RSK, c-Jun, JNK1/2, β-catenin, GSK3β, c-myc, 
HIF-1α, VEGF, NFκB p50 and p52. In addition, various other proteins involved in 
proliferation, metastasis and apoptosis were found to be differentially expressed in 
treated MeWo and PC-3 cells.  
Taken together, the results showed that Phyllanthus extracts possess anticancer 
effects through inhibition in proliferation, metastasis and angiogenesis as well as 
induction of apoptosis on human melanoma, MeWo and prostate adenocarcinoma, PC-3 
cells. Thus, Phyllanthus is a promising candidate for the development of future 
anticancer agents and could possibly be introduced as a part of diet to prevent cancer 
development. 
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ABSTRAK 
Terapi rawatan kanser moden seperti pembedahan, kemoterapi, dan imunoterapi 
telah dianggap tidak berhasil kerana ketidakberkesanan, isu-isu keselamatan dan kos 
yang tinggi. Oleh sebab tidak semua pesakit kanser bertindak balas secara positif 
kepada ejen antikanser, kadar kematian kanser semakin meningkat termasuk 
“melanoma” dan kanser prostat. 
Perubatan tradisional yang berasaskan penggunaan produk semulajadi yang 
sering dibayangi oleh perubatan moden, telah kembali menjadi salah satu pendekatan 
dalam penjagaan kesihatan masyarakat. Pendekatan "kembali kepada asas" ini adalah 
disebabkan oleh sejarah panjang penggunaannya dalam rawatan penyakit dan nilai 
farmakologi/nutrisi produk ini yang dipercayai dapat menghentikan/melambatkan 
perkembangan kanser. 
Dalam kajian ini, aktiviti antikanser dari empat Phyllanthus (P.amarus, P.niruri, 
P.urinaria dan P.watsonii) telah dikaji terhadap sel melanoma, MeWo dan kanser 
prostat, PC-3. Matlamat utama kajian ini adalah untuk mengenalpasti sifat-sifat “anti-
proliferation”, “anti-metastasis”, “anti-angiogenesis”, induksi apoptosis dan mekanisme 
ekstrak tumbuhan Phyllanthus terhadap sel-sel kanser ini. 
Ekstrak Phyllanthus telah menghalang pertumbuhan sel MeWo dan PC-3 pada 
nilai IC50 pada julat 155.0-260.0 μg/ml bagi ekstrak “aqueous” dan 54.2-153.3 μg/ml 
bagi ekstrak “methanolic”. Penghalangan pertumbuhan sel-sel ini adalah disebabkan 
oleh penyekatan di kitaran sel pada fasa G1 dalam sel PC-3 dan fasa S dalam sel 
MeWo, serentak dengan pengumpulan sel-sel apoptotik di Sub-G1. Induksi apoptosis 
sekaligus dikaitkan dengan pengaktifan “caspase-3/7”, kehadiran sel positif TUNEL 
dan “DNA fragmentations” serta dengan peningkatan aktiviti protein Bax pro-apoptotik 
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di dalam sel-sel kanser. Tahap rendah LDH telah dikesan dalam sel MeWo dan PC-3 
yang diakibatkan oleh kerosakan pada “cytoplasmic membrane”, yakni, menunjukkan 
tanda apoptosis lewat atau nekrosis. Selain itu, Phyllanthus menunjukan tahap rendah 
“cytotoxicity” terhadap sel-sel manusia biasa (CCD-1127Sk, RWPE-1 dan HUVECs). 
Aktiviti “anti-metastatic” dan “anti-angiogenic” Phyllanthus telah diperhatikan 
apabila ekstrak Phyllanthus menghalang beberapa langkah penting semasa metastasis 
dan angiogenesis; (i) “adhesion”, (ii) “migration”, (iii) “invasion”, (iv) transendothelial 
migration” dan (v) “microcapillary-like tube formation”. Ini adalah disebabkan oleh 
pengurangan aktiviti “matrix metalloproteinase”-2, -7 dan -9 dalam sel-sel yang 
dirawati Phyllanthus.  
Aktiviti antikanser dalam ekstrak Phyllanthus dipercayai berpunca daripada 
kesan penghalangan tumbuhan tersebut dalam pelbagai “signalling pathways”; MAPKs, 
Wnt, Myc/Max, Hypoxia dan NFκB, melalui perubahan aktiviti “intracellular 
signalling” seperti pan-Ras, c-Raf, Akt, Elk1, RSK, c-Jun, JNK1/2, β-catenin, GSK3β, 
c-myc, HIF-1α, VEGF, NFκB p50 dan p52. Disamping itu, pelbagai protein lain yang 
terlibat dalam “proliferation”, “metastasis” dan “apoptosis” juga didapati berbeza dalam 
sel-sel MeWo dan PC-3 setelah dirawati oleh Phyllanthus. 
Kesimpulannya, hasil penyelidikan menunjukkan bahawa ekstrak Phyllanthus 
mempunyai aktiviti antikanser melalui penghalangan dalam proliferasi, metastasis dan 
angiogenesis serta induksi apoptosis pada sel melanoma, MeWo dan prostat kanser, PC-
3. Dengan itu, Phyllanthus berkemungkinan dapat dijadikan agen antikanser pada masa 
depan dan diperkenalkan sebagai sebahagian daripada diet untuk menghalang 
perkembangan kanser. 
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CHAPTER 1: INTRODUCTION 
1.1 CANCER 
1.1.1 Overview 
The first description of cancer is recorded in an ancient Egyptian papyrus dated 
between 3000 and 1500 B.C., about eight cases of breast tumours that were treated by 
cauterization. However, the origin of the word “Cancer” was first described by the 
ancient Greek physician, Hippocrates (460-370 B.C.), known as the “Father of 
Medicine”. Hippocrates was the first person who clearly recognized and differentiated 
between benign and malignant tumours after noticing the presence of blood vessels only 
in malignant tumours. Carcinos and carcinoma were the terms used by Hippocrates to 
describe non-ulcer forming and ulcer-forming tumours, respectively. In Greek, both 
words refer to a crab, most likely applied to the disease where the finger-like spreading 
projections from a cancer mimic claws of a crab. Later, the Roman physician, Celsus 
(28-50 B.C.), translated these terms into the Latin word, “Cancer” which is also known 
as crabs and until today is still widely used in medicine (Cohen, 1997; 
MedicineWorld.Org, 2012). 
Cells are the building blocks of all living things in this world and all cells are 
derived from pre-existing cells. Every cell carries out respiration, reproduction 
(meiosis) and growth (mitosis), which are controlled by regulating gene expression at 
the DNA level. In a normal cell, disruptions or mutations in their DNA will initiate a 
repair system on the involved DNA or leading to cell death (Anagnostopoulos et al., 
2008). However, in cancer cells, neither the DNA is repaired nor cell death occurs; 
instead, the mutated cell will continuously generate new mutated cells, which all have 
the same damaged DNA as the first cell does. These mutated cells may have acquired 
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various abnormalities, including aneuploidy, chromosomal rearrangements, 
amplifications, deletions, gene rearrangements, and loss- or gain-of-function mutations 
(Mills, 2003). Most cancer cases are genetically inherited because the mutated DNA can 
be passed along the generations. Most mutation in DNA can occur during cell 
replication and/or caused by carcinogens such as cigarette smoking, diet or oncoviruses 
such as Epstein–Barr virus (Kim et al., 1994; Vincent & Gatenby, 2008; Cancer 
Research UK, 2012).   
Cancer is a name given to a group of diseases that arise from a single (mutated) 
cell when it starts to grow abnormally in an uncontrollable manner to form a group of 
undifferentiated cells, known as a tumour. Tumours are classified into two categories, 
benign or malignant. Not all benign tumours are cancerous but all malignant tumours 
are (Hanahan and Weinberg, 2000). The main difference is that benign tumour lacks 
metastatic ability, grows locally and is less harmful. However, some benign tumours 
can transform into malignant tumours that possess  metastatic ability to invade and 
spread to other parts of the body via the blood or lymphatic circulation and form 
secondary tumours and eventually cause death (Vincent & Gatenby, 2008; Hanahan & 
Weinberg, 2011). 
1.1.2 Development of Cancer (Carcinogenesis) 
Cancer develops through a multistep process known as carcinogenesis, where by 
normal cells are transformed into cancerous cells. The process involves cellular and 
genetic changes and eventually reprograms a cell, thus forming a malignant mass. 
Carcinogenesis involves three significant steps; initiation, promotion and progression 
(Figure 1.1) (Van der Kamp & Jaspers, 1984; Pitot, 2006). An initiation stage is a 
permanent and irreversible event, which involves one or more cellular changes arising 
upon exposure to carcinogens, which leads to alteration in DNA and may result in a 
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mutated cell to divide rapidly (hyperplasia). These transformed (initiated) cells can 
remain harmless, unless exposed to a stimulator, which enhances the tumour to grow 
into a larger mass. This is a reversible process, known as the promotion stage. The 
progression stage is an irreversible conversion of a benign tumour to become a 
malignant tumour. The progression stage includes increased growth rate, invasiveness 
and metastatic capability of the malignant cells (Pitot, 2006). This carcinogenesis 
process usually takes 10 years or more to develop and usually depends on the internal 
(biological) and external (environmental) factors of the patient (Pitot, 2006; Hanahan & 
Weinberg, 2011). 
 
Figure 1.1: Schematic representative of carcinogenesis development (Tang & Sekaran, 
2011). 
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1.1.3 Prostate Cancer 
1.1.3.1 Anatomy and Physiology of Prostate Gland 
The prostate gland is a compound tubuloalveolar exocrine gland of the male 
reproductive system, which is responsible for the production and storage of seminal 
fluids. These fluids are enriched with zinc, citric acid, choline, and various proteins and 
hormones that provide a protective medium for sperms as they make their way through 
the vagina for fertilization. Without this protective medium, most sperm would die soon 
after ejaculation. Before ejaculation, sperms will enter the vas deferens that is connected 
to the urethra, a tube that extends from the bladder to the tip of penis and builds the 
opening for semen and urine. During ejaculation, the muscular contractions in the 
prostate gland help to expel the semen out of the body through the urethra. It also 
produces a protein known as prostate-specific antigen (PSA) that turns the semen into 
liquid. The normal adult human prostate is about the size of a walnut and is located at 
the neck of the urinary bladder and surrounds part of the urethra (National Cancer 
Institute, 2009). Within the prostate, there is a prostatic urethra, an extension of the 
urethra coming from the bladder, and merges with the two ejaculatory ducts.  
The prostate gland is classified in two different ways, by lobe or by zone 
(National Cancer Institute, 2009). The zone classification is often used in medicine so 
that physicians are able to classify the complications based on the different zones in the 
prostate and hence able to deliver proper treatment. In zone classification, the prostate 
gland is divided into four zones. The outermost zone is called peripheral zone (PZ) and 
it covers about 70% of the normal prostate gland in an adult. Most of prostate cancers 
(70-80%) originate from this zone. The central zone (CZ) covers 25% of the normal 
gland and surrounds the ejaculatory ducts. About 2.5% of prostate cancers originate 
from this zone and tend to be more aggressive and likely to invade into the seminal 
  
5 
 
vesicle. The third zone known as transition zone (TZ) covers 5% of normal prostate 
volume and this region is associated with prostate enlargement problems. The last zone 
known as anterior fibro-muscular zone or stroma, is devoid of any glandular parts but 
composed mainly of muscles and fibrous tissues.  
In anatomy, prostate gland is divided into four lobes; anterior lobe, posterior 
lobe, lateral lobes and median lobe (National Cancer Institute, 2009). Anterior lobe 
refers to the anterior portion of the gland lying in front of the urethra. This lobe lacks 
glandular tissue and completely composed of fibromuscular tissue. Median lobe is a 
cone-shaped portion of the gland situated between the two ejaculatory ducts and the 
urethra. The lateral lobes form the main mass of the gland and are continuous 
posteriorly. There are two lobes (right and left lobes) separated by the prostatic urethra. 
The last part is the posterior lobe, which is used by anatomists to describe the 
posteromedial part of the lateral lobes that can be palpated through the rectum during a 
digital rectal exam (DRE). 
 
Figure 1.2:  Zones (left) and lobes (right) classifications of prostate gland (National 
Cancer Institute, 2009). 
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1.1.3.2 Prostate Cancer 
In 2008, according to GLOBOCAN report, there were about 12.7 million newly 
diagnosed cancer cases with 7.6 million cancer deaths (Ferlay et al., 2010). Prostate 
cancer is the second most frequently diagnosed cancer after lung cancer. The incidence 
and mortality rates of prostate cancer are increasing in Asia as well as in the United 
States over the past few decades (Ferlay et al., 2010), while in Malaysia, prostate cancer 
is the 6th most common cancer among men (Hew, 2012). 
Prostate cancer, also knowns as adenocarcinoma, develops when the semen-
secreting prostate gland cells are transformed into cancer cells. The schematic 
representation in Figure 1.3 shows the evolution of prostate cancer which starts with 
alterations at the genetic level, followed by a series of molecular changes, eventually 
resulting in an immortal cancer cell. The accumulation of genetic and molecular 
changes over the years allows visible histopathology of cancer cells. The malignancy of 
prostate tumour is a slow-growing process, and hence likely to be detected among the 
elderly. Prostate tumours can only be detectable when they reach relatively larger in 
size (0.3 cm
3
) by screening of prostate-specific antigen (PSA), or via digital rectal exam 
(DRE) and/or transrectal echography of the prostate. It is important to mention that 
when diagnosis has become possible by screening, approximately 60% of the prostate 
cancers have metastasized outside of the prostate and are no longer organ confined 
(Labrie et al., 2000; National Cancer Institute, 2009).  
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Figure 1.3: Schematic representation of prostate cancer progression. Depending upon 
the genes involved, the degree of prostate cancer growth is variable between individuals 
and the scale shown is an estimated average. Adapted from (Labrie et al., 2000).  
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1.1.3.3 Symptoms and Diagnosis 
The high mortality rate in prostate cancer patients is due to late detection as 
prostate cancer is usually asymptomatic or the symptoms appear only during the 
advanced stage of disease. Patients will experience difficulties during urination such as 
nocturia, hematuria, dysuria, pain, and may also have limited sexual functions and 
performance. The presence of pain in one or more bones such as in flares in the pelvis, 
the lower back, the hips, or the upper legs; may indicate the occurrence of metastases. 
In rare cases, patient may experience significant unexplained weight loss and fatigue. 
About 50% of prostate cancer patients are usually diagnosed with bone metastasis 
(National Cancer Institute, 2009).   
There are several methods to diagnose prostate cancer in male patients, such as, 
detection of prostate tumour marker, prostate specific antigen, transrectal 
ultrasonography, digital rectal examination and biopsy (National Cancer Institute, 
2009). Prostate-specific antigen (PSA) is a specific protein produced by prostate gland. 
PSA occurs in the serum of healthy men is in small quantities, and therefore abnormally 
high levels of serum PSA indicate the presence of prostate cancer. Federal Drug 
Administration (FDA) has approved the screening of the PSA in conjunction with a 
digital rectal exam (DRE) in men for early detection. A digital rectal examamination 
(DRE) is to check for abnormal growth or enlargement of the prostate gland in men as 
presence of prostate tumour can be felt as a hard lump. Transrectal ultrasonography 
(TRUS) uses high energy ultrasound to provide qualitative as well as quantitative 
measurements of prostate tissue stiffness. Biopsy is the removal small pieces of prostate 
tissue through transrectal (rectum) or transperinal (between scrotum and rectum) for 
microscopic examination by urologists and oncologists. 
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1.1.3.4 Stages and Treatments 
It is important to determine the stage of prostate tumour in order to choose and 
deliver the best modalities of treatment to patientw. There is a differential response to 
treatment in the different stages of prostate cancer. Several tests will be conducted in 
order to determine the stage of prostate tumour in patients, that includes CT 
(computerised tomography) scan, MRI (magnetic resonance imaging), PSA (prostate-
specific antigen) test and tumour biopsy (National Cancer Institute, 2009).  
There are four stages in prostate tumour (Figure 1.4) (National Cancer Institute, 
2009). Stage I is where cancer cells are found in prostate gland with low PSA levels 
(<10 ng/ml). In stage II, PSA levels are between 10-20 ng/ml and it is further 
subdivided into two groups; IIA and IIB. In stage IIA, cancer cells may be found in one-
half or less than one lobe, but in stage IIB, cancer cells may be seen in both lobes of the 
prostate gland. In stage III, cancer could spread beyond the outer layer of prostate gland 
and may spread to the seminal vesicles with PSA values ranging from 2-10 ng/ml. In 
stage IV, the PSA can be any level because cancer has spread to nearby or other organs 
such as rectum, bladder and bone.    
Currently, there are four standard treatments for prostate cancer; watchful 
waiting, surgery, radiation therapy and hormone therapy. In watchful waiting, a patient 
will be closely monitored by doctors and no treatment will be given until symptoms 
start to appear. While in surgery, the prostate gland from patients will be removed 
before the cancer cells spreads to organs in the vicinity. In radiation therapy, high 
energy X-rays will be used to kill cancer cells. Antiandrogens, estrogens and luteinizing 
hormone-releasing hormone agonists, are the few examples used in hormone therapy to 
stop the growth of cancer cells. Other treatments are includes chemotherapy and proton-
beam radiation therapy (National Cancer Institute, 2009).  
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Figure 1.4: Stages of prostate cancer (National Cancer Institute, 2009).
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1.1.4 Malignant Melanoma  
1.1.4.1 Anatomy and Organization of Human Skin 
The skin is the soft outermost covering of the human body. In mammals, the 
skin is the largest organ of the integumentary system, composed of multiple layers of 
ectodermal tissue. The functions of skin includes protection of the underlying muscles, 
bones and internal organs, sensation, heat regulation, control of evaporation, excretion, 
absorption and water resistance (Miller & Mihm, 2006).   
1.1.4.2 Skin Cancer (Nonmelanoma and Melanoma) 
Skin cancer is the most commonly diagnosed type of cancer. There are three 
main types of skin cancers; basal cell carcinoma, squamous cell carcinoma, and 
malignant melanoma (Table 1.5) (National Cancer Institute, 2012). The less common 
skin cancers accounting for less than 1% of nonmelanoma skin cancers includes 
dermatofibrosarcoma protuberans, merkel cell carcinoma, kaposi's sarcoma, 
keratoacanthoma, sebaceous carcinomas, microcystic adnexal carcinoma, Pagets's 
disease of the breast, atypical fibroxanthoma, leimyosarcoma, and angiosarcoma (Skin 
Cancer Info Line, 2012). Each cancer is named based on the type of skin cell from 
which it arose.  
Nonmelanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) 
is the most common type of skin cancer, whereas melanoma is least common, but is the 
most aggressive and serious type of skin cancer. Basal cell carcinoma presents as a 
raised, smooth, pearly bump on the sun-exposed skin of the head, neck, back, chest, or 
shoulders. It is considered as the least deadly form when compared to others skin 
cancers. Squamous cell carcinoma is the second most common skin cancer and appears 
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as red, scaling, thickened patch on sun-exposed skin and ulceration and bleeding may 
occur.  
Melanoma is a tumour arising from the melanocyte, which are melanin-
producing cells located in the basal layer of the epidermis (Figure 1.6). The main 
function of this cell is to produce melanin through a process called melanogenesis. 
Melanin provides protection to the hypodermis from ultraviolet rays (DNA 
photodamage). Fair-skinned populations are more susceptible to melanoma 
development as compared to dark-skinned populations due to the low activity and 
number of melanocytes in their skin. Malignant melanoma is an aggressive and life-
threatening skin cancer because it has a high tendency to metastasize to other parts of 
the human body. In most of the cases, melanomas are typically pigmented (having a 
brown or dark colour), but in rare cases, this pigment can be flesh-coloured and this is 
known as amelanotic melanoma (Miller & Mihm, 2006).  
Most of the melanoma cases start from an uncontrolled proliferation of 
melanocytes into benign nevus, or mole, in the human epidermis skin layer (Figure 
1.5D). These pre-existing benign nevi will continue to progress into dysplastic nervus. 
However, there are exceptions where some melanomas will begin from dysplastic 
nevus, which are not really invasive malignancies, but rather just moles that have some 
aberrant growth. A radial growth phase melanoma is where the melanoma starts to grow 
through the epidermis into the upper region of dermis, where blood vessel and 
lymphatics are located. The melanoma continues to progress in a vertical growth phase 
and spreads deeper into the dermis and starts invading the blood vessels and/or 
lymphatic systems. Eventually, the metastasized melanoma forms a secondary tumour 
at a distant site in the body (lung, liver or brain) (Miller & Mihm, 2006).  
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The American Cancer Society has estimated 76,690 individuals will be 
diagnosed with melanoma with 9,480 expected deaths in 2013 (Siegel et al., 2013). 
Australia and New Zealand have the highest incidence rate of skin cancer in the world 
(Cancer Council Australia, 2012). In 2010, there were 12,818 new cases of malignant 
melanoma diagnosed in the United Kingdom alone (Cancer Reserach UK, 2012).  
 
Figure 1.5: Three most common types of skin cancer; (A) Basal cell carcinoma (B) 
Squamous cell carcinoma (Romito & Burr, 2011), and (C) Malignant melanoma (Skin 
Cancer Specialists, 2012). (D) Progression of malignant melanoma, adapted from 
(Miller & Mihm, 2006).  
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1.1.4.3 Types of Melanoma 
In general, melanomas are categorized based on their clinical characteristics and 
histologic at features. Melanoma can be divided into two main categories, in situ and 
invasive. In situ melanoma is the least dangerous type of melanoma. In situ melanoma 
rarely spread and is curable if removed early with a 5 mm margin of normal skin. 
However, invasive melanomas are not confined only to the epidermis, and are able to 
grow into the dermis layer of the skin. The deeper the growth of melanoma into the 
dermis, the greater the risk that it may spread to distant sites as there are blood vessels 
and lymphatic systems, which aids melanoma to metastasize. There are four basic types 
of invasive melanoma, which differ in occurrence and distribution in the human body; 
superficial spreading melanoma (SSM), nodular melanoma (NM), lentigo maligna 
melanoma (LMM), and acral lentiginous melanoma (ALM) (de Braud et al., 2003) 
(Figure 1.6). 
Superficial spreading melanoma (SSM) is the most common form of cutaneous 
melanoma accounting for about 70% of all diagnosed melanoma cases. It may occur at 
any age and body site. It usually appears flat, and is irregular in shape and colour, with 
various shades of black and brown. SSM is characterized by a noticeable intraepidermal 
proliferation (Lemon & Burns, 1998; de Braud et al., 2003). It exhibits a slow-growing 
radial growth pattern that may progress into a nodular appearance. The regressions of 
patches are frequently seen in an amelanotic area. It then becomes an asymmetrically 
raised patch with sculpted edges and is irregularly pigmented with colours varying from 
pale blue and pink to mottled brown-black variegation, sometimes completely black (de 
Braud et al., 2003). 
Nodular melanoma (NM) is the most aggressive type of melanoma and accounts 
for 15 to 30% of all diagnosed melanoma patients (de Braud et al., 2003). NMs are 
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more common in men and often seen in non-weight-bearing areas such as trunk, head 
and neck regions. It appears as a nodule with sharply demarcated borders on the skin, 
often shiny with a slightly infiltrated base. The colour of NM is generally darkly 
pigmented. However, some can be light brown or even colourless (non-pigmented) and 
more uniform than SSM (Sagebiel, 1993). These lesions are characterized by a 
relatively rapid vertical growth phase, which is capable of growing more rapidly in 
thickness (penetrate into the skin) rather than growing radially (growth in diameter to 
form a peduncle). It usually has a well-defined border as compared to superficial SSM 
(Sagebiel, 1993; Lemon & Burns, 1998). Ulceration and bleeding may occur in NM 
patients.  
Lentigo maligna melanoma (LMM) accounts for approximately 5% of all 
melanoma cases (Weinstock & Sober, 2006). It is often diagnosed in elderly patients 
who are more than 50 years of age and appears in sun-exposed areas such as the face, 
forearms, head and neck. LLM arises from a pre-existing lentigo with irregular edges, 
rather than a mole. The colour of the lesion varies between dark to brown-black 
variegation (Weinstock & Sober, 2006). The growth pattern of LLM is more radial than 
other types of melanomas, remain in situ for up to approximately 20 years, thus 
resulting in decreased incidence of metastasis (Lemon & Burns, 1998). However, this 
horizontal non-invasive growth phase may divert to vertical growth. The vertical growth 
phase usually involves spindle-like cells invading into the reticular dermis surrounded 
by fibrotic stroma (dermoplastic) or may form fascicles displaying neural features 
infiltrating the perineural structures of the skin (de Braud et al., 2003).   
Acral lentiginous melanoma accounts for less than 5% of all diagnosed 
melanomas. As its name dictated, it mainly occurs on non-hairy skin of the acra (palm, 
sole, nailbed), and generally appears as a plantar lesion on the weight-bearing surface of 
the foot (Piliang, 2009). The appearance of this lesion may be vary due to the skin 
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thickness at these sites (de Braud et al., 2003). This is the most common type of 
melanoma seen in dark-skinned people (African Americans, Hispanics, and Asians), 
and rarely occurs in white people (de Braud et al., 2003; Piliang, 2009). This aggressive 
type of melanoma has the ability to metastasize much like nodular melanomas (Lemon 
& Burns, 1998).  
 
Figure 1.6: Types of invasive melanoma: (A) superficial spreading melanoma (Lehrer, 
2011) , (B) nodular melanoma (Gupta, 2012),  (C) lentigo maligna melanoma (Oakley, 
2012), and (D) acral lentiginous melanoma (Swetter et al., 2004). 
 
  
  
17 
 
1.1.4.4 Diagnosis 
Malignant melanoma is diagnosed according to its pigmentation. “A-B-C-D-E” 
acronym is a guideline used in the identification of pigmented lesions evaluated with 
biopsy (Figure 1.7) (Abbasi et al., 2004). Asymmetry (A) is where two halves of 
median line through a mole is not a match of each other. Border (B) is where the 
borders of an early melanoma tend to be irregular or uneven. The edges may be 
scalloped or notched. Having a variety of colour (C) is another warning signal for 
melanoma. The mole or lesion is not one uniform colour but rather a combination 
ranging from light brown to dark brown, black, red, blue or white. Diameter (D) of 
melanoma usually greater than 1/4 inch or 6 mm. Evolution (E) refers to any noticeable 
change occurring in a mole or lesion over time regardless of size, shape, colour, 
elevation, or any new symptoms such as bleeding, itching or crusting (Bono et al., 
1999). 
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Figure 1.7: Diagnosis of melanoma according “A-B-C-D-E” acronym (Abbasi et al., 
2004). 
1.1.4.4.1 Stages and Treatments  
It is important to determine the depth of melanoma growth into the skin and its 
degree of metastasis. This information is important to determine the appropriate 
treatment to be delivered, risk of reoccurrence, and the ability to metastasize into the 
nearby lymph nodes. Most melanomas occurring at an early stage have high cure rates. 
However, the effectiveness of treatment is diminished in advanced melanoma and has a 
50% survival rate, ranging from 2 to 8 months with only 5% generally surviving for 5 
years or more (Jemal et al., 2011).  
The American Joint Committee on Cancer (AJCC) TNM classification is the 
most often classification for melanoma staging. TNM classification is based on the size 
of primary tumour (T), number of regional lymph nodes (N) and presence or absence of 
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distant metastases (M) (Balch et al., 2009). The T stage is based on vertical thickness of 
the lesions in millimeters (Breslow’s thickness) and the anatomic level of invasion into 
the dermal layers of skin and subcutaneous fat (Clark’s classification). The N stage is 
determined by the distance of metastasized melanoma to nearby lymph nodes. The M 
stage is simply based on the presence or absence of metastasis to distant sites.  
Melanoma is further grouped into different stages according to the revised TNM 
staging system. The combinations of T, N, and M groups will give an overall stage, 
using Roman numerals I to IV (Table 1.1). This process is known as stage grouping 
(Kim et al., 2002; Balch et al., 2009). In general, the patients with lower stage cancers 
have high chances of cure. Therefore, correct staging is important because best 
modalities of treatment to be delivered to patient are generally based on this parameter.  
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Table 1:1:  Treatment of melanoma according stages (Melanoma Institute Australia, 
2012; National Cancer Institute, 2012; Sosman, 2012).  
Stages of 
Melanoma 
Description Treatments 
Stage 0  
(in situ) 
 Appears as abnormal discoloured or 
dark coloured mole. 
 Only in the epidermis and has not 
spread into dermis layer 
 
 Surgery, or 
 Cream on sensitive areas on 
the face 
 
Stage I  Stage IA:  thickness is less or about 
1 mm, with no ulceration and no 
mitoses 
 
 Stage IB: thickness is less or about 1 
mm, with ulceration or mitoses 
 
 Surgery (depends on the 
thickness of the melanoma) 
 
Stage II  Stage IIA: 
 thickness is 1 - 2 mm with 
ulceration or thickness is 2 - 4 
mm with no ulceration 
 No spread into nearby lymph 
nodes or distant metastasis 
 
 
 
 Stage IIB:  
 thickness is 2 - 4 mm with 
ulceration or greater than 
thickness 4 mm with no 
ulceration 
 No spread into nearby lymph 
nodes or distant metastasis  
 Stage IIC:  
 thickness is greater than 
thickness 4 mm with ulceration 
 No spread into nearby lymph 
nodes or distant metastasis 
 
 Surgery, or 
 Adjuvant therapy with 
interferon after surgery 
 
Stage III  Stage IIIA: 
 thickness ranges from less that 1  
mm to more than 4 mm with no 
ulceration 
 Micrometastasis into 1 – 3 
nearby lymph nodes  
 No distant metastasis 
 
 Stage IIIB:  
 thickness is ranging from less 
 Surgery  
 Lymph node dissection, 
 Adjuvant therapy (radiation 
therapy) with interferon 
after surgery 
 Injections with Bacille 
Calmette-Guerin (BCG) 
vaccine or interleukin-2 
directly into the melanoma 
or  
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that 1  mm to more than 4 mm 
with or without ulceration  
 Macrometastasis into 1 – 2 
nearby lymph nodes 
 No distant metastasis  
 
 Stage IIIC:  
 thickness is ranging from less 
that 1  mm to more than 4 mm 
with or without ulceration  
 Macrometastasis into 1 – 2 
nearby lymph nodes 
 Metastasis in 4 or more lymph 
nodes and present of matted 
lymph nodes 
 No distant metastasis  
 
 Topical immunotherapy 
imiquimod  
 Chemotherapy, 
immunotherapy with 
cytokines, or both combined 
(biochemotherapy). 
 
Stage IV  Melanoma has metastasized into 
other organs such as the liver, lungs 
and brain. 
 High levels of LDH 
 
 Surgery 
 Immunotherapy drugs 
(Ipilimumab, interferon or 
interleukin-2), and  
 Chemotherapy drugs 
(Dacarbazine, 
temozolomide) 
 Radiation therapy  
 
There are four standard treatments for melanoma; surgery, chemotherapy, 
immunotherapy and radiation therapy (Table 1.1). Surgery is the usual recommended 
treatment of choice for malignant melanomas (Lemon & Burns, 1998). If melanomas 
are detected at an early stage, surgical excision itself is sufficient with lower chances of 
reoccurrence (Garbe et al., 2008). Patients with intermediate thickness of melanomas 
(0.76-4.00 mm) who received wide excision and elective lymph node dissection 
(ELND) usually have a significantly higher survival rate than those who received wide 
excision alone (Krag et al., 1995; Balch et al., 1996; Agnese et al., 2003). ELND is the 
removal of all lymph nodes from the area surrounding the primary melanoma (Balch et 
al., 1996).  
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Chemotherapeutic agents have been widely used in the treatment of different 
types of cancer including malignant melanoma. Chemotherapeutic agents that have 
shown anticancer activities against malignant melanoma include dacarbazine, cisplatin, 
carboplatin, temozolomide, vinca alkaloids, platinum compounds, nitrosoureas and 
taxanes (Cocconi et al., 1992; Grossman & Altieri, 2001; Mouawad et al., 2010). The 
first anticancer agent for malignant melanoma treatment approved by FDA was 
dacarbazine with the highest response rate compared to other drugs (Cocconi et al., 
1992). Polytherapy or combination therapy has been evaluated to improve the efficiency 
of chemotherapeutic agents (Sosman, 2012). The most widely used combinations 
including (i) cisplatin, vinblastine and dacarbazine; (ii) cisplatin, dacarbazine, 
carmustine and tamoxifen; (iii) bleomycin, vincristine, carmustine and dacarbazine; and 
(iv) carmustine, hydroxyurea and dacarbazine (Cocconi et al., 1992; Jilaveanu et al., 
2009; Mouawad et al., 2010).  
Immunotherapy is a form of treatment that directly or indirectly, uses the host 
immune responses to fight cancer cells in patients (National Cancer Institute, 2012). 
Interferon alpha (IFN-α) has shown moderate activity against stage IV melanoma with 
10% to 22% overall response rates (Chowdhury et al., 1999; Jilaveanu et al., 2009).  In 
addition, IFN-α also possesses immunomodulatory effects to enhance the functions of 
natural killer cells, macrophages and T-lymphocyte functions as well as inhibit 
angiogenesis (Chowdhury et al., 1999; Mouawad et al., 2010). Another 
immunotherapeutic agent is interleukin-2 (IL-2), and has been approved by the FDA for 
therapy of patients with advanced stage melanoma. It acts through a variety of 
mechanisms including activation of cytotoxic T-cells and natural killer cells as well as 
production of other cytokines (Enk et al., 1998; Chowdhury et al., 1999; Atkins et al., 
2000). However, the application of these immunotherapeutic agents is limited due to 
their high toxicity. Therefore, these biological agents have been used in smaller doses in 
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combination with chemotherapy (biochemotherapy) to increase efficacy and to reduce 
toxicity (Yee et al., 2000; Jilaveanu et al., 2009). 
1.2 Hallmarks of Cancer 
The hallmarks of cancer is comprised of at least eight biological capabilities 
acquired during the multistep development of human tumours (Hanahan & Weinberg, 
2011). Each of these hallmarks is derived upon changes in the normal cell’s physiology 
and interacts with each other to promote malignant growth. The hallmarks constitute an 
organizing principle for rationalizing the complexities of neoplastic disease. This 
includes sustaining proliferative signalling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis and metastasis, 
reprogramming of energy metabolism and evading immune destruction.  
1.2.1 Sustaining Proliferative Signalling 
Normal cells are carefully monitored for the production and release of growth-
promoting signals to ensure a balance or homeostasis between cell numbers and cell 
death. Generally, growth factors such as epidermal growth factor (EGF), transforming 
growth factor (TGF) and tumour necrosis factor alpha (TNF-α), binds to specific 
receptors on the surface of their target cells, typically containing intracellular tyrosine 
kinases. This engagement transmits signals via branched intracellular signalling 
pathways to regulate progression of cell cycle as well as cell growth (Aaronson, 1991). 
The conversion of a normal cell to a transformed cell usually starts from mutations in 
DNA, which causes the cells to no longer depend on growth signals, thus promoting 
uncontrolled growth and proliferation. (Hanahan & Weinberg, 2011).  
There are several alternatives by which cancer cells acquire the ability to sustain 
proliferative signalling: (1) autocrine proliferative stimulation where cancer cells 
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produce their own growth factors to which they respond in autocrine manner via 
expression of cognate receptors (Lippman et al., 1986; Iihara et al., 2006), (2) paracrine 
proliferative stimulation where cancer cells may send signals to stimulate normal cells 
in its vicinity to produce various growth factors required for cancer cells (Bhowmick et 
al., 2004; Cheng et al., 2008), (3) increases the number of cell surface receptor at the 
cancer cell to hyperrespond to growth factors, or (4) structural alteration in the surface 
receptors of cancer cells to mediate ligand-independent response (Hanahan & 
Weinberg, 2011).  
There are various cellular signalling pathways in a cell that are interconnected to 
form complex networks (Hanahan & Weinberg, 2011). A cell will integrate all 
information from each signal to regulate diverse functions, such as protein synthesis and 
cell growth, motility, differentiation, and cell death. The ability of intracellular 
signalling networks to integrate and distribute regulatory information requires a 
signalling molecule to respond to multiple inputs and output signals. However, the same 
signalling molecules will control different processes within different signalling 
complexes or at different intracellular locations. In addition, in different cell types, the 
activation of a signalling molecule may also have distinct consequences (Martin, 2003; 
Bazigou & Rallis, 2007).   
During tumour progression, cancer cells acquire a number of alterations at both 
the cellular and genetic levels. All cancer cells derive an advantage by either 
dysregulating, upregulating, or deregulating signalling pathways that confer these cells 
the capacities to grow independently of growth and anti-growth signals, metastasis, 
initiate an angiogenetic response, and evade from apoptosis (Bazigou & Rallis, 2007).  
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1.2.1.1 Mitogen Activated Protein Kinase (MAPK) Signalling 
Mitogen-activated protein kinase (MAPK) pathway contains conserved kinases 
that transmit extracellular signals to the host cell machinery that controls important 
cellular processes such as growth, proliferation, differentiation, migration and apoptosis. 
Three-tier kinases have been well characterized and widely studied in mammalian cells; 
a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAPK (Johnson 
and Lapadat, 2002). In addition, at least six members of the MAPK family have been 
discovered; extracellular signal-regulated kinase: ERK1/2, ERK3/4, ERK5, ERK7/8, 
Jun N-terminal kinase/stress activated protein  kinases (JNK1/2/3; also called SAPKs) 
with many splice variants (Fang & Richardson, 2005; Wagner & Nebreda, 2009; 
Rodríguez-Berriguete et al., 2011) and the p38 kinases (p38 α/ß/γ/δ) (Olson & 
Hallahan, 2004; Wagner & Nebreda, 2009) In general, MAPK/ERK pathway is 
activated by binding of a growth factor to cell surface receptors, whereas the 
MAPK/JNK and p38 pathways are activated by stress, inflammatory cytokines and 
growth factors. Aberrant regulation of MAPK signalling contributes to development and 
progression of cancer including cancer cell proliferation, survival, migration and 
invasion (Fecher et al., 2008).  
The MAPK/ERK pathway is well-studied as its dysregulation can be found in 
approximately one-third of all human cancers (Figure 1.8). The biological consequences 
of active ERK pathway including the enhancement of cancer cells’ proliferation, 
differentiation, angiogenesis, motility and invasiveness. Upon activation by the binding 
of growth factors such as TNF-α, the extracellular signal is transmitted to small GTP 
binding proteins (Ras), which in turn activates the kinase cascades; starting from 
MAPKKK (Raf) to MAPKK (MEK1/2), and lastly to MAPK (ERK). Cancer cells 
usually will create an autocrine feedback loop in promotion of Ras-mediated 
transformation and Raf-mediated gene expression changes. Therefore, an aberrant 
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activation of Ras and Raf proteins can be found in different types of human cancers 
(breast, prostate, lung, colon cancers, etc) (Hilger et al., 2002; Gollob et al., 2006; 
Roberts & Der, 2007).  
 
Figure 1.8: Oncogene activation of the MAPK/ERK cascade (Roberts & Der, 2007). 
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The JNK family of MAP kinases is mainly activated in response to diverse 
stimuli including inflammatory cytokines, ultraviolet (UV) and gamma radiation, 
growth factor deprivation, DNA-damaging (cytotoxic) agents, and certain G-protein 
coupled receptors (Figure 1.9) (Weston & Davis, 2002; Hui et al., 2007). There are 
three JNK isoforms – JNK1, JNK2 and JNK3. JNK1 and JNK2 are ubiquitously 
expressed in all types of cells, whereas JNK3 expression is only localized in brain, heart 
and testis. JNK activation requires dual phosphorylation on tyrosine and threonine 
residues by MEK4 and MEK7. Both MEK4 and MEK7 are activated by several 
MAPKKKs, including MEKK1–4, MLL2 and 3, YTpl-2, DLK, TAO1 and 2, TAK1 
and ASK1 and 2. Once activated, JNK will be translocating from the cytoplasm into the 
nucleus where it regulates transcription factors including AP-1, Elk-1, c-myc, p53, as 
well as anti-apoptotic proteins such as Bcl-2 and 14-3-3 (Heasley & Han, 2006; Bode & 
Dong, 2007; Turjanski et al., 2007). The JNK also plays a part in the regulation of p53 
transcriptional activity and stability (Buschmann et al., 2000; She et al., 2002b; Wu, 
2004).  
Several studies showed an aberrant activation of JNK activity in various types of 
cancers including prostate, breast, pancreas and lung (Lin, 2002; Xu et al., 2006; 
Wagner & Nebreda, 2009). The main aim of JNK signalling is the formation a complex 
known as activating protein-1 (AP-1) via combination of c-Jun and c-Fos proteins. This 
transcription factor controls cellular physiology including cell proliferation, apoptosis, 
differentiation and developmental processes. (Eferl & Wagner, 2003; Kennedy et al., 
2003). Several studies have shown that the deficiency of c-Jun protein in fibroblasts 
could inhibite transformation of normal cells to cancer cells (Dérijard et al., 1994; 
Johnson et al., 1996; She et al., 2002a), highlighting the importance of JNK signalling 
pathway in the regulation of proliferation in tumourigenesis (Schreiber et al., 1999; 
Eferl & Wagner, 2003). In addition, JNK has also been shown to promote cancer 
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metastasis by activating matrix metalloproteinases, MMP-2 and -9 (Hong et al., 2005; 
Liang et al., 2007). Therefore, aberrant activation of JNK/c-Jun/AP-1 is implicated in 
tumour development (Eferl & Wagner, 2003; Kennedy et al., 2003).  
In mammals, p38 isoforms are strongly activated by physical and chemical 
stress signals, oxidative stress, hypoxia, inflammatory cytokines, heat and osmotic 
shock (Figure 1.9). The four isoforms of p38, namely p38 α, β and γ and δ are 
characterized by the presence of the conserved Thr-Gly-Tyr (TGY) phosphorylation 
motifs in their activation loop with some differences in their functions (Kumar et al., 
2003). The expression of p38 α and p38 β are ubiquitous in all cells, whereas, p38γ and 
p38δ are confined in certain tissues such as muscle, testis, lung and kidney. These 
conserved motif is a target of phosphorylation by MEK3 and MEK6. However, in some 
cases, p38 can also be activated by MEK4, an activator kinase of JNK. Once activated, 
cytoplasmic p38 proteins will translocate into the nucleus where they regulate several 
genes including NFκB, Elk-1, p53 and Max, that are involved in apoptosis, cell cycle 
progression, growth and differentiation (Dhillon et al., 2007). 
Several studies have established that p38 plays an important role in the 
progression of leukemia, lymphoma, breast, prostate, gastric and lung cancers (Park et 
al., 2003; Uzgare et al., 2003; Olson & Hallahan, 2004; Hui et al., 2007). The 
expression of upstream kinases (PAK1, MEK6, and MEK4) and p38 are found in 
prostate cancer cells (Park et al., 2003; Uzgare et al., 2003; Xu et al., 2006). Besides, 
p38 plays a vital role in a hypoxic environment that increases survival, clonogenecity, 
migration and invasiveness of prostate cancer cells by increasing expression of matrix 
metalloproteinases (Uzgare et al., 2003; Khandrika et al., 2009; Kwon et al., 2009).  
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Figure 1.9: Overview of activation JNK and p38 MAPK pathways (Wagner & Nebreda, 
2009). 
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1.2.1.2 Wnt Signalling 
Wnt signalling pathway regulates cellular processes including proliferation, 
differentiation, motility, as well as survival and/or apoptosis. It plays an important role 
during embryogenesis and maintain homeostasis in mature tissues (Polakis, 2000). 
There are at least three distinct Wnt pathways: (1) the canonical (β-catenin) pathway, 
which activates target genes in the nucleus; (2) non-canonical (planar cell polarity, PCP) 
pathway, which involves JNK and cytoskeletal rearrangements; and (3) Wnt/Ca
2+
 
pathway (Kolligs et al., 2002; Polakis, 2007) (Figure 1.10).   
In the canonical Wnt pathway, the binding of Wnt ligand to receptor complex 
comprised of Frizzled/low-density lipoprotein receptor-related protein (FZ/LLP) and 
cytoplasmic disheveled (Dsh) to stabilize cytoplasmic β-catenin through the inhibition 
of the β-catenin degradation complex (Figure 1.10). This binding will leads to activation 
of Dsh protein and in turn, inhibits glycogen synthase kinase 3β (GSK3β) from 
phosphorylating its substrates such as axin, APC and targeting β-catenin for degradation 
(Itoh et al., 1998; Kishida et al., 1999; Barker & Clevers, 2000; Giles et al., 2003). In 
normal cells, unphosphorylated β-catenin will translocate into nucleus where it binds to 
transcription factors such as T-cell transcription factor (TCF)/lymphoid enhancer-
binding factor (LEF) family of transcription factors and activates Wnt-regulated genes 
such as c-myc and cyclin D (Morin, 1999; Shtutman et al., 1999; Barker & Clevers, 
2000; van de Wetering et al., 2002). The activity of the Wnt signalling pathway is 
tightly regulated by the amount of β-catenin. Normally, β-catenin is present in the 
cytoplasm and is maintained at a low level through ubiquitin-proteasome-mediated 
degradation, which is regulated by a multiprotein “destruction” complex containing 
axin, adenomatous polyposis coli (APC), and glycogen synthase kinase-3β (GSK3β) 
(Kolligs et al., 2002; Polakis, 2007).  
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In the non-canonical (Planar cell polarity, PCP) pathway, this pathway will leads 
to the activation of the small GTPases RHOA (RAS homologue gene-family member 
A) and RAC1, allowing the activation of JNK and ROCK (RHO-associated, coiled-coil-
containing protein kinase 1). This will cause changes in cell adhesion and motility, and 
allows remodelling of the cytoskeleton. The Wnt/Ca
2+
 pathway, meanwhile, is mediated 
by G proteins and phospholipases (PLC) and leads to a brief increase in free calcium in 
cytoplasm and subsequently activates the PKC (protein kinase C), CAMKII (calcium 
calmodulin mediated kinase II) and phosphatase calcineurin. The activation of cell 
division control protein 42 (Cdc42) PKC allows cell adhesion, migration, and tissue 
separation (Polakis, 2000; Moon et al., 2004; Katoh, 2005).  
Mutations in APC and Axin have been found in some tumours lead to the 
dysregulation of this pathway in human cancers (Polakis, 2000; Moon et al., 2004; 
Polakis, 2007). In addition, alteration of Wnt5a, a tumour suppressor gene, could also 
lead to tumour formation, amplification or overexpression of positive regulators of 
components of this pathway are observed in several type of cancers (Nagahata et al., 
2003; Okino et al., 2003). Besides that, Frizzled-related protein 1 (FRP1/ FRZB), a 
secreted Wnt inhibitor is frequently absent in human cancers (Ugolini et al., 1999).  
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Figure 1.10: The Wnt signalling pathway. Three distinct pathways: (1) the canonical (β-
catenin, blue) pathway, (2) non-canonical (planar cell polarity, PCP, orange) pathway, 
and (3) Wnt/Ca
2+
 pathway (green) (Huelsken & Behrens, 2002). 
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1.2.1.3 Myc/Max Signalling 
MYC gene was first identified as a viral oncogene (v-myc) in the acutely 
transforming MC29 virus, which induces myelocytomatosis and tumours in chickens 
(Sheiness et al., 1978; Dalla-Favera et al., 1982; Watson et al., 1983). The linkage 
between MYC gene and tumour formation is related by several homologs of myc in 
tumours such as c-myc in Burkitt’s lymphoma and N-myc in neuroblastoma (DePinho 
et al., 1991; Evan & Littlewood, 1993).   
The MYC gene is located on chromosome 8 in the human genome and encodes 
for c-myc proteins (Battey et al., 1983). Normally, expression of c-myc is only transient 
and at low levels in response to mitogenic signalling. The dimerization of c-myc with 
Max protein is necessary to induce expression of a number of genes through it binding 
on consensus sequences; Enhancer Box sequences (E-boxes). It is a key regulator for 
cell growth, proliferation, metabolism, differentiation, and apoptosis (Hermeking, 
2003b; Xu et al., 2010) (Figure 1.11). 
High levels of c-myc were found in different types of cancer; breast, ovaries, 
lung, prostate, and skin, as well as leukemias and lymphomas (Hermeking, 2003b; Xu et 
al., 2010). In cancer cells, the constitutively active c-myc promoter integrates diverse 
mitogenic signalling cascades and promotes cell proliferation by regulating the 
expression of cell survival genes. Cell cycle inhibitors such as p21, p15, and p27 will be 
suppressed by c-myc, thus allowing unrestricted cell cycle progression and uncontrolled 
proliferation of cancer cells (Hermeking, 2003b).  
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Figure 1.11: Impact on the epigenetic program of cells with Myc/Max. Adapted from 
(Felsher, 2003). 
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1.2.1.4 Nuclear Factor Kappa Beta (NFκB) 
The nuclear factor kappa B (NFκB) is a family of transcription factors involved 
in the regulation of immune responses and inflammation. Incorrect regulation of NFκB 
has been linked to a number of disease including septic shock, viral infection 
inflammatory and autoimmune diseases as well as cancer (Migliazza et al., 1994; 
Mukhopadhyay et al., 1995; Caamaño et al., 1996; Shukla et al., 2004; Dolcet et al., 
2005; Prusty et al., 2005; Bindhu et al., 2006).  
NFκB is not a single gene but a family of closely related transcription factors, 
p50 (NFκB1), p52 (NFκB2), RelA (p65), c-Rel and RelB (Karin & Lin, 2002; 
Moynagh, 2005). These five transcription factors shared a domain in their sequence, 
known as Rel Homology Domain (RHD). This domain allows (1) dimerization to occur 
(homodimers and/or heterodimers), (2) interacttion with their specific inhibitors, IκBs 
and (3) mediation of DNA binding. Only RelA (p65), c-Rel and RelB contains C-
terminal transcriptional activation domains (TADs) to regulate their target genes. Both 
p50 and p52 can participate in their target gene regulations by forming heterodimers 
with RelA, c-Rel, or RelB. In addition, p50 and p52 homodimers form a complex with 
nuclear protein Bcl-3 to act as a transcriptional activator (Moynagh, 2005). 
In normal cells, cytoplasmic NFκB dimer interacts with inhibitors of NFκB 
(IκBs) and therefore remains in an inactive state in the cytoplasm. There are four 
members of IκB; IκBα, IκBβ, IκBɛ and Bcl-3. These IκB members contain two 
conserved serines that become targets of phosphorylation by the IκB kinases (IKK). The 
IKK complex contains highly homologous kinase subunits, catalytic subunits (IKKα 
and IKKβ) and the regulatory subunit (IKKγ or NEMO). Upon phosphorylation, IkB 
members dissociate from NFκB and undergo proteasome-dependent degradation (Karin 
& Lin, 2002; Moynagh, 2005).  
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There are two signalling pathways in NFκB; the canonical pathway (or classical 
pathway) and the non-canonical pathway (or alternative pathway) (Figure 1.12) (Karin 
& Lin, 2002; Moynagh, 2005; Gilmore, 2006). In the canonical signalling pathway, 
ligand-receptor interactions (such as TRAF) will recruit and activate the IkB kinase 
(IKK) complex. Activation of IKK complex will mediate phosphorylation-induced 
proteasomal degradation of the IkB inhibitor. This subsequently allows the active NFκB 
transcription factor subunits to translocate into the nucleus and regulate their target 
genes. The canonical pathway activates NFκB dimers comprised of RelA, c-Rel, RelB 
and p50 (Gilmore, 2006; Hayden & Ghosh, 2008).   
The non-canonical pathway involves the activation of p100/RelB complexes. 
The IKK complex in this pathway is only comprised of two catalytic IKKα subunits, but 
not NEMO. Upon receptor binding, NFκB-inducing kinase (NIK) will be activated and 
phosphorylated to activate the IKK complex. In turn, this complex phosphorylates p100 
or p105 resulting in p52/RelB or p50/RelA active heterodimer, respectively, (Moynagh, 
2005; Hayden & Ghosh, 2008), then is tranlocated into the nucleus to regulate target 
genes. 
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Figure 1.12: Overview of the cannonical (Left) and non-cannonical (Right) of NFκB 
pathways (Hooper, 2012). 
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1.2.2 Evading Growth Suppressors 
Cancer cells negatively regulate cell proliferation by inhibition of tumour 
suppressor genes. There are a number of tumour suppressors in a cell and their main 
function is to protect cells from transforming to cancer cells. One of the well-studied 
tumour suppressor proteins is p53 that governs both cell proliferation and activate 
apoptotic programs (Hanahan & Weinberg, 2011).   
A TP53 gene is a tumour suppressor gene located on chromosome 17 and 
encodes p53 protein. The p53 protein is a transcription factor that interacts with a large 
number of proteins and plays an important role in regulating cell cycle, growth, 
proliferation, and apoptosis (Vogelstein et al., 2000). Upon DNA damage, p53 protein 
will bind to DNA, to induce production of p21 protein which is a potent cyclin-
dependent kinase inhibitor (CKI). The p21 protein inhibits cell cycle progression by 
inhibiting the activity of cyclin-CDK2 or -CDK1 complexes until damaged DNA is 
repaired. If the extent of DNA damage exceeds the capacity of the repair mechanism, 
the cell will be destroyed via apoptosis. However, deregulation of p53 proteins in 
cancers causes p53 to no longer bind to DNA in an effective way, and as a consequence 
the p21 protein is not available to act as the 'stop signal' for cell division. Therefore, 
cells divide uncontrollably, and form tumours. Loss of p53 in many cancers leads to 
genome instability, impaired cell cycle regulation, and inhibition of apoptosis (Nikolova 
et al., 2000; Joerger & Fersht, 2007; Song et al., 2007).  
This tumour suppressor protein is also activated in response to oncogene 
activation, hypoxia and DNA damage, leading to growth arrest and/or apoptosis by 
stimulating the expression of various p53 target genes including p21, Bax, Puma, Noxa, 
Apaf-1, Fas and DR5 (Vousden & Lu, 2002) or by repressing the expression of anti-
apoptotic proteins such as Bcl-2 and Bcl-XL (Xu et al., 2001; Hoffman et al., 2002). 
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Besides involvement at the nuclear level, p53 can also translocate into mitochondria 
where it interacts with Bcl-XL, resulting in permeability transition and release of 
cytochrome c (Findley et al., 1997; Mihara et al., 2003). 
Mouse double minute 2 (Mdm2) (HDM2 in humans, henceforth as Mdm2) 
oncoprotein is a negative regulator of p53 (Figure 1.13). Mdm2 is a transcription target 
of p53, thus producing an auto regulatory feedback loop (Picksley & Lane, 1993; 
Vogelstein et al., 2000; Lahav et al., 2004). Mdm2 will promote the ubiquitination and 
rapid degradation of p53 to keep p53 at a low level. Mdm2 activity is positively 
regulated by serine/threonine kinase (Akt) which is activated in response to survival 
signals from growth factor receptors (Gottlieb et al., 2002). Akt will promote Mdm2-
mediated suppression of p53 by suppressing the action of the adenosine diphosphate-
ribosylation factor (ARF), a tumour suppressor gene. ARF expression is dependent on 
the activity of adenovirus E2 gene promoter region binding factor 1 (E2F-1) and by the 
action of oncogenes such as c-myc, Ras and β-catenin (Henriksson et al., 2001). 
Increased ARF activity leads to activation of p53 and induction of apoptosis. Aberrant 
accumulations of proto-oncogenes such as β-catenin, Ras, Myc and E1a have been 
documented in melanoma, breast, colorectal and prostate cancers (Sherr & Weber, 
2000).  
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Figure 1.13: The p53-Mdm2 interactions. Arrows indicate positive inputs; horizontal 
bars indicate inhibitory inputs (Oren et al., 2002). 
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1.2.3 Resisting Cell Death 
Inhibition of apoptotic cell death in cancer cells allows the cells to expand their 
number during carcinogenesis. Apoptosis is known as one of the most important types 
of cell death in response to cytotoxic treatment. The administration of anticancer drugs 
from natural products has shown to be capable of inducing apoptotic death of cancer 
cells (HemaIswarya & Doble, 2006). This offers new opportunities in identifying new 
targets for therapeutic intervention and pharmacological manipulation in cancer 
research.  
1.2.3.1 Bcl-2 family 
The Bcl-2 (B-cell lymphoma 2) family consists of regulatory proteins that 
tightly regulates apoptosis including pro-apoptotic (Bax and Bak), and anti-apoptotic 
proteins (Bcl-xL, Bcl-w, Mcl-1, A1) (Reed, 1998; Korsmeyer, 1999). When anti-
apoptotic proteins, Bax and Bak are activated, the integrity of the outer mitochondrial 
membrane is changed, causing the release of cytochrome c. The released cytochrome c 
activates a cascade of caspases that act via their proteolytic activities to induce the 
multiple cellular changes associated with the apoptotic program (Chao & Korsmeyer, 
1998; Gross et al., 1999; Korsmeyer, 1999). 
1.2.3.2 Caspases 
Caspases (cysteinyl, aspartate-specific protease) are a family of cysteine 
proteases that plays an important role in cell death. Caspases are present as inactive pro-
forms or zymogens within a cell. There are two types of caspases: initiator caspases 
(caspase-2,-8,-9,-10) and effector caspases (caspase-3,-6,-7). Caspases are activated 
either by the mitochondrion-mediated (intrinsic) pathway or death receptor-mediated 
(extrinsic) pathway (Cohen, 1997; Stennicke & Salvesen, 2000). The activated initiator 
caspases will activate the effector caspases in a cascade by cleaving their inactive pro-
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forms. In turn, the effector caspases will cleave other important cellular protein within 
the cell that lead to the morphological and biochemical features associated to apoptosis 
(Cohen, 1997; Earnshaw et al., 1999). One of the downstream substrates of caspases is 
caspase-activated deoxyribonuclease (CAD), which induce DNA fragmentation in 
apoptotic cells. In normal conditions, CAD will bind to its inhibitor (ICAD) to form a 
complex in the nucleus. During apoptosis, activated caspase-3 will dissociate CAD from 
the complex and DNA fragmentation to take place. In addition, caspases target 
structural proteins such as lamin A, actin, Gas2 and fodrin, to produce apoptosis 
morphological characteristics including membrane blebbing, cell shrinkage, chromatin 
condensation and apoptotic body formation (Fan et al., 2005; Herrera-Esparza et al., 
2011).  
1.2.3.3 Apoptosis 
Apoptosis or programmed cell death plays an important role in physiological 
growth and tissue homeostasis. In anticancer research, apoptotic cell death is a crucial 
strategy to kill tumour cells via activation of apoptosis signal transduction pathways: 
intrinsic and/or extrinsic pathways (Bold et al., 1997; Fulda & Debatin, 2006). 
The intrinsic pathway occurs in response to cellular signals resulting from DNA 
damage, a defective cell cycle, hypoxia, loss of cell survival factors, or other types of 
severe cell stress as well as chemotherapeutic drugs (Figure 1.14) (Kaufmann & 
Earnshaw, 2000; Johnstone et al., 2002). Upon cellular stress, the equilibrium of 
activity between pro- and anti-apoptotic members of the Bcl-2 superfamily of proteins 
in a cell will be disrupted. In turn, these pro-apoptotic proteins will be activated and 
induce the opening of mitochondrion permeability transition pores (MPTPs). 
Cytochrome c will be released into the cytosol and it will bind to the adapter apoptotic 
protease activating factor-1 (Apaf-1). The recruitment of cytochrome c, Apaf-1, pro-
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caspase 9, dATP (deoxyadenosine triphosphate) or ATP will form a multi-protein 
complex, known as apoptosome (Tsujimoto, 2001; Adams & Cory, 2002; Marsden et 
al., 2002). Apoptosome aids the cleavage of procaspase-9 to form active caspase-9, and 
later activates caspase-3 and -7, ultimately resulting in cell death (Figure 1.14A).  
The extrinsic pathway begins outside the cell through the activation of specific 
pro-apoptotic receptors on the cell surface, known as the death receptor such as Fas or 
TNFR-1 (Tumour Necrosis Factor receptor-1) (Figure 1.14). These death receptors are 
activated by specific molecules known as pro-apoptotic ligands. These ligands include 
Apo2L/TRAIL and CD95L/FasL which will bind to their cognate receptors DR4/DR5 
and CD95/Fas, respectively (Fulda & Debatin, 2006). This binding induces receptor 
clustering and recruitment of the adaptor protein Fas-associated death domain (FADD) 
and procaspase-8, forming a death-inducing signalling complex (DISC). Formation of 
the DISC will cause an autocatalytic processing in procaspase-8 to form active caspase-
8. Alternatively, caspase-8 will activate effector caspase-3, -6, and -7, thereby 
converging on the intrinsic pathway (Fulda & Debatin, 2006; Liu et al., 2006a). In 
addition, caspase-8 triggers mitochondrion-mediated pathway by cleaving Bid (a pro-
apoptotic Bcl-2 family member) into its active form, truncated Bid (tBid), which 
translocates into mitochondria. The combination of tBid with other proapoptotic Bcl-2 
family members, Bax and Bak, will induce the release of cytochrome c and apoptosis-
inducing factor (AIF) into cytosol. AIF will induce DNA fragmentation and chromatin 
condensation (Figure 1.14B) (Fan et al., 2005; Fulda & Debatin, 2006).   
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Figure 1.14: Schematic diagram illustrating (A) intrinsic and (B) extrinsic pathways of apoptosis (Fan et al., 2005). 
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1.2.3.4 Necrosis 
Necrosis is another type of cell death in multicellular organisms and is derived from 
the Greek “nekros” for corpse. It is a passive form of cell deaths. Necrosis also plays a role 
in some physiological processes such as inner ear development (Zong & Thompson, 2006), 
tissue renewal of small and large intestines (Barkla & Gibson, 1999; Murdoch et al., 1999), 
follicular maturation during oogenesis and loss of interdigital cells in the mouse embryo 
(Chautan et al., 1999; Murdoch et al., 1999).  
It can be initiated by external factors (viruses, bacteria, protozoa, toxins) and 
internal factors such as complements, activated natural killers and peritoneal macrophages 
(Bortner et al., 1997; Dong et al., 1997; Blom et al., 1999; Arantes et al., 2000; Shimizu et 
al., 2000; Warny et al., 2000). In addition, inadequate levels of cytokines, nitric oxide (NO) 
and reactive oxygen species (ROS) secretion in some pathological conditions also causes 
necrotic cells death (Proskuryakov et al., 2003).  
Although apoptosis and necrosis have been defined based on their distinguishable 
morphological criteria, however, they may involve several common signalling and 
execution mechanisms (Leist et al., 1999b). The caspase-independent cell death is likely to 
resemble necrosis as it lacks the typical features of apoptosis (Table 1.2) (Holler et al., 
2000; Leist & Jaattela, 2001; Fan et al., 2005). Adenosine triphosphate (ATP) levels also 
play critical decisive regulatory roles between apoptosis and necrosis. If the amount of ATP 
is below a certain critical level, it can either switch apoptotic cell death to necrosis or 
initiate necrosis by itself (Eguchi et al., 1997; Leist et al., 1999a; Proskuryakov et al., 
2003). In contrast to apoptosis that requires potassium (K
+
) and calsium (Ca
2+
) ions efflux 
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to induce cell shrinkage, necrosis requires sodium ion (Na
+
) influx to induce cell swelling 
(Table 1.2) (Bortner et al., 1997). 
 
Table 1:2:  Differential features of apoptosis and necrosis (Bold et al., 1997; Bortner et al., 
1997; Cohen, 1997) 
Apoptosis Necrosis 
Biochemical characteristic 
Tightly regulated by physiological 
homeostasis 
Initiate by nonphysiological trama 
Activation of caspase cascades 
 
No caspases are require 
Active process (ATP-dependent) 
 
Passive process (no energy require) 
Apoptotic DNA fragmentation 
(demonstrates a "ladder" pattern at ~180bp 
intervals on agarose gels) 
Random DNA fragmentation (demonstrates 
a smear pattern on agarose gels) 
Morphological characteristic 
Formation of membrane blebbing, but no 
loss of integrity 
Loss of membrane integrity 
Formation of apoptotic bodies 
 
Swelling of organelles and eventually cell 
lysis 
Lysosome still intact Lysosomal leakage 
Physiological features 
Death of individual cells Death of groups of cell 
No inflammatory response  Inflammatory response evoked 
Phagocytosis by nearby cells and 
macrophages 
Phagocytosis by macrophages 
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1.2.4 Enabling Replicative Immortality 
Cell cycle is a series of events controlled by complex signalling pathways 
leading to cell DNA replication and division to form new cells. This process possesses 
checkpoints to ensure fidelity or errors (mutated DNA) are corrected, otherwise, the 
cells will be initiated to undergo cell death. In cancer, due to genetic mutations, this 
regulatory process can malfunction and cause uncontrolled cell proliferation (Hartwell 
& Kastan, 1994; Evan & Vousden, 2001). Cell cycle can be divided into four distinct 
phases: G1-, S-, G2- and M-phases (mitosis). M phase is composed of two tightly 
coupled processes: mitosis and cytokinesis. Mitosis is where the cell's chromosomes are 
divided into the two ‘daughter’ cells, while cytokinesis is where the cell's cytoplasm 
divides in half to forms distinct cells (Hartwell & Kastan, 1994; Shapiro & Harper, 
1999).   
There are two key classes of regulatory molecules, cyclins and cyclin-dependent 
kinases (CDKs) that determine a cell's progress through the cell cycle (Figure 1.15). 
During the G1 phase, cyclin D will form a complex with CDKA; cyclin D/CDKA. This 
complex will phosphorylate their negative regulator, the retinoblastoma protein (pRB), 
to release E2F transcription factors. The free E2F will regulate genes needed for the G1 
to S transition. To enter the S phase, cyclin D will be replaced by cyclin E to from 
cyclin E/CDKA complex. During S phase, cyclin A will be produced and its binding 
with CDKA is important for DNA synthesis. At the late S phase, cyclin B will be 
synthesized and is likely to form a complex with CDKA. This complex will promote the 
cell to enter G2 phase (Figure 1.15) (Hartwell & Kastan, 1994; Shapiro & Harper, 1999; 
Evan & Vousden, 2001). CDKIs such as p21 and p27 also play essential roles in 
controlling cell cycle progression by negatively regulating CDK activities (Toyoshima 
& Hunter, 1994; Coqueret, 2003). 
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The relationship between cell cycle and cancer are obviously related, since the 
cell cycle machinery controls cell proliferation while cancer is a disease of 
inappropriate cell proliferation. Progression through the cell cycle is tightly regulated by 
activity of cyclins, cyclin-dependent kinases (CDKs), cyclin-dependent kinase 
inhibitors (CDKIs), growth factors (GFs), their receptors (GFRs), and inhibitory (GFR-
I) factors. Thus, disrupting these controlling factors might cause cell cycle arrest 
(Waldman et al., 1997). Many of the anticancer agents from natural products and 
chemotherapy agents exert their effects via interrupting cell cycle progression (Shapiro 
& Harper, 1999).  
 
Figure 1.15: Schematic representation of cell cycle regulation (Andrietta et al., 2001). 
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1.2.5 Invasion and Metastasis 
About 90% of cancer-associated mortality is caused by cancer metastasis and 
yet it still remains poorly understood in cancer pathogenesis (Hanahan & Weinberg, 
2000; Gupta & Massagué, 2006). It is one of the most challenging complications in 
cancer treatment. Metastasis is a complex and multistep process whereby cancer cells 
spread throughout the body, forming secondary tumours at a distance from its origin 
(primary tumour). Only small fractions from primary tumour are capable of metastasis. 
Metastatic cascades start from; (a) detachment of cancer cells from the primary tumour 
mass, (b) invasion to local tissue stroma, (c) penetration into nearby local lymphatic 
and/or blood vessels, (d) survive within the circulation, (e) arrested in capillaries or 
venules at other organs, (f) penetrate through corresponding parenchyma, (g) adapt to 
the new local microenvironment, and (h) divide to form the new secondary tumour 
(Figure 1.16) (Gupta & Massagué, 2006).  
During metastasis, metastatic cancer cells must acquire five distinct functions 
including interaction with the local microenvironment, migration, invasion, resistance to 
apoptosis, and induction of angiogenesis (Figure 1.16) (Roy et al., 2009). The secretion 
of matrix metalloproteinases is a critical component for metastatic tumour cell to 
migrate to different tissues. Matrix metalloproteinases (MMPs) are zinc-dependent 
endopeptidases that are capable of degrading and remodeling extracellular matrix 
(ECM) process (Gialeli et al., 2011). MMPs have been divided into four distinct groups 
based on their substrate specificity; collagenases, gelatinases, stromelysins and 
matrilysins. The activity of MMPs is tightly regulated by its inhibitor, tissue inhibitors 
of metalloproteinases (TIMPs). The balance between MMPs and TIMPs is largely 
responsible for the remodeling of tissues associated with various physiological 
processes such as embryonic development, angiogenesis, and tissue repair. 
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Dysregulation of this balance is implicated in various diseases including cancer 
invasion and metastasis (Figure 1.16). Thus, MMP have been implicated in progression 
and metastasis of different tumours (Bacac & Stamenkovic, 2008; Roy et al., 2009; 
Gialeli et al., 2011).  
Several members of MMP family have been implicated in the degradation of 
ECM and associated with tumour growth and angiogenesis such as MMP-2 and MMP-
9. Tumour cells always overexpress of MMP enzymes in order to degrade the basement 
membrane, invade a nearby lymphatic and/or blood vessel (intravasation) and 
extravasate at a distant site and invading the surrounding tissue in order to form 
secondary tumours. Besides ECM components, MMPs also can degrade other 
molecules including growth factor precursor (e.g. VEGF, FGF) to induce angiogenesis. 
Activation of growth factors and cleavage of adhesion molecules are believed to 
attribute to MMP-induced EMT (Bacac & Stamenkovic, 2008; Roy et al., 2009). 
Epithelial–mesenchymal transition or transformation (EMT) is a hallmark of cancer 
progression to metastasis. It is the process that allows an epithelial cell to lose its 
interaction with the basement membrane and possesses a mesenchymal cell phenotype, 
which includes enhanced migratory ability, invasiveness, and resistance to apoptosis 
(Yilmaz & Christofori, 2009; Singh & Settleman, 2010). In addition, degradation of E-
cadherin by MMPs could disrupt cell-cell interactions and integrins between tumour 
cells and ECM which enhances the migration and invasion of tumour cells (Noë et al., 
2001; Bacac & Stamenkovic, 2008; Bourboulia & Stetler-Stevenson, 2010).  
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Figure 1.16: Schematic representative of cascade steps in cancer metastasis (Bacac & 
Stamenkovic, 2008). 
 
  
  
52 
 
1.2.6 Angiogenesis 
Angiogenesis, or neovascularisation, is a term referring to the physiological 
process of new blood vessels formation as an extension from the pre-existing blood 
vessel. Angiogenesis plays a fundamental role in tumour growth and metastasis and has 
been labelled as one of the hallmarks of cancer. Therefore, tumour growth and 
metastasis depends on angiogenesis and remains a main cause of high cancer morbidity 
and mortality rates. Besides providing oxygen and nutrients for tumour growth, 
angiogenesis also provides a path to allow the tumour cells to metastasize (Weidner et 
al., 1991; Zetter, 1998; Kerbel, 2000).  
A tumour will produce and release angiogenic growth factors such as vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), basic 
fibroblast growth factor (bFGF) and angiopoietin. These angiogenic growth factors will 
bind to their respective receptors on the surface of endothelial cells (EC) in nearby pre-
existing blood vessels. This binding will activate ECs to proliferate and start producing 
several proteases including MMP enzymes. ECs will migrate out through the degraded 
basement membrane (BM) of vessel walls by MMP enzymes, towards the tumour mass. 
Adhesion molecules such as integrins (αvß3 and αvß5) will guide the sprouting new 
blood vessel (remodeling of EC) to sprout forward to the tumour. Besides degradation 
of ECM, MMPs also degrade other components in the tissue in front of the sprouting 
vessel tip in order to provide space for new vessel to grow forward. As the new blood 
vessel extends, the surrounding tissue is remolded around the vessel and the sprouting 
EC will roll up to form a blood vessel tube. Combination of individual blood vessel 
tubes will form blood vessel loops that can circulate blood. Finally, newly formed blood 
vessel tubes will be stabilized by specialized muscle cells (smooth muscle cells and 
pericytes) that provide structural support (Figure 1.17) (Li et al., 2012).  
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In the absence of angiogenesis, tumours cannot grow exceeding the size of 2 mm 
diameter and this small size is limited for simple diffusion of nutrients and oxygen and 
the removal of waste from the tumour. Therefore, this limitation of growth leads to 
tumour dormancy for many years in human body (Folkman, 1974; Weidner et al., 
1991). Tumour-induced blood vessels are weaker than normal vessels because tumour-
associated endothelial cells are abnormal in shape and grow on top of each other, and 
thus lead the tumour vessels to be highly disorganized, thin walled, leaky, an irregular 
diameter with less supporting pericytes and smooth muscle cells. Therefore, tumour 
angiogenesis is now an active area of promoting research for cancer therapy. 
 
Figure 1.17: Schematic representation of the tumour angiogenesis cascade  (Li et al., 
2012). 
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1.2.7 Reprogramming of Energy Metabolism 
A fast-growing cancer cell requires an adjustment in its energy metabolism to 
continuously supply the building blocks required for continuously growth and division. 
Under aerobic conditions, glucose is the main energy source that will convert to 
pyruvate via glycolysis and the subsequently released free energy is used to generate 
ATP and NADH in mitochondria. However, under anaerobic conditions, normal cells 
will undergo apoptosis due to stress on the mitochondria. In contrast, cancer cells can 
reprogram their glucose metabolism and energy production, by limiting their energy 
metabolism in mitochondria. This reprogramming of energy metabolism in cancer cells 
is known as the “Warburg effect” after Otto Warburg (Warburg, 1956; Kim & Dang, 
2006; Vander Heiden et al., 2009).  
This reprogramming of energy metabolism has allowed cancer cells to reduce 
their ATP production 18-folds than in normal cells. To compensate the efficiency of 
ATP production, cancer cells have up-regulated their glucose transporters, notably 
GLUT1 to increase glucose intake into the cytoplasm (Airley et al., 2001; Jones & 
Thompson, 2009; Veronica et al., 2010). The markedly increase of glucose uptake by 
human tumours is observed with a radiolabeled analog of glucose (18F-
fluorodeoxyglucose, FDG), used as a reporter in positron emission tomography (PET)  
(Gillies et al., 2008).  
The rapid growth of cancer cells usually outpaces the new blood vessel 
generation, and hence results in insufficient blood supply/oxygen to the tumour tissues, 
and thus causes the cancer cells fall into a hypoxic, or oxygen deprivation state. There 
are two major regulators in hypoxic stress; hypoxia-inducible factors (HIF-1α and HIF-
1β). The importance of these transcription factors in tumour cell survival is reflected in 
the finding where the levels of HIF-1α in glioma tumour cells is proportional to the 
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grade of the tumour (Zagzag et al., 2000). During tumour progression, HIF-1 induces 
several glycolytic enzymes and glucose transporters such as aldolase A and pyruvate 
kinase M to produce energy in hypoxic environments (Schäfer et al., 1997; Discher et 
al., 1998). In addition, HIF-1 decreases mitochondrial oxygen consumption by 
regulating pyruvate dehydrogenase kinase I and inhibiting the citric acid cycle 
(Papandreou et al., 2006). 
During activation of the hypoxia pathway, the mRNA of HIF-1α is transcribed 
by binding of specificity protein 1(Sp1), P300, and HIF-1β on HIF-1α gene in the 
nucleus. In normal cells, HIF-1α is either hydroxylated and ubiquinated, or mostly 
degraded by proteasomes (under normal oxygen conditions) (Discher et al., 1998). 
However, during hypoxic condition, HIF-1α will re-enter the nucleus and form a 
transcription complex with the HIF-1β subunit (Schäfer et al., 1997). This complex will 
regulate its target genes such as vascular endothelial growth factor (VEGF) and 
cathepsin D to induce new blood vessels production, or angiogenesis to supply more 
oxygen and nutrients for tumour growth (Figure 1.18).  
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Figure 1.18: Schematic representation of the hypoxia-inducible factor (HIF)-1 pathway 
(Ziello et al., 2007). 
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1.2.8 Evading Immune Destruction 
The immune system is the defense system in the human body that monitors 
tissue homeostasis by providing protection against infectious pathogens and eliminates 
damaged cells including cancer cells. However, the interaction of immune system and 
tumour progression is still poorly understood. A tumour is believed to possess the 
capability of avoiding detection by the immune system or have been able to limit the 
extent of immunological killing, thereby evading eradication (Vajdic & van Leeuwen, 
2009; Hanahan & Weinberg, 2011).  
Studies found that immunodeficient mice that lack different components of the 
immune system are likely to develop tumours than immunocompetent mice (Hanahan & 
Weinberg, 2011). Several studies have showed that tumours arose more frequently 
and/or grew more rapidly in the immunudeficient mice, particularly lacks of CD8+ 
cytotoxic T lymphocytes (CTLs), CD4+ Th1 helper T cells, or natural killer (NK) cells, 
relative to immunocompetent mice (Kim et al., 2007; Teng et al., 2008). These studies 
indicate that both the innate and adaptive cellular immune system plays a significant 
role in immune surveillance and thus eradication of the tumour (Kim et al., 2007; 
Nelson, 2008; Teng et al., 2008).   
A better prognosis is seen in colon and ovarian tumour patients which is heavily 
infiltrated with CTLs and NK cells compared to those that lack these cells  (Nelson, 
2008). Cancer cells may evade from destruction by inhibiting some components in the 
human immune system and/or modulated their surface receptors to escape from immune 
surveillance. For example, cancer cells can inhibit CTLs and NK cells through the 
secretion of TGF-β or other immunosuppressive factors (Shields et al., 2010; Yang et 
al., 2010) or by activation of regulatory T cells (Tregs) and myeloid-derived suppressor 
cells (MDSCs) which inhibits the actions of cytotoxic lymphocytes. 
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1.3 Natural Products 
1.3.1 History and background of the use of natural products as therapeutics 
agents   
Since the dawn of human history, humans have relied on plants and herbs as 
vital source for survival. Besides being a mainstay of nutrition, plants and herbs are also 
plays an important role in the treatment of illness. The earliest records on the usage of 
natural products in the treatment is including cuneiform in Mesopotamia, Chinese herbs 
guide documents and Ayurvedic hymns (Cragg & Newman, 2005; Ji et al., 2009). One 
of the best examples is the discovery and development of Artemisinin (antimalaria 
drug) from Artemisia annua L, which was used in China for almost 2000 years for 
treating various infectious and chronic conditions (van Agtmael et al., 1999).  
By definition, a natural product refers to a compound that is present in or 
produced naturally and not man-made or artificial. Natural product can originate from 
microbes or plants sources (Table 1.3). Generally, a natural product is the common term 
for herbs, dietary supplements, traditional Chinese medicine, or alternative medicine 
(Cragg & Newman, 2005).  
Natural product-based traditional medicine, often overshadowed by modern 
medicine, has returned to be an alternative approach for health care in many societies. 
The World Health Organization (WHO) estimated about 80% of world’s populations 
still relies on traditional medicines as primary health care. Although the number of 
natural products based drugs introduced to market is low, but the interest of these drugs 
has not dropped in worldwide pharmaceutical companies (WHO, 2008). This is because 
the degree of chemical diversity and novelties of molecular structures found in natural 
products are broader than any sources. In addition, natural products are sometimes 
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preferred in medicine due to the fact that they can balance the combination of 
therapeutic effects with minimum side effects. The importance of natural products as 
therapeutic agents has stated by N.R. Farnsworth, an eminent scientist in ethnobotanical 
field; “each plant is a unique chemical factory capable of synthesizing an unlimited 
number of highly complex and unusual chemical substances whose structures could 
escape the imagination of synthetic chemists could” (Farnsworth et al., 1985).  
The plant-derived natural products have widely used in medicine including as 
antipyretics, neurotransmission modulators, antihypertensive agents and anti-
inflammatory agents. Narcotic morphine is the ﬁrst commercial pure natural product 
which was marketed by Merck in 1826 (Newman et al., 2000). In 1899, Bayer 
introduced the ﬁrst semisynthetic pure drug based on a natural product, aspirin 
(Spainhour, 2005). 
1.3.2 Plants as source of anticancer agents 
Chemotherapy is deemed relatively unsuccessful due to its ineffectiveness, 
safety issues and costliness. As not all cancer patients respond positively to current 
anticancer agents, mortality rates of cancer are on a continuous rise. Therefore, 
scientists have begun to focus on natural-products as alternatives to produce new 
therapeutic agents for cancer treatments. Herbs and plants-derived medicines have a 
long history of use in various treatments and now, they still remain as important sources 
for the development of anticancer drugs. More than 3000 plants species have been 
reported to be involved in the development of anticancer drugs (Shoeb, 2006). The 
exploration of anticancer agents from plant sources started in the 1950s. Since then, 
extensive research has been conducted and has led to the discovery and development of 
several anticancer agents derived from plants such as taxol, vinblastine and vincristine. 
From 1940-2006, more that 40% of drugs in the market are anticancer agents and 65% 
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of these anticancer drugs mimic natural compounds (Cragg & Newman, 2005). Some 
example of anticancer agents derived from natural products include zapotin (Casimiroa 
edulis, apoptotic inducer); apigenin (Mezoneuron cacullatum, antimutagenesis); and 
resveratrol (Cassia quinquangulata, cyclooxygenase inhibitor) (Table 1.3) (Holt & 
Chandra, 2002; Shoeb, 2006). 
Besides as a direct medical application as drug, natural products could also serve 
as templates for the design, synthesis, and semisynthesis of new compounds. Paclitaxel 
and vincristine are the two examples of semisynthetic compounds used in the treatment 
of human cancers. Natural product provides those treating cancer with new avenue of 
treatment of the most aggressive forms of the disease (Farnsworth et al., 1985; Cragg & 
Newman, 2005; Shoeb, 2006).  
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Table 1:3:  Natural products-plant derived anticancer drugs (Pezzuto, 1997; da Rocha et al., 2001; Amin et al., 2009). 
           Compound Trade name Action Cancer Plant Source 
1. Docetaxel Taxotere Anti-mitotic Breast, ovarian, and prostate lung cancers 
 
Taxus brevifolia 
2. (a) Etoposide 
 
(b) Teniposide 
Eposin, VP-16, 
 
Vumon, VM-26 
 
Inhibits topoisomerase 
II 
Lung, prostate, testicular cancers, lymphoma, 
leukemias, Ewing's sarcoma and brain 
tumour. Restinoblastoma, ALL. 
 
Podophyllum peltatum 
3. (a) Irinotecan 
 
(b) Topotecan 
Camptosar, Campto 
 
Hycamtin 
 
Inhibits topoisomerase I Colon, ovarian, cervical and rectal cancers, 
small lung cancer cell (SLSC) 
Camptotheca 
acuminate 
 
4. Paclitaxel Taxol, Onxal Anti-mitotic Ovarian, breast, melanoma, lung, bladder, 
prostate, head and neck cancers,  
 
Taxus brevifolia 
5. (a) Vinblastin  
 
(b) Vincristine 
 
Velban, velbe 
 
Oncovin 
Anti-mitotic Lung, breast and testicular cancer, leukemia 
lymphoma 
 
Catharanthus roseus 
6. Combresastin Combretastatin A4 Inhibits topoisomerase I Liver, prostate, breast and lung cancers Combretum caffrum 
 
7. Homoharring-
tonine 
Myelostat, 
Ceflatonin 
Anti-angiogenesis, 
apoptosis inducer  
Leukemia Cephalotaxus 
harringtonia 
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1.4 Phyllanthus 
1.4.1 History and conventional usage of Phyllanthus  
Phyllanthus is the largest genus in the family of the Phyllanthaceae 
(Euphorbiaceae s.l.). It is widely distributed throughout the tropical and subtropical 
regions of world including Malaysia, India, Brazil, Cuba and the Amazon (Lee et al., 
1996; Etta, 2008). To date, there are more than 700 species of Phyllanthus have been 
reported (Unander et al., 1990) that includes P. amarus, P. elegans, P. emblica L., P 
caroliniensis P. flexuosus, P. reticulatus, P.discoideus, P. muellerianus, P. multiﬂorus 
Willd., P. tenellus Roxb,  P. virgatus Forst. f., P. urinaria L., P. niruri, P. reticulatus, P. 
conami Sw, P. lathyroides, P. casticum and P. madagascariensi. In different countries, 
Phyllanthus is known by different names such as “Dukung Anak” in Malaysia, “Hsieh-
hsia Chu” in China, “Quebra Pedra” in Brazil and in India, it known as “Pitirishi” 
and/or “Budhatri” (Taylor, 2003). 
This plant has a long history in the medical herbalism system. It is mainly used 
to treat kidney and urinary bladder disturbances. In Ayurvedic medicine, Phyllanthus 
has a long tradition of use to treat jaundice, gonorrhea, frequent menstruation, dysentery 
and diabetes as well as skin ulcers, sores, swelling, and itchiness (Calixto et al., 1998). 
In Traditional Chinese Medicinal (TCM), Phyllanthus has been used for generations to 
eliminate gallstones and kidney stones, as well as an immune system stimulator (Taylor, 
2003). 
Due to different climates and geographically regions, Phyllanthus grows in 
different forms such as annual and perennial herbs, shrubs, and pachycaulous succulents 
in order to survive. It can grow up to 12-24 inches in height and blooms with many 
greenish white flowers. One of the famous Phyllanthus species is P.niruri. In Amazon, 
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it is named as “stone breaker” due to its effectiveness in the elimination of gallstones 
and kidney stones and other treatments including diabetes and intestinal infections 
(Taylor, 2003). Table 1.4 shows the various usage of Phyllanthus niruri in different 
societies. 
  
 
Figure 1.19: P.urinaria (Fito Pharma 2011), P.amarus (Find me cure, 2011) and 
P.niruri (GardenSeed, 2011). 
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Table 1:4: Worldwide ethnobotanical uses of P. niruri (Taylor, 2003). 
Region Uses 
Amazonia Anodyne, apertif, blennorrhagia, carminative, colic, diabetes, digestive, 
diuretic, dropsy, dysentery, dyspepsia, emmenagogue, fever, flu, gallstones, 
gonorrhea, itch, jaundice, kidney aliments, kidney stones, laxative, malaria, 
proctitis, stomachache, stomachic, tenesmus, tonic, tumour, vaginitis, 
vermifuge 
 
Bahamas/ 
Caribbean 
Antihepatotoxic, antispasmodic, appetite stimulant, antiviral, aperitif, 
bactericidal, cold, constipation, diuretic, fever, flu, hypoglycemic, laxative, 
stomachache, typhoid 
 
Brazil Abortifacient, ache (joint), albuminuria, analgesic, antibacterial, 
anticancerous, antidiabetic, anti-inflammatory, antilithic, antispasmodic, 
antiviral, aperient, arthritis, biliary conditions, bladder problems, bladder 
stones, calculi, catarrh (liver and kidney), chologogue, cystitis, deobstruent, 
diabetes, diaphoretic, digestion stimulant, diuretic, fever, gallbladder, 
gallstones, gastritis, gastrointestinal problems, gout, hepatitis, 
hepatoprotective, hydropsy, hypertension, hypoglycemic, jaundice, kidney 
colic, kidney pain, kidney stones, liver, m alaria, muscle relaxant, obesity, 
prostatitis, purgative, renal colic, renal problems, stomachic, sudorific, tonic, 
uric acid excess, urinary problems, uterine relaxant 
 
Haiti Carminative, colic, digestive, diuretic, fever, indigestion, malaria, 
spasmolytic, stomachache, stomachic, tenesmus 
 
India Anemia, asthma, astringent, bronchitis, conjunctivitis, cough, deobstruent, 
dropsy, diabetes, diarrhea, diuretic, dysentery, fevers, eye disorders, 
galactagogue, genitourinary disorders, gonorrhea, hepatitis, jaundice, 
leucorrhea, menorrhagia, oligogalactia, ringworm, scabies, stomachic, thirst, 
tuberculosis, tumour (abdomen), urogenital tract infections, warts 
 
Malaysia Caterpillar sting, dermatosis, diarrhea, diuretic, emmenagogue, itch, 
miscarriage, piscicide, purgative, renosis, syphilis, vertigo 
 
Peru Calculus, diuretic, emmenagogue, gallstones, hepatitis, kidney pain, 
kidney problems, kidney stones, renal problems, urinary infections, 
vermifuge 
 
United States Analgesic, bronchitis, chologogue, deobstruent, diabetes, fever, 
gallbladder problems, gallstones, gout, hepatitis, hypertension, kidney 
problems, kidney stones, liver disease, uric acid excess, urinary tract 
infections 
 
Elsewhere Analgesic, antipyretic, appetite stimulant, blennorrhagia, bruises, 
chologogue, cough, cuts, diabetes, diarrhea, diuretic, dropsy, dysentery, 
dyspepsia, emmenagogue, eye diseases, fever, gallstones, gonorrhea, itch, 
jaundice, kidney disease, kidney stones, laxative, malaria, menorrhagia, 
menstrual problems, poultice, purgative, rectitis, stomachache, tonic, 
tuberculosis, urinary tract infections, vaginitis, venereal diseases 
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1.4.2 Scientifically proven pharmacological activities of Phyllanthus and its 
constituents 
Phyllanthus is believed to have originated from India and by the late 1980s, 
these plants have gained attention from scientists worldwide. One of its species, P. 
niruri has showed clinical efficacy against viral Hepatitis B (Calixto et al., 1998; Padma 
& Setty, 1999). Therefore, substantial studies of this genus regarding its chemistry, 
pharmacological activity and clinical effectiveness have been extensively carried out. 
The extract of these plants had been reported to have a variety of pharmacological 
effects and is listed in Table 1.5.  
 
Table 1:5: Various pharmacological activities of Phyllanthus species. 
Pharmacological 
activities 
Description 
Antiviral  Inhibits cellular proliferation, DNA polymerase, hepatitis B 
surface antigen (HBsAg) gene expression  
(Venkateswaran et al., 1987; Blumberg et al., 1990; Yeh et al., 
1993; Ott et al., 1997; Huang et al., 2003; Lee et al., 2003a) 
 
 Growth inhibitions of HIV-1 and HIV-2  
(Venkateswaran et al., 1987; Naik & Juvekar, 2003) 
  
Antibacterial  Growth inhibitions of Escherichia coli, Enterococcus faecium, 
Pseudomonas aeruginosa, Staphylococcus aureus, 
Mycobacterium smegmatis, Bacillus stearothermophilus, 
Bacillus subtilis, Micrococcus leuteus, Salmonella typhi, 
Enterobacter aerogenes, Proteus mirabilis, and Proteus vulgaris 
(Mensah et al., 1990; Mazumder et al., 2006; Komuraiah et al., 
2011) 
 
Hepatoprotective 
and 
gastroprotective  
 Reduces liver infiltration, focal necrosis and intracellular level of 
reactive oxygen species  
(Lee et al., 2006a; Naaz et al., 2007) 
  
 Protects liver tissues against oxidative damage and improves 
liver repair mechanism  
(Bhattacharjee & Sil, 2006) 
 
 Gastroprotective (Shokunbi & Odetola, 2008) 
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Hypoglycaemia or 
anti-diabetic 
 Hypoglycemic effect 
(Raphael et al., 2002; Adeneye et al., 2006; Kumar et al., 2008) 
 
Anticancer and 
antitumour 
 Anticancer properties against liver, renal,  breast, colon, lung, 
cervical, ovarian, colorectal, melanoma and leukemia cancer 
cells 
(Pettit et al., 1984; Jeena et al., 1999; Rajeshkumar & Kuttan, 
2000; Huang et al., 2004b; Rajkapoor et al., 2007; Ratnayake et 
al., 2008; Ngamkitidechakul et al., 2010) 
 
 Antitumour properties against sarcoma, Dalton's Lymphoma 
Ascites (DLA),  Ehrlich Ascites Carcinoma (EAC), 
hepatocarcinoma, and skin tumour 
(Rajeshkumar & Kuttan, 2000; Rajeshkumar et al., 2002; 
Ngamkitidechakul et al., 2010) 
 
 
Others  Diuretic and hypotensive effects 
(Srividya & Periwal, 1995) 
 
 Antioxidant properties  
(Khopde et al., 2001; Kumaran & Joel Karunakaran, 2007) 
  
 Lipid lowering activity  
(Khanna et al., 2002)  
 
 Anti-inflammatory effect 
 (Ihantola-Vormisto et al., 1997; Kiemer et al., 2003) 
 
 Antinociceptive effect  
(Santos et al., 1995; Santos et al., 2000) 
 
 Analgesic effect  
(Santos et al., 1994) 
 
 Antimalaria 
 (Totte et al., 2001) 
 
 Antimutagenic and antigenotoxic properties  
(Sripanidkulchai et al., 2002) 
 
 Anti-babesial and anti-plasmodialactivity 
(Totte et al., 2001; Subeki et al., 2005) 
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1.5 Justification and Objectives of the Study 
Melanoma is the most fatal form of skin cancer, with higher morbidity and 
mortality rates in fair-skinned populations, whereas, prostate cancer remains one of the 
major life-threatening cancers in men. Typically, tumour metastasis is the main cause 
for high morbidity and mortality rates in cancer patients. Currently, the best treatments 
for melanoma and prostate cancers include patient management as well as standard 
treatments to control metastasis such as chemotherapeutic drugs, surgery and/ or 
radiation therapy. Conversely, these treatments are often accompanied by undesirable 
side effects such as vomiting, nausea and alopecia. Distressingly, not all cancer patients 
respond positively to current anticancer agents and the mortality rates have increased 
inspite of treatment. Hence, intense effort is required to acquire anticancer agents that 
have minimal side effects and could also target cancer metastasis. 
Natural product-based traditional medicine, is often overshadowed by modern 
medicine, has returned to be a holistic approach for health care in many societies. This 
“back to basic” approach is due to its long history of usage in disease treatment and the 
pharmacological/nutritional value of these products are believed to be able to halt/delay 
cancer progression. The well-known examples of plant-derived anticancer drugs include 
taxol (antimicrotubule agent) and vincristine (mitotic inhibitor) (Shoeb, 2006). Herb- 
and plant-derived medicines that are widely used in traditional cultures have gained 
popularity in modern society as natural alternatives to produce new potential therapeutic 
compounds (Shoeb, 2006).  
Phyllanthus plant is widely distributed in subtropical and tropical regions. A 
variety of pharmacological effects have been reported including antiviral, antibacterial, 
anti-hepatotoxic as well as having anti-diabetic properties. These effects are mainly 
attributed to the presence of various of bioactive compounds in Phyllanthus plant such 
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as gallic acid, ellagic acid, corilagen and rutin. Most of these bioactive compounds have 
been well-documented for their pharmacological effects. However, as no individual 
class of components could be fully responsible for the activity/effect produced by a 
whole extract, therefore it is more meaningful to assess the activity of Phyllanthus 
extract as a whole mixture of bioactive compounds rather than as their individual 
compounds. 
Hence, in this study the anticancer properties of four species of Phyllanthus 
(P.amarus, P.niruri, P.urinaria and P.watsonii) against two high metastatic potential 
cancer cell lines; a human melanoma (MeWo) and prostate adenocarcinoma (PC-3), 
were evaluated. The main aims of this study were to identify the anti-proliferation, anti-
metastasis, anti-angiogenesis properties, apoptosis induction and mechanisms of 
inhibition of Phyllanthus plant extracts on these cancer cells. 
Hence the objectives of this study were: 
1. To investigate the anti-proliferative effects of four plants species of Phyllanthus 
(P.amarus, P. niruri, P.urinaria and P. watsoni) on two human cancer cell lines; 
namely MeWo and PC-3 cells and their respective normal cell lines (CCD-
1127Sk and RWPE-1).  
2. To study the mechanism of cell death induced by Phyllanthus extracts. 
3. To investigate the anti-metastasis properties of Phyllanthus extracts 
4. To investigate the anti-angiogenesis properties of Phyllanthus extracts 
5. To investigate the underlying anti-carcinogenic mechanisms (cell signalling 
pathway and protein-protein interaction) of Phyllanthus extract.  
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CHAPTER 2: METHODOLOGY 
2.1 Cell Culture and Maintenance  
2.1.1 Normal and Cancer Cell Lines 
In this study, human skin melanoma cells, MeWo (ATCC: HTB-65) and prostate 
adenocarcinoma cells, PC-3 (ATCC: CRL-1435), normal human skin cells, CCD-
1127Sk (ATCC: CRL-2565) and normal human prostate cells, RWPE-1 (ATCC: CRL-
11609) as well as human umbilical vein endothelial cells, HUVECs (ATCC: CRL-
2873) were used. All these cell lines were purchased from American Type Culture 
Collection (ATCC) and cultured with different media, EMEM (Eagle’s minimum 
essential medium) for MeWo cells, RPMI-1640 (Roswell Park Memorial Institute) for 
PC-3 cells, keratinocyte growth medium-chemically defined, KGM™-CD medium 
(CC-4455, Lonza, USA) for RWPE-1 cells, DMEM (Dulbecco’s modified Eagle 
Medium) for CCD-1127Sk cells and endothelial growth media, EGM-2 Bullet Kit (CC-
3162, Lonza, USA) for HUVECs. Growth media were supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Flowlab, Australia). All cells were grown in 5 ml 
in 25 cm
2
 flasks or 20 ml in 75 cm
2
 flasks (Nunc, Denmark). Cells were maintained at 
37°C under humidified air with 5% CO2. Cells were harvested using 0.25% trypsin-
EDTA (Hyclone) when they reach 70–80% confluency in culture flasks. Cells 
undergoing exponential growth were used throughout the experiments. 
2.1.2 Culture Medium 
KGM™-CD (Chemically Defined) and EGM-2 BulletKit media were purchased 
from Lonza and were supplemented with SingleQuots™ Kit, consisting of essential 
growth factors, cytokines, and supplements. Culture media (EMEM, DMEM and 
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RPMI-1640) were purchased from Flowlab, Australia and stored at 4°C until further 
reconstitution for use. The powder was reconstituted by dissolving the medium together 
with 3.7 g of sodium bicarbonate and 4.7 g of HEPES (Sigma-Aldrich, Ireland Ltd) in 
one liter of sterile double-distilled water or milliQ water. After complete dissolution of 
the powder, the medium was then filter-sterilized with 0.2 µm membrane filter 
(Nalgene, USA) using air pressure from a machine diaphragm pump. The medium was 
stored at 4°C till further use. Fetal Bovine Serum (FBS, Flowlab, Australia) was heat 
inactivated at 56°C for 30 minutes, aliquoted into 50 ml tubes (Nunc, Germany) and 
stored at -20°C till required for reconstitution as complete growth medium. Heat-
inactivated FBS was added freshly into medium at 10% concentration just before use.  
2.1.3 Culture Technique 
All cell culture procedures were conducted under sterile conditions in a vertical 
flow hood (Microflow, Birmingham, UK) to avoid contaminations. Cell passaging is the 
process of splitting cultured cells to yield large or low number of cells from pre-existing 
cells, depending on the purpose. Briefly, old growth media was discarded, rinsed with 
sterile PBS and trypsinized with trypsin-EDTA (0.25%) for 5 minutes. The detached 
cells were resuspended in serum-containing growth medium and the suspension was 
gently aspirated few times to avoid cell clumps. At ratio 1:1, cell suspension was mixed 
with 0.2% trypan blue solution (Sigma-Aldrich, Ireland Ltd) and loaded into the 
haemocytometer chamber. The cells were counted under an inverted microscope 
(Olympus CK-40).   
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The calculation of cell number in 1ml of solution is as following:  
  Cell number/1 ml = A x B x C  
  Where,  
  A = average number of cells counted in four large corner squares,  
  B = dilution factor is 2 (1:1 dilution of cell suspension with trypan blue), and 
  C = volume of 0.1 mm
3
 square is equivalent to 10
-4 
ml but substitute with 10
4
 in        
calculation as for conversion factor to convert 10
-4 
ml to 1 ml.  
Cryoperservation of the cells was performed to store the cells in liquid nitrogen 
for future use. The freezing medium consists of culture medium, pure fetal bovine 
serum (FBS) and the freeze substitute, dimethyl sulphoxide (DMSO, Sigma-Aldrich, 
Ireland Ltd) at 6:3:1 ratio. Briefly, cell suspension was spun down at 1,500 rpm 
(Eppendorf Centrifuge 5810R, Germany) for 10 minutes at 4°C. Cell pellet was 
resuspended with freezing medium and transferred to a cryogenic vial (Nunc, Denmark) 
at 2x10
6
 cell/vial. The vial was tightly capped, properly labeled with cell line, passage 
number, and date of freeze down, and placed in a freezing container which was then 
stored at -80°C overnight before transferring it into the liquid nitrogen tank for long 
term storage. 
Cryopreserved cells from the liquid nitrogen were thawed when required for 
experiments. Briefly, cryogenic vial was thawed by rapid agitation of in a 37°C water 
bath (Memmert). Contents in cryovial were transferred to a 25 cm
2
 culture flask 
containing warm growth media and incubated overnight. On the following day, the flask 
was rinsed with PBS to remove any floating dead cells and residual DMSO and 
replaced with new growth medium. 
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2.2 Preparation of Serial Dilutions of Samples and Standard Anticancer Drugs   
Aqueous and methanolic extracts of four different species of Phyllanthus 
(P.amarus, P.niruri, P.urinaria, and P.watsonii) were prepared and provided by Dr. 
Indu Bala, Biotechnology Centre, Malaysian Agricultural Research and Development 
Institute (MARDI). The freshly harvested whole plants (P.amarus, P.niruri, P.urinaria, 
and P.watsonii) except the root part were collected, washed, and dried at room 
temperature. The dried materials were cut into smaller pieces and freeze dried with 
liquid nitrogen into powder form. For the aqueous extract, the dried sample was mixed 
with extraction buffer (ultra pure water, diethyldithiocarbamic acid and formic acid), 
while absolute methanol was used for the methanolic extract. The mixtures were then 
centrifuged at 8,900 rpm at 4°C for 5 minutes. The supernatant was collected after three 
rounds of extraction and filtered with 15 WHATMAN No.4. The powder form of each 
extract was prepared after vacuum dried and kept at -20°C. For the experiment, the 
master stock of aqueous extract (10 mg/ml) and methanolic extract (40 mg/ml) were 
prepared by dissolving into sterile miliQ water and DMSO, respectively. Standard 
anticancer drugs, Doxorubicin (Dox) and 5-Fluorouracil (5’FU) were used as positive 
control in this study. Master stock of plant extracts and standard drugs were aliquoted 
into 1 ml tubes and kept at -20°C. 
2.3 High performance liquid chromatography coupled with electronspray 
ionization (ESI) and mass spectrometry (LCMS- MS) analysis 
For aqueous extracted samples, 2 ml of supernatant was dried in a vacuum 
concentrator (Concentrator 5301 eppendorf, Germany) and re-dissolved into 20 mg/ml 
with 30% methanol before being subjected for LC-MS-MS analysis. For those samples 
extracted with methanol, total supernatant was evaporated using rotary evaporator 
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(Rotavapor RII, BUCHI, Switzerland) and re-dissolved again with 20% methanol. 
Samples were then separated with solid phase extraction (SPE) column (LiChrolut RP-
18, 1000 mg/6 ml, Merck, Germany) with mobile phase of 60% methanol and 70% 
methanol. All elutes were concentrated to 0.5 ml, then diluted 8 times with 40% 
methanol before being subjected for LC-MS-MS analysis.  
Samples were separated using HPLC system comprising of a HPLC binary 
pump, an autosampler injector compartment and diode array detector (DAD) (1200 
series, Agilent Technologies, Germany). Separations were carried out using a reverse 
phase C- 18, 150 mm X 4.6 mm i.d, 5 µm particle size Thermo Hypersil GOLD column 
(Thermo Scientific, UK). Separation was developed using a mobile phase of 0.1% 
formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) with a 
gradient setting of solvent B: 5% (5 min), 5–90% (60 min), 5% (4 min) at flow rate of 1 
ml/min. The injection volume was set at 20µl and the detections were both at 280 nm 
and 360 nm. For mass spectrometry analysis, 3200 QTrap LC/MS/MS system (Appiled 
Bioscience – MDS Sciex) was used with the iron source and voltage was maintained at 
500°C and -4.5 kV for negative ionization, respectively. Nitrogen generator was set to 
be operated at 60 psi curtain gas flow, 90 psi source gas flow and 60 psi exhaust gas 
flow. Two types of scanning modes were chosen: enhance mass spectrometer (EMS) 
and enhance ion product (EPI) for a full scan mass spectra ranging from m/z 100–1200. 
2.4 Assessment of Cancer Cell’s Proliferation 
The anti-proliferative activity of Phyllanthus was measured using a 
colourimetric MTS assay, which is composed of solutions of a novel tetrazolium 
compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphonyl)-
2H-tetrazolium, inner salt, MTS and an electron coupling reagent (phenazine 
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methosulphate; PMS) (Promega, Madison, WI). This assay is based on the cleavage of 
the yellow dye MTS to purple formazan crystals by dehydrogenase activity in 
mitochondria of viable cells (Husoy et al., 1993). Cancer (MeWo and PC-3) and normal 
(CCD-1127Sk and RWPE-1, HUVECs) cells in cultured flasks were washed thoroughly 
with sterile PBS (1X), collected by addition of trypsin-EDTA (1X) solution and re-
suspended in the culture medium. The cancer and normal cell lines were then counted 
and seeded at 1x10
5
 cells per well in a 96-wells flat-bottom plate. For endothelial cells 
(HUVECs), cells were seeded at 5x10
3
 cells per well into a fibronectin pre-coated 96-
well plate. The seeded cells were incubated overnight at 37°C for cell attachment.  
The master stock solution of Phyllanthus crude extracts were serially diluted and 
added to the cells to reach a final concentration at a range of 31.3–500.0 µg/ml and 
further incubated for 72 hours. The percentage of DMSO in working concentration of 
methanolic extracts was not exceeding 1.3% to avoid toxicity to cell. Anticancer drugs, 
Doxorubicin (Calbiochem, USA) and 5’Fluorouracil (Duchefa, The Netherlands) were 
used as positive controls for PC-3 and MeWo cells, respectively. In addition, the 
fractions of crude aqueous extract of Phyllanthus species, fraction 1 and 2 were also 
tested for their anti-proliferative effect on normal and cancer cells for comparison with 
the crude extracts. After 72 hours, the cytotoxicity screening was performed using 
CellTiter 96®AQueous Non-Radioactive Cell Proliferation Assay kit (Promega, USA), 
according to the manufacturer’s instructions. Briefly, an equal volume of MTS/PMS 
solution was added in each well and the plate was stored in dark for an hour before 
determining their absorbance at 490 nm with the reference wavelength at 600 nm using 
GloMax Multi Detection System (Promega, USA). The absorbance is directly 
proportional to the number of viable cells in the culture. At least three replications for 
each sample were used to determine the anti-proliferative activity. The percentage of 
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cell viability of Phyllanthus extracts on both human cancer and normal cell lines were 
determined using following formula:   
  Percentage of cell viability  
  =        [Mean OD of the tested cells – Mean OD of the medium]      
          [Mean OD of the untreated cells – Mean OD of the medium]  
Half-maximal inhibitory concentration (IC50) value is a concentration of tested 
sample that kills 50% of cell population as compared to the untreated control. The IC50 
was determined as cut-off values of each Phyllanthus plant extracts to have anti-cancer  
properties according to US National Institute of Health (NIH) plant screening program 
and will be used in subsequent experiments.  
2.5 Assessment of Cell Cycle Distribution 
Assessing the damaged DNA of cancer cells resulting from exposure to 
anticancer agents is important in cancer biology and toxicology studies. The 
susceptibility and variation of DNA to damage can differ between cell types. Thus, 
assessment of anti-proliferative activity of Phyllanthus was determined by measuring 
the amount of cellular DNA damage in a cancer cell population (MeWo and PC-3) 
through flow cytometric application.  
Flow cytometric analysis allows the measurement of changes in cellular DNA 
content during the various phases of the cell cycle. Optimization of flow cytometric 
DNA was performed to increase the sensitivity in detecting levels of DNA damage 
(strand breaks) and allowed the measurement of the extent of DNA damage by 
providing adequate resolution, linearity and sensitivity to distinguish single cells from 
aggregates in flow cytometry. In addition, optimization of flow cytometry is to ensure 
stability of the system performance and reproducibility of the results. Propidium iodide 
X 100% 
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(PI) dye was used as it intercalates with DNA and allows evaluation of cell viability and 
DNA content at excitation/emission wavelength the 480/490 nm.  
Melanoma (MeWo) and prostate cancer cells (PC-3) were seeded at 2.5x10
5
 
cells per well in a 6-wells plate and allowed to incubate overnight. Cells treated with 
respective IC50 value of Phyllanthus extracts were incubated at different time intervals; 
24, 48, 60 and 72 hours. The floating and trypsin-detached cells were collected and 
fixed in 70% ethanol. The ethanol-fixed cells were spun down and washed twice with 
ice-cold PBS. The cell pellet was stained with propidium iodide (10 µg/ml) (Sigma-
Aldrich, Ireland Ltd) in PBS (Flowlab) containing RNase A (1 mg/ml) and was 
incubated in a 37°C water bath (Memmert) for 30 minutes in the dark before being 
analyzed on a FASCalibur flow cytometer (Becton Dickinson, USA). Cell cycle 
distribution is presented as the number of cells versus the amount of DNA as indicated 
by the intensity of fluorescence. The percentage of cells in sub-G1, G0/G1, S and G2/M 
phases of cell cycle was quantitated using WinMDI software. The percentage of 
hypodiploid cells (Sub-G1) over total cells was calculated and expressed as percentage 
of apoptotic cells. 
2.6 Apoptosis Assays 
Inhibition of apoptosis in cancer is a major causative factor leading to malignant 
transformation of the cancer cells, metastasis and resistance to anticancer agents. The 
induction of apoptosis in cancer cells is important to halt cancer progression. Therefore, 
induction of apoptosis by Phyllanthus plant extracts in cancer cells (MeWo and PC-3) 
was studied using caspases detection, TUNEL and DNA fragmentation.  
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2.6.1 Caspase-3/7 Detection 
Caspases (caspase-3 and -7) are member of executioners in apoptosis induction. 
Their activity was measured by caspase-Glo-3/7 assay (Promega, Madison, WI). This is 
a luminescent assay that allows measurement of caspase-3 and -7 activities by providing 
proluminescent caspase–3/-7 substrate, Z-DEVD. The cleavage of this Z-DEVD by 
these caspases will produce aminoluciferin that generate luminescent signals.  
Cancer (MeWo and PC-3) cells were seeded at a density of 1x10
4
 of cells/well 
in 96-wells white-walled flat bottom plates and incubated overnight for cell attachment. 
Cells were then treated with the respective IC50 value of Phyllanthus extracts for 72 
hours. Control well consists of cells with culture medium without extracts while blank 
wells contained culture medium only. The Z-DEVD substrate reagent was added at 1:1 
ratio to the cells. After an hour of incubation at room temperature, caspase-3/7 activity 
of treated cells was determined by measuring luminescence signal using GloMax Multi 
Detection System (Promega, USA). The percentage of caspase-3/7 of Phyllanthus 
extract-treated cell was determined, where the background luminescence associated 
with the culture media and assay reagent (blank reaction) was subtracted from the 
experimental values of treated cells. The percentage activity of caspase-3/7 level was 
presented as mean of three independent experiments conducted in triplicates. 
  Percentage of caspase-3/7 activity  
  =         [Mean RLU of the tested cells – Mean RLU of the medium]      
          [Mean RLU of the untreated cells – Mean RLU of the medium]  
  Where, 
  RLU = Relative Luminescence Units 
 
X 100% 
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2.6.2 TUNEL Assay and Apoptotic Index 
DNA fragments produced by Phyllanthus treatment was determined using the 
ApopTag@Plus Peroxidase In Situ Apoptosis Detection Kit (Cemicon International, 
USA) based on the terminal deoxynucleotidyl-transferase mediated dUTP nick end 
labeling (TUNEL) assay according to the manufacture’s instruction. Cancer cells 
(MeWo and PC-3) were treated with respective IC50 values of Phyllanthus extracts for 
72 hours. The cells were fixed with 1% paraformaldehyde in PBS (pH 7.4) and dried on 
a silanized glass slide. Pre-cooled ethanol:acetic acid (2:1 v/v) was used for post-
fixation of cells on the slide for 5 minutes at -20°C. Endogenous peroxidase was 
quenched with 3% H2O2 at room temperature for 5 minutes. The apoptotic DNA 
fragments were labelled with digoxigenin antibody with TdT (terminal 
deoxynucleotidyl transferase) enzyme and then conjugated with anti-digoxigenin 
antibody. The labelled peroxidase-apoptotic DNA fragments were then treated with 
peroxidase substrate, diaminobenzidine (DAB) to produce permanent and localized 
brown-coloured stain. Methyl green (Sigma-Aldrich, Ireland Ltd) was used to 
counterstain the cells to further differentiate the apoptotic cells from viable normal cells. 
The slide was observed under light microscope (Olympus BX41) and photographed 
with Olympus U-CMAD3 camera. The number of apoptotic cells were calculated from 
a total of at least 1000 apoptotic cells at 100x magnification and presented as an 
apoptotic index. Apoptotic cells were identified in TUNEL assay by brown coloured 
cells from blue coloured viable cells.  
2.6.3 DNA Fragmentation 
During apoptosis, chromatin DNA were cleaved by the activated endogenous 
endonucleases into internucleosomal fragments with 180 base pairs (bp) and multiples 
thereof (360, 540, etc.) which can be detected using agarose gel electrophoresis assay. 
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Cancer cells (MeWo and PC-3) were treated with respective IC50 values of Phyllanthus 
extract for 72 hours. After incubation, both floating and trypsin-detached cells were 
collected and then centrifuged at 1,500 rpm for 5 minutes at 4°C. The cell pellet was 
resuspended with sterile PBS and then lysed with ice-cold lysis buffer (1 M Tris-HCl, 
pH 8.0, 0.5 M EDTA, 100% Triton X-100 and distilled water) for 35 minutes at 4°C. 
The cell lysates were centrifuged at 7,800 rpm for 30 minutes at 4°C and supernatant 
was collected. The DNA sample was extracted from supernatant with 25:24:1 (v/v/v) 
equal volume of neutral phenol:chloroform:isoamyl alcohol (Sigma-Aldrich, Ireland 
Ltd). The DNA sample was precipitated by adding two volumes of isopropanol (Fisher 
Scientific, Canada) and 0.1 volume of 3 M sodium acetate (pH 5.2) into the supernatant 
and left undisturbed at -20°C overnight. The precipitate containing the DNA fragment 
was centrifuged at 7,800 rpm for 30 minutes at room temperature. The RNA in the 
sample was digested with 30 μl of deionized water-RNase solution (10 mg/ml RNase, 
Sigma, Ireland Ltd) for 30 minutes at 37°C. The DNA was loaded and electrophoresed 
on 1.2% agarose gel (Vivantis, UK) containing 0.5 μg/ml of ethidium bromide 
(Invitrogen, Canada). DNA fragments were visualized under UV light using UV 
transilluminator (Vilbert loumat, France) at 312 nm and photographed using Olympus 
C-5060 camera.  
2.7 Necrosis Assay 
The leakage of LDH enzyme from damaged membrane cells may indicate for 
late stages of apoptosis or necrosis (Edinger & Thompson, 2004). The measurement of 
LDH levels in Phyllanthus treated cells was determined by CytoTox-One Homogenous 
Membrane Integrity Assay kit (Promega, USA). Cancer cells (MeWo and PC-3) were 
seeded at 1x10
4
 cells per well in black-coloured 96-wells flat bottom plate and 
incubated for overnight. The cells were treated with respective IC50 value of 
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Phyllanthus extract for 72 hours. The negative control wells were cell with culture 
medium only whereas blank wells contained culture medium. The CytoTox-One reagent 
containing diaphorase was added into cells and incubated at room temperature for 10 
minutes. The generated fluorescence signal indicated LDH activity was measured at an 
excitation wavelength of 560 nm and an emission wavelength of 640 nm by using 
GloMax Multi Detection System (Promega, USA). The LDH levels were presented as 
the mean of three independent experiments conducted in triplicate manner. 
  Percentage of LDH level  
   =    [Mean RFU of the tested cells – Mean RFU of the medium]      
       [Mean RFU of the untreated cells – Mean RFU of the medium]  
  Where,  
  RFU = Relative Fluorescence Units 
2.8 Anti-Metastasis Assays 
Cell migration is defined as the movement of cells from one area to another in 
response to chemoattractant and it is one of the important phenotype changes in cancer 
cells during metastasis (Zetter, 1998). Cell invasion is similar to cell migration except in 
cell invasion; the cells have to invade through an extracellular matrix (ECM) barrier by 
enzymatically degrading this barrier in order to become established in a new site 
(Weidner et al., 1991). Besides cancer cells, endothelial cells migration is essential 
during tumour-induced angiogenesis. During angiogenesis, endothelial cells migrate 
from existing vessels, invade surrounding tissue into new areas, proliferate and 
assemble into new capillaries that supply oxygen and nutrients to tumour mass 
(Delgado et al., 2011). The transwell migration/invasion assay is a commonly used 
assay to study the migratory/invasion response of cell to chemical signals. This assay is 
X 100% 
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also known as the Boyden or modified Boyden chamber assay. Migration and invasion 
assays were performed using transwell filter culture plate, which has an upper chamber 
containing polycarbonate filters of 8.0 µm pore size (Corning, USA). The wound 
healing assay was performed to confirm findings from transwell migration assay. The 
anti-metastatic effect of Phyllanthus in cancer cells (MeWo and PC-3) and HUVECs 
was studied in terms of migration, invasion and adhesion.  
2.8.1 Transwell Migration assay  
Both cancer (MeWo and PC-3, 2.5x10
5
 cells/well) and HUVECs (2x10
5
 
cells/well) were seeded in 6-wells plate and incubated overnight. After incubation, the 
cells were treated with various concentrations of Phyllanthus extracts (31.3-500.0 
µg/ml) for 72 hours. After 72 hours, pre-treated cells were suspended with serum-free 
culture media and added to the upper chamber and the lower chamber was filled with 
culture media supplemented with chemoattractant (10% FBS for cancer cells and 10 
ng/ml of VEGF (Sigma-Aldrich, Ireland Ltd) for HUVECs). After 12 hours incubation 
at 37°C, the cells at the upper side of the upper chamber filter were removed using a 
cotton-tipped swab. The cells at the lower chamber were fixed with methanol and 
stained with 0.5% crystal violet. The migrated cells were examined under the light 
microscope (Olympus BX41) and were photographed with Olympus U-CMAD3 
camera. Number of cells at the lower side of the upper chamber was calculated in five 
random fields under 100X magnification.  
  Percentage of Migrated Cells  
  =             [Total number of treated (migrated) cells]      
               [Total number of untreated (migrated) cells]  
 
X 100% 
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2.8.2 Transwell Invasion assay  
For invasion assay, the same protocol was performed as migration assay with the 
exception that the filter surface of upper chamber was coated with (1) 10.0 mg/ml of 
extracellular matrix (ECM) (Sigma-Aldrich, Ireland Ltd) for cancer cells (MeWo and 
PC-3) and (2) 50.0 µg/ml of fibronectin (Roche, Germany) for endothelial cells 
(HUVECs). Both cancer (MeWo and PC-3, 2.5x10
5
 cells/well) and HUVECs (2x10
5
 
cells/well) were seeded in 6-wells plate and incubated overnight. After incubation, the 
cells were treated with various concentrations of Phyllanthus extracts (31.3-500.0 
µg/ml) for 72 hours. After 72 hours, pre-treated cells were collected, suspended with 
serum-free culture media and added to the upper chamber while the lower chamber was 
filled with culture media supplemented with chemoattractant (10% FBS for cancer cells 
and 10 ng/ml of VEGF for HUVECs). After 12 hours incubation at 37°C, the cells at the 
upper side of the upper chamber filter were removed by using a cotton-tipped swab. The 
cells at the lower side of the upper chamber were fixed with methanol and stained with 
0.5% crystal violet. The invaded cells were examined under the light microscope and 
were photographed with Olympus U-CMAD3 camera. Number of cells at the lower side 
of the upper chamber was calculated in five random fields under 100X magnification.  
  Percentage of Invaded Cells  
  =            [Total number of treated (invaded) cells]      
              [Total number of untreated (invaded) cells]  
 
2.8.3 Wound healing assay  
The wound migration assay is a simple and inexpensive method which allows 
dual studies; cancer cell migration and cell-cell interactions. This assay was performed 
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to confirm previous findings in transwell migration assay and allows investigation of 
cancer cell-cell interaction after Phyllanthus treatment. Cancer cells (MeWo and PC-3) 
were seeded at 1.0x10
5
 cells per well in a 24-wells plate (Corning, USA) and cultured 
until sub-confluence (80-90%). The cells were washed with PBS before substitution of 
serum free media. After 24 hours, the plates were scraped firmly with the tip of a 
disposable pipette to generate an acellular 1-mm-wide lane per well, known as denuded 
zone or wound on the cell monolayer. After washed with sterile PBS, cells were further 
incubated with various concentrations of Phyllanthus extract for 24 hours for PC-3 cells 
and 48 hours for MeWo cells at 37°C. At the end of incubation time, the cells were 
photographed (Olympus µ1040) and the numbers of migrated cells into the denuded 
zone were calculated using ImageJ software. At least five different random fields were 
quantified for cell migration. 
  Percentage of Migrated Cells Acrossed into the Denuded Zone    
  =            [Total number of treated migrated cells]      
              [Total number of untreated migrated cells]  
 
2.8.4 Cancer Cell (Cell-Matrix) Adhesion assay  
The interaction of cancer cells with extracellular matrix (ECM) proteins such as 
fibronectin, laminin and collagen is important to enables cancer cells to adhere, invade 
and metastasize (Hay, 1991). Disruption of these interactions could halt cancer 
progression. Cell-matrix adhesion assay was performed to study the interaction of PC-3 
cells to type-IV collagen and MeWo cells to fibronectin after treatment with 
Phyllanthus extracts. Ninety-six-well plate was pre-coated with adhesion molecules; (1) 
50 µg/ml of type-IV collagen (Sigma-Aldrich, Ireland Ltd) for PC-3 cells and (2) 50 
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µg/ml of fibronectin for MeWo cells, for 2 hour at 37°C. The pre-coated paltes were 
incubated with 1% bovine serum albumin (BSA) (Sigma-Aldrich, Ireland Ltd) to block 
nonspecific binding, for an hour prior to the experiment. The Phyllanthus-treated and 
untreated cancer cells were harvested, suspended into new media and seeded into the 
pre-coated plates and incubated for an hour at 37°C. The non-adherent cells were then 
removed with two washes of sterile PBS. The number of adhered cells was then 
quantified with CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit 
(Promega, USA). Background values of the seeded cells with fibronectin (for MeWo 
cells) and type-IV collagen (for PC-3 cells) was subtracted from with the wells coated 
with adhesion molecule alone (blank). 
  Percentage of Adherent Cells  
  =        [Mean OD of the test cells – Mean OD of the blank]      
      [Mean OD of the untreated cells – Mean OD of the blank]  
 
2.8.5 Tumour Transendothelial Migration Assay 
Adhesion and migration of tumour cells on and across the vascular endothelium, 
known as transendothelial migration is a critical step of the metastatic cascade (Lee et 
al., 2003b). This cascade step was studied via the transendothelial migration assay. 
Fibronectin (50 µg/ml) was pre-coated onto the upper chamber of transwell plate for 2 
hours at 37°C. HUVECs (5x10
4
 cells/well) were then added onto the fibronectin-coated 
chamber and cultured for 72 hours to allow formation of cell monolayer. Pre-treated 
cancer (MeWo and PC-3) cells were suspended in serum-free media and were added 
onto HUVECs monolayer and allowed to incubate for 16 hours before analysis of 
transmigration. The lower chamber was filled with growth culture media with 10% FBS 
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used as chemoattractant. The cells on the upper side of the upper chamber filter were 
removed by cotton-tipped swab. The cells at lower side of the upper chamber were fixed 
and stained with 0.5% crystal violet as previously described and were examined under 
the light microscope (Olympus BX41) and photographed with Olympus U-CMAD3 
camera. Number of transendothelial migrated cancer cells was calculated from five 
random fields under 100X magnification. 
  Percentage of Transendothelial Migrated Cells  
  =             [Total number of treated transendothelial migrated cells]      
               [Total number of untreated transendothelial migrated cells]  
2.8.6 Gelatin and casein Zymographies 
Matrix metalloproteinases (MMPs) are involved in the degradation of 
extracellular matrix (ECM) during the tumour angiogenesis and metastasis (Zetter, 
1998). MMPs can be analysed with substrate zymography techniques depending on the 
degradation of their preferential substrate (Cockett et al., 1998). The activities of MMP-
2 and MMP-9 were assessed by gelatin zymography and MMP-7 by casein 
zymography.  
Cancer cells (MeWo and PC-3) cells and HUVECs were pre-treated with various 
concentrations of Phyllanthus extracts (31.3-500.0 µg/ml) for 72 hours. After 72 hours, 
pre-treated cells were washed twice with sterile PBS and incubated with serum-free 
culture media for 48 hours. Supernatant was collected and centrifuged at 1,500 rpm for 
20 minutes at 4°C to remove cellular debris. The supernatant was collected and stored at 
-80°C until further analysis. Mixture of supernatant and sample buffer (0.5 M Tris-HCI 
(pH 6.8), 50% glycerol, 10% SDS and 0.1% bromophenol blue) in ratio 1:1 were loaded 
and electrophoresis was conducted under non-reducing conditions on 10% SDS 
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polyacrylamide separating gel containing 0.1% gelatin (for gelatin zymography) or 
0.2% of casein (casein zymography). For casein zymography, the gel was 
electrophoresed twice; first without any samples to remove the excess casein and the 
second was loaded with samples. After electrophoresis, the gels were washed with 2.5% 
Triton-X100 for 1 hour to remove SDS. Subsequently, the gels were incubated in 
renaturing buffer (50 mM Tric-HCI, pH 6.8; 200 mM NaCI2; 5 mM CaCI2) for 16 hours 
at 37°C. The gels were stained with 0.5% Coomasie Blue for 1 hour at room 
temperature and then destained with destaining solution (Methanol: acetic acid: water; 
2:1:7) until proper contrast was achieved. The detected MMPs bands were measured 
using ImageJ software and the percentage of MMP activitiy was determined using 
following formula.  
   Percentage of MMP activity  
   =         [Mean of treated band intensity]      
             [Mean of untreated band intensity]  
2.9 In vitro anti-angiogenesis assay – ECM gel-induced capillary tube formation 
The extracellular matrix (ECM) gel-induced capillary tube formation assay is 
one of the most widely used in vitro assays to mimic the reorganization phase of 
angiogenesis. This assay measures the ability of endothelial cells to form capillary-like 
tube structures, with the support of extracellular matrix. The resulting tubes will 
eventually form hollow lumens and become guidance pathways that facilitate tumour 
cell metastasis (Akhtar et al., 2002). Thus, ECM gel-induced capillary tube formation 
assay was used to assess the anti-angiogenic effects of Phyllanthus extracts. The 
extracellular matrix (ECM) gel is derived from Engelbreth Holm-Swarm mouse 
sarcoma and contains various proteins such as laminin, collagen, heparan sulfate 
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proteoglycan, entactin and other minor components (Sigma-Aldrich, Ireland Ltd). 
Extracellular-matrix was coated onto sterile 24-well culture plates prior the experiment. 
Two hundred microliter of ECM (10 mg/ml) was added into each well of a 24-well plate 
and incubated for 2 hours prior to the experiment. 
HUVECs were seeded (2x10
5
 cells/well) at 6-wells plate for overnight. After 
incubation, HUVECs were treated with different concentrations of Phyllanthus extracts 
(31.3-500.0 µg/ml) and further incubated for 72 hours. Phyllanthus-treated and 
untreated HUVECs were harvested and seeded into the ECM-coated 24-well culture 
plate at concentration of 1x10
4
 cells/well and incubated for 16 hours. The formation of 
microcapillary-like tube structures by HUVECs on ECM gel were observed and 
photographed (Olympus µ1040) after 16 hours under a phase contrast microscope. The 
complete formations of microcapillary-like tubes were counted using ImageJ software 
and percentage of microcappillary-like tubes formed according to following formula.  
  Percentage of Microcapillary-like Tubes Formed  
  =       [Total number of micro-capillary tubes formed in treated cells]      
          [Total number of micro-capillary tubes formed in untreated cells] 
 
2.10 Molecular Mechanisms of Anti-carcinogenic Properties of Phyllanthus 
extracts 
2.10.1 Dual luciferase pathway reporter transient transfection 
Many vital biological processes including uncontrolled proliferation, metastasis, 
angiogenesis and inhibitions of apoptosis, are tightly regulated by complex signalling 
networks and signal transduction in cancer cells to ensure its malignancy. Ten different 
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cancer-related pathways were studied using the Cignal Finder 10-Pathway Reporter 
Arrays (SA Biosciences, QIAGEN, USA).  
Reverse transfection protocol was implemented for this assay. Prior to 
transfection, 2 µl of Lipofectamine® 2000 transfection reagent (Invitrogen, USA) was 
diluted into 25 µl of Opti-MEM® Reduced Serum Media and incubated for 5 minutes. 
Meanwhile, 100 ng of plasmid construct of transcription factor-responsive reporter of 
each pathway and control were mixed with 25 µl of Opti-MEM® Reduced Serum Media 
(Invitrogen, USA). After 5 minutes, the diluted plasmid construct of each pathway and 
control were mixed with diluted Lipofectamine® 2000 in ratio 1:1 and further incubated 
for 20 minutes at room temperature. Meanwhile, cancer cells (MeWo and PC-3) were 
washed with PBS, trypsinized with trypsin-EDTA (0.25%) and resuspended to 4x10
5
 
cells/ml in Opti-MEM® containing 5% of fetal bovine serum and 1% NEAA. After the 
20 minutes incubation time, 50 µl of transfection cocktail was added to 4x104 cells/well 
and further incubated for 16 hours at 37°C. After transfection, the old media was 
discarded and the transfected cells were treated with Phyllanthus extracts at their 
respective IC50 values in complete growth medium (MEM supplemented with 10% 
FBS, 0.1 mM NEAA, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 μg/ml 
streptomycin) and further incubated for another 24 hours. Each transfection condition 
was carried out in triplicate.   
Each of the pathways/reporters consist an inducible transcription factor 
responsive firefly luciferase reporter and constitutively expressing Renilla construct.  
Renilla construct is to act as an internal control for normalizing transfection efficiencies 
and monitor cell viability. After 24 hours of Phyllanthus treatment, the changes in 
expression of each pathway were determined by measuring the generated firefly and 
Renilla luminescent signals using the Dual-Glo Luciferase Assay system (Promega, 
Madison, WI) on Glomax machine (Promega, USA). The fold changes of each 
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reporter’s expression between Phyllanthus-treated and untreated cells were calculated 
from the relative luciferase units, generated from the firefly/Renilla luciferase activity 
ratio.  
2.10.2 Western Blot Analysis 
After identifying the cancer-related pathways altered by Phyllanthus in cancer 
cells (MeWo and PC-3), the underlying molecular mechanism was investigated. The 
intracellular signalling molecules in MAPK (pan-Ras, c-Raf, Elk, RSK, c-Jun, JNK1/2, 
Akt and p38), Wnt (GSK3β, β-catenin and DSH), Myc/Max and Hypoxia (c-myc, HIF-
α, and VEGF) and NFκB (p50 and p52) pathways as well as apoptotic (Bcl-2 and Bax) 
proteins were chosen for western blot analysis to determine their expression upon 
Phyllanthus treatment in cancer cells. All these antibodies were purchased from Merck 
(USA). 
Cancer cells were cultured in 25 cm
2
 culture flask until 80-90% confluency. The 
old medium was discarded and treated with respective IC50 value of Phyllanthus 
extracts and incubated for 72 hours. After 72 hours, the floating and trypsin-detached 
treated cells were collected and spun down at 1,500 rpm for 5 minutes. The cell pellet 
was lyzed with lysis buffer on ice for 30 minutes. Supernatant was collected after 
centrifuged at 12,000 rpm for 10 minutes at 4C° to remove cellular debris, and kept at -
80°C until further analysis.   
Total amount of proteins was determined as described in section 2.11.1, prior to 
the experiment. Twenty micrograms of protein lysates were mixed with sample buffer 
in ratio 1:1 and resolved on a 12% SDS-PAGE gels. After electrophoresis, proteins 
were transferred onto nitrocellulose membranes. Nonspecific binding of the membrane 
was blocked with Tris-buffered saline (TBS) containing 5% (w/v) nonfat dry milk and 
0.1% (v/v) Tween-20 (TBST) for 2 hours. Membranes were washed with TBST for 
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three times, each with 10 minutes and incubated with appropriate dilution of specific 
primary antibodies overnight at 4°C. Subsequently, the membranes were washed with 
TBST and incubated with appropriate secondary antibodies (horseradish-conjugated 
goat anti-mouse or anti-goat IgG) for 1 hour. Membranes were washed three times with 
TBST for 10 minutes; and the band was visualized after incubation with chromogenic 
substrate containing 4-chloro-1-napthol and hydrogen peroxide. Reaction was stopped 
by washing with distilled water. The membrane was then scanned and ImageJ software 
was used to measure the band intensity.  
Percentage of protein expression  
   =         [Mean of treated band intensity]      
             [Mean of untreated band intensity]  
 
2.11 2-Dimensional Gel Electrophoresis for Protein Identification 
2.11.1 Sampel Preparation and Protein Quantification 
Total proteins were extracted from untreated and treated groups by incubation 
with lysis buffer on ice for 30 minutes. The protein pellet was re-solubilized in 
rehydration solution (8 M urea, 2% CHAPS, 40 mM DTT, 0.5% IPG buffer pH 3-
11NL, bromophenol blue) and kept at -80°C until further analysis. Total amount of 
proteins was determined using 2-D Quant kit (GE Healthcare Bio-Sciences, USA). This 
assay is based on the specific binding of copper ions to protein. The colour intensity is 
directly proportional to the protein concentration. The working colour reagent was 
prepared by mixing colour reagent A and B in ratios 1:100.  
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Table 2:1: Standard curve for protein quantification 
Tube number 1 2 3 4 5 6 
Volume of 2 mg/ml 
0 µl 5 µl 10 µl 15 µl 20 µl 25 µl BSA standard solution 
Protein quantity 0 µg 10 µg 20 µg 30 µg 40 µg 50 µg 
 
Six tubes were prepared accoding to Table 2.1 to construct a standard curve for 
protein quantification. Meanwhile, 10 µl of tested sample was aliquoted into a tube and 
labelled as sample tube. Five hundred microliters of precipitant was added into each 
standard and sample tube, and incubated for 2-3 minutes at room temperature. Five 
hundred microliter of co-precipitant was added into each tube. Tubes were then 
centrifuged at 10,000xg for 5 minutes and supernatant was completely removed. Five 
hundred microliters of diluted copper solution was added into each tube to dissolve the 
protein pellet. Working colour reagent was prepared by diluting concentrated copper 
solution into de-ionized water in ratios 1: 4. One milliliter of working colour reagent 
was added to each tube and mixed. The tubes were then allowed to stand at room 
temperature for 15 minutes. One hundred microliters of samples was transferred into a 
well of 96-wells flat bottom plate. At least three replications of each sample were 
prepared and absorbance was read at 480 nm. A standard curve for absorbance of the 
standard against protein amount was generated and used to determine the protein 
amount in sample.    
2.11.2 First and Second Dimensional Separation 
A total of 500 mg of total proteins were rehydrated into 13 cm immobilized pH 
gradient (IPG) strips (pH 3-11 nonlinear) (GE Healthcare, USA). The first dimension 
was run on the IPGphor III machine (GE Healthcare, USA) at 20°C with the following 
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settings: step 1 at 500V for 1 hour; step 2 at 500-1000V for 1 hour; step 3 at 1000-
8000V for 2.5 hours, and step 4 at 8000V for 0.5 hour. 
Upon completion of first dimensional separations, the strip was equilibrated as 
following; first reduction with 64.8 mM of dithiothreitol-SDS equilibration buffer (50 
mM Tris-HCl [pH 8.8], 6 M urea, 30% glycerol, 2% SDS, 0.002% bromophenol blue) 
for 15 minutes, followed by alkylation with 135.2 mM of iodoacetamide-SDS 
equilibration buffer for another 15 minutes. The second dimension electrophoresis was 
performed by electrophoresing the samples in 12.5% SDS acrylamide gels by using the 
SE600 Ruby system (GE Healthcare) at 25°C in an electrode buffer (25 mM Tris, 192 
mM glycine, and 0.1% [wt/vol] SDS) with the following settings: step 1 at 100V/gel for 
45 minutes; step 2 at 300V/gel until the run is completed. After electrophoresis, the gels 
were fixed with destaining solution for 30 minutes, followed by staining with hot 
Coomasie blue for 30 minutes. Lastly, the gels were scanned using Ettan DIGE Imager 
(GE Healthcare). Gel images were analyzed using PDQuest 2-D Analysis Software 
(Bio-Rad, USA) and only protein spots which showed significant differences (more 
than 1.0 fold) were selected for mass spectrometry analysis.  
2.11.3 Protein Digestion, Desalting and MALDI-TOF/TOF Analysis 
The significant protein spots were manually excised from polyacrylamide gels 
and were kept in sterile 1.5 ml eppendorf tubes. Excised spots (gel plugs) were washed 
with destaining solution (50% Acetonitrile (ACN) in 50 mM NH4HCO3) until the gel 
plugs are clear. The destaining solution was discarded and the gel plugs were then 
incubated with reducing solution (100 mM ammonium bicarbonate (NH4HCO3) 
containing 10 mM dithiothreitol (DTT)) for 30 minutes at 60°C. Then, the gel plugs 
were alkylated with 100 mM NH4HCO3 containing 55 mM iodoacetamine for 20 
minutes in the dark and followed with three times washing with 50% acetone in 100 
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mM NH4HCO3 for 20 minutes each. The gel plugs were rehydrated with 100% ACN 
and dried in speed vacuum concentrator (Savant SpeedVac®, Thermo Scientific, USA). 
In-gel digestion using trypsin gold (Promega, Mass Spectrometry Grade) in 50 mM 
NH4HCO3 was added into gel plug and incubated overnight in 37°C. Proteins were 
extracted from gel plugs and purified by Ziptip (Ziptip C18, Millipore, Bedford, MA, 
USA). The eluted proteins were mixed with MATRIX solution and spotted on MALDI 
plate using dry droplet method and analysed using Ab Sciex Tof/Tof
TM
 instruments. 
The generated peptides were blasted with MASCOT Search Algorithm (Version 2.1.0) 
to identify the possible proteins. 
2.12 Statistical analysis 
From all the experiments, results were expressed as mean ± standard error 
(SEM) of data obtained from three independent experiments using SPSS software 
(version 16). The Student t-test, followed by Dunnett’s test were used where values of 
*p<0.05 and **p<0.01 were considered significant.  
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CHAPTER 3: RESULTS 
3.1 Identification of Bioactive Compounds 
The bioactive compounds in both aqueous and methanolic extracts of four 
species of Phyllanthus plant were identified by subjecting the extracts to HPLC (High 
Performance Liquid Chromatography) analysis coupled with photodiode array (PDA) 
and MS/MS detection. Twelve main bioactive compounds were identified based on 
their retention time, UV spectra, parent mass spectra and secondary fragmentation 
patterns. These bioactive compounds are comprised of ten water-soluble compounds 
and four methanol-soluble compounds (Table 3.1).  
In aqueous crude extracts of Phyllanthus, all the species consist of at least eight 
bioactive compounds and seven of them are identical; gallic acid, 
galloylglucopyronoside, corilagen, geraniin, rutin, quercetin glucoside and caffeolquinic 
acid. Among these identified bioactive compounds, geraniin is the only compound 
which can be found in both aqueous and methanolic extracts (Table 3.1). P.urinaria 
contains the highest number of bioactive compounds, followed by P.watsonii, P.amarus 
and P.niruri. 
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Table 3:1: Bioactive compounds in aqueous and methanolic extracts of Phyllanthus 
species (P.A: P.amarus, P.N: P.niruri; P.U: P.urinaria and P.W: P.watsonii) (Tang et 
al., 2010). 
 Compound Retention 
time 
[M-H] 
m/z 
MS-MS 
Fragment-
ation 
Phyllanthus species 
A
q
u
eo
u
s 
ex
tr
a
ct
 
Gallic acid 3.8 169 125,169 P.A, P.N, P.U, P.W 
Galloyl-
glucopyronoside 
2.8 331 125,169,211,
271 
P.A, P.N, P.U, P.W 
Corilagen 18 633 301, 125, 169 P.A, P.N, P.U, P.W 
Geraniin 22 951 301, 125, 
169, 463 
P.A, P.N, P.U, P.W 
Rutin 26 609 301, 179,151 P.A, P.N, P.U, P.W 
Quercetin 
glucoside 
27 463 301, 179,151 P.A, P.N, P.U, P.W 
Caffeolquinic acid 23 353 191 P.A, P.N, P.U, P.W 
Digalloyl-
glucopyronoside 
15.0 483 125,169,211, 
271, 313 
P.A, P.N, P.W 
Quercetin 
rhamnoside 
30 447 301, 151 P.U, P.W 
Trigalloyl-
glucopyronoside 
23 
 
635 125,169,211, 
271, 313,465 
P.U 
      
M
et
h
a
n
o
li
c 
ex
tr
a
ct
 Geraniin 12 951 301, 125, 
169, 463 
P.A, P.N, P.U, P.W 
Trigalloyl-
glucopyronoside 
13 635 125,169,211, 
271, 313,465 
P.U 
Tetragalloyl-
glucopyronoside 
15 787 169,211, 313, 
465 
P.U 
Quercetin 
diglucoside 
9 625 463, 301 P.N 
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3.2 Anti-proliferative effect of Phyllanthus extracts, fractions and standard 
anticancer drugs on growth of cells 
The MTS assay was used to investigate the potential anti-proliferative 
(cytotoxic) effect of Phyllanthus’ crude extracts and their fractions on different cancer 
(MeWo and PC-3) and normal cells (RWPE-1, CCD-1127Sk and HUVECs), where the 
cells were treated at different concentrations ranging 31.3 to 500.0 µg/ml for 72 hours. 
In this study, two standard anticancer drugs namely, 5’Flurouracil (5’FU) and 
Doxorubicin (Dox) were used as positive controls.  
3.2.1 Human melanoma (MeWo) cells 
For aqueous extracts, the IC50 values were in the range of 160.0-260.0 µg/ml and 
56.2-153.3 µg/ml for methanolic extracts of Phyllanthus. As presented in Table 3.2, 
methanolic extracts showed stronger anti-proliferative effect on MeWo cells, as their 
IC50 values were lower than aqueous extracts. P.urinaria showed the strongest anti-
proliferative effect on MeWo cells with the lowest IC50 value at 160.0 µg/ml (p<0.05) 
for aqueous and 56.2 µg/ml (p<0.05) for methanolic extracts. As compared to standard 
anticancer drugs, both 5’Fluorouracil and doxorubicin showed much stronger anti-
proliferative effect on both MeWo and normal skin cells (CCD-1127Sk) with an IC50 
values of 2.5 µg/ml (p<0.05) and 1.0 µg/ml (p<0.05), respectively.  
Fractions (fraction 1 and 2) of crude aqueous extract of Phyllanthus were also 
evaluated for its cytotoxicity. The IC50 values of fraction 1 of P.niruri, P.urinaria and 
P.watsonii were in the range of 433.0–460.0 µg/ml on MeWo cells, and P.amarus did 
not show any anti-proliferative effect. On the other hand, fraction 2 of all Phyllanthus 
species exhibited lower IC50 values (220.0-240.0 µg/ml) as compared to fraction 1. Both 
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fractions exhibited toxicity towards the normal skin cell line (CCD-1127Sk) but not 
affected by both aqueous and methanolic extracts of Phyllanthus as shown in Table 3.2.  
 
Table 3:2: The IC50 values of Phyllanthus extracts on human skin cancer (melanoma, 
MeWo) and normal (CCD-1127Sk) cell lines. Data represent the mean (± SEM) of three 
independent experiments, each performed in triplicate. All showed significant 
difference between untreated cells and Phyllanthus-treated cells, p<0.05 (Tang et al., 
2010). 
    IC50 ± SEM (µg/ml) 
Phyllanthus species Extracts 
Skin cells 
Cancer Normal 
(MeWo) (CCD-1127Sk) 
P.amarus 
Aqueous 193.3 ± 1.3 > 500 
Methanolic 133.3 ± 2.9 > 500 
P.niruri 
Aqueous 260.0 ± 2.4 > 500 
Methanolic 153.3 ± 2.6 > 500 
P.urinaria 
Aqueous 193.3 ± 1.1 > 500 
Methanolic 56.2 ± 3.2 > 500 
P.watsonii 
Aqueous 160.0 ± 3.2 > 500 
Methanolic 100.7 ± 2.0 > 500 
Positive control 
5’Fluorouracil 2.3 ± 0.5 0.8  ± 0.5 
Doxorubicin 2.5  ± 0.5 1.0  ± 0.2 
    
Fraction 1 (Aqueous) 
P.amarus > 500 > 500 
P.niruri 433.3 ± 16.9 376.2 ± 21.2 
P.urinaria 460.0 ± 16.4 392.2 ± 26.2 
P.watsonii 437.3 ± 23.4 394.2 ± 31.3 
Fraction 2 (Aqueous) 
P.amarus 248.2 ± 21.4 114.2 ± 9.4 
P.niruri 243.9 ± 21.3 99.2 ± 14.2 
P.urinaria 220.2 ± 10.2 108.4 ± 14.4 
P.watsonii 225.2 ± 22.0 119.3 ± 21.4 
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3.2.2 Human Adenocarcinoma (PC-3) cells 
Aqueous extracts of Phyllanthus, exhibited IC50 values in the range of 155.0-
178.3 µg/ml (p<0.05), while for the methanolic extracts, the IC50 values were at ranged 
54.2-117.7 µg/ml (p<0.05) (Table 3.3). In comparison, methanolic extracts showed 
stronger anti-proliferative effect on PC-3 cells as their IC50 value were lower than that 
of aqueous extracts. Overall, P.urinaria showed the strongest anti-proliferative effect on 
PC-3 cells as compared to other Phyllanthus species. Both 5’Fluorouracil and 
doxorubicin showed stronger anti-proliferative effect than Phyllanthus on PC-3 and 
normal prostate cells (RWPE-1) with IC50 values of 2.5 µg/ml (p<0.05) and 1.0 µg/ml 
(p<0.05), respectively.  
Semi-purification of crude aqueous extract of Phyllanthus yielded two fractions 
(fraction 1 and 2). Both fractions were evaluated for their cytotoxicity on PC-3 and 
RWPE-1 cell lines. The IC50 values of fraction 1 for P.niruri, P.urinaria and P.watsonii 
were in the range of 456.0–497.7 µg/ml, but undetected in P.amarus-treated cells. On 
the other hand, the IC50 values of fraction 2 for all Phyllanthus species were lower 
compared to fraction 1 which at ranged 185.4–228.4 µg/ml. The normal prostate cell 
line (RWPE-1) was affected by fraction 1 and 2 but not affected by both aqueous and 
methanolic extracts of Phyllanthus as shown in Table 3.3. 
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Table 3:3: Cytotoxicity (IC50 ± SEM) values of Phyllanthus extracts on human prostate 
adenocarcinoma (PC-3) and normal (RWPE-1) cell lines. Data represent the mean (± 
SEM) of three independent experiments, each performed in triplicate. All showed 
significant difference between untreated cells and Phyllanthus-treated cells, p<0.05 
(Tang et al., 2010). 
    IC50 ± SEM (µg/ml) 
Phyllanthus 
species 
Extracts 
Prostate cells 
Cancer Normal 
(PC-3) (RWPE-1) 
P.amarus 
Aqueous 178.3 ± 2.8 > 500 
Methanolic 84.3 ± 1.1 > 500 
P.niruri 
Aqueous 155.0 ±1.2 > 500 
Methanolic 117.7 ± 2.1 > 500 
P.urinaria 
Aqueous 155.7 ± 2.1 > 500 
Methanolic 54.2 ± 2.1 > 500 
P.watsonii 
Aqueous 156.7 ± 2.4 > 500 
Methanolic 100.5 ± 1.2 > 500 
Positive control 
5’Fluorouracil 1.0  ± 0.3 1.0  ± 0.5 
Doxorubicin 2.5  ± 0.5 1.0  ± 0.1 
    
Fraction 1 
(Aqueous) 
P.amarus > 500 > 500 
P.niruri 483.3 ± 21.1 302.5 ± 21.2 
P.urinaria 456.0 ±31.2 315.6 ± 13.2 
P.watsonii 497.7 ±2 2.1 323.4 ± 17.6 
Fraction 2 
(Aqueous) 
P.amarus 228.4 ± 9.4 108.4 ± 21.4 
P.niruri 214.1 ± 12.5 116.2 ± 26.2 
P.urinaria 185.4 ± 21.4 132.6 ± 25.7 
P.watsonii 191.5 ± 13.0 115.2 ± 22.0 
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3.2.3 Human Umbilical Vein Endothelial Cells (HUVECs) 
Endothelial cells play an important role in the development of new blood 
vessels. The excessive proliferation and transformation of endothelial cells would lead 
to pathological angiogenesis, which is described as one of the hallmarks of cancer. The 
anti-proliferative effect of Phyllanthus extracts on HUVECs was exerted in the range of 
125.0-500.0 µg/ml. However, Phyllanthus showed low cytotoxicity against HUVECs 
was observed at the maximal dose of all extracts (both aqueous and methanolic) 500.0 
µg/ml (Figure 3.1).  
 
Figure 3.1: Anti-proliferative effect of Phyllanthus extracts on the growth of HUVECs. 
Figure shows HUVECs were treated with various concentrations of Phyllanthus. Data 
represent the mean (± SEM) of three independent experiments, each performed in 
triplicate. The asterisk indicates a significant difference between untreated and 
Phyllanthus-treated cells, *p<0.05. 
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3.3 Induction of Cancer Cell Cycle Arrest 
Cell cycle is a biological process that involves a sequence of molecular events to 
ensure correct transmission of the genetic material to subsequent generations. Defects in 
cell cycle can lead to genetic modification (mutation) and hence develop uncontrolled 
cell proliferation. An uncontrolled proliferation and the ability to evade apoptosis by 
cancer cells are the hallmarks of cancer (Hanahan & Weinberg, 2011). Targeting the 
cell cycle could be an approach for anticancer agents to halt the uncontrolled 
proliferation of cancer cells and initiate them to undergo apoptosis.  
The growth arrest on cell cycle and apoptotic induction by Phyllanthus extracts 
on cancer (MeWo and PC-3) cells were assessed using propidium iodide DNA 
incorporation with flow cytometry. Both MeWo and PC-3 cells were treated with 
respective IC50 value of Phyllanthus extracts for 24, 48, 60 and 72 hours. Changes in the 
distribution in cell cycle were observable by 24 hours after being treated with 
Phyllanthus extracts for both cell lines. 
3.3.1 S-phase arrest in human melanoma (MeWo) cells  
Phyllanthus extracts exhibited anti-proliferative effect on MeWo cells by growth 
arrest at the S-phase at 24 hours and remained evident after 72 hours of treatment. This 
was accompanied by accumulation of cells in Sub-G1 (apoptotic cells) phase for both 
aqueous and methanolic extracts (Figure 3.2). The percentage of apoptotic cells had 
increased in a time-dependent manner from 1.8% at 24 hours to 6.1% at 72 hours as 
compared to the untreated cells. Meanwhile, the percentage of cells at the S-phase of 
treated MeWo cells was elevated to 15.0% above the controls at 72 hours of treatment. 
Furthermore, the percentage of cells at Go/G1 and G2/M phases decreased with time 
upon treatment with Phyllanthus extracts due to the fact that treated cells have been 
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arrested at S-phase and subsequently accumulated at Sub-G1 (apoptosis) phase. 
However, the potency of Phyllanthus extracts to induce S-phase arrest was not as strong 
as the standard anticancer drug (5’Fluorouracil), with a 22.1% difference at 72 hours 
post treatment. 
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Figure 3.2: The kinetic of cell cycle distribution of Phyllanthus extracts-treated MeWo 
cells.  
Figure shows the percentage of Phyllanthus extracts-treated cells at Sub-G1, Go/G1, S, 
G2/M phases of MeWo cells at different time intervals (24, 48, 60 and 72 hours) of 
treatment. Data represent the mean (± SEM) of three independent experiments, each 
performed in triplicate. All showed significant difference between untreated cells and 
Phyllanthus-treated cells, p<0.05 (Tang et al., 2010). 
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3.3.2 G1-phase arrest in human prostate adenocarcinoma (PC-3) cells  
Phyllanthus extracts exhibited anti-proliferative effect by disrupting the cell 
cycle distribution of treated PC-3 cells and arresting them at the G1-phase with an 
accumulation of apoptotic cells at the Sub-G1 (apoptosis) phase (Figure 3.3). The 
accumulation of apoptotic cell was 3.4% at 24 hours increased up to 7.4% at 72 hours 
(p<0.05), as compared to the untreated cells. The percentage of treated PC-3 cells at Go/ 
G1-phase was 13.7% at 24 hours and this has increased to 18.8% at 72 hours as 
compared to the untreated cells (p<0.05). However, the percentage of treated-PC-3 cells 
at the S and G2/M phases decreased with time of treatment due to the fact that treated 
PC-3 cells were arrested at Go/G1 phase and subsequently accumulated at Sub-G1 
phases. The standard drug, doxorubicin showed a G2/M phase arrest on PC-3 cells at 24 
hours and remained evident after 72 hours of treatment. 
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Figure 3.3: The kinetic of cell cycle distribution of Phyllanthus extracts-treated PC-3 
cells.  
Figure shows the percentage of Phyllanthus extracts-treated cells at Sub-G1, Go/G1, S, 
G2/M phases of PC-3 cells at different time intervals (24, 48, 60 and 72 hours) of 
treatment. Data represent the mean (± SEM) of three independent experiments, each 
performed in triplicate. All showed significant difference between untreated cells and 
Phyllanthus-treated cells, p<0.05 (Tang et al., 2010).  
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3.4 Mechanism (s) of Cancer Cell Death 
3.4.1 Phyllanthus induced Caspases-3/7 Activation 
Activation of caspases (aspartate specific cysteine protease) is one of the 
biochemical changes that occur during apoptosis. Caspase-3 and -7 were chosen to be 
studied because they can be activated by both the death receptor and mitochondrial 
pathways (Cohen, 1997). Furthermore, they are the major executor class of caspases and 
both are essential for the induction of DNA fragmentation as well as apoptosis (Nagata, 
2000). Phyllanthus extrcats induced caspases-3/7 activation in both PC-3 and MeWoc 
ells. The levels of caspases-3/7 induced by Phyllanthus treatment were markedly 
increased (3–4 folds) as compared to the control group (Figure 3.4) for both extracts of 
Phyllanthus. The level of caspases-3/7 induced by standard drugs (5’Fluorouracil and 
doxorubicin) in MeWo and PC-3 cells were 6-folds and 0.5-folds higher than control 
group (untreated cells) and Phyllanthus-treated cells, respectively. These indicates that 
apoptosis induced by Phyllanthus extracts was mediated via activation of caspases. 
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Figure 3.4: The level of caspases-3/7 in cells treated with Phyllanthus extracts and 
standard drugs).  
Figure shows the data represent the mean (± SEM) of three independent experiments, 
each performed in triplicate. All showed significant difference between untreated cells 
and Phyllanthus-treated cells, p<0.05 (Tang et al., 2010). 
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3.4.2 Phyllanthus induced DNA Fragmentation in Cancer Cells 
Caspases activation is followed by DNA fragmentation (Nagata, 2000). Therefore, 
early and late detections of DNA fragmentation in treated cancer cells were performed 
with TUNEL assay and agarose gel electrophoresis, respectively. 
3.4.2.1 TUNEL labeling of DNA Fragmentation 
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay is 
a technique to allow detection of apoptotic cells by labelling the free end of apoptotic 
DNA with a marker which can be visualized under light microscope. Apoptotic cells 
were observed in Phyllanthus extracts-treated MeWo (Figure 3.5A, red arrow) and PC-3 
(Figure 3.5B, red arrow) cells as brown-colour cells and its appearance was similar to 
apoptotic cells were present in positive control, apoptotic-inductive anticancer drugs 
(5’Fluorouracil and Doxorubicin). Viable cells were stained in blue colour. 
The populations of cell death can be calculated and expressed in as an apoptotic 
index. The percentage of apoptotic cells (AI) of treated-MeWo and PC-3 cells were 
markedly increased up to 50% compared to the untreated cells (control group) at 72 
hours of treatment with Phyllanthus extracts (p<0.05) (Figure 3.6). Only 8% difference 
in AI values between Phyllanthus and standard drugs (p<0.05) were noted indicating 
that the potential of causing apoptotic cell death by Phyllanthus was close to standard 
anticancer drugs.    
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Figure 3.5: TUNEL analysis of MeWo and PC-3 cancer cells after treatment with 
Phyllanthus extracts with magnification 100X.  
Figure shows TUNEL-positive (apoptotic) cells were observable as brown staining cells 
(red arrow) in Phyllanthus extract-treated (A) MeWo and (B) PC-3 cells and normal 
viable cells stain as blue colour (Tang et al., 2010). 
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Figure 3.6: Percentage of apoptotic index (%) of untreated and treated (Phyllanthus 
extracts and anticancer drugs) of MeWo and PC-3 cancer cells from TUNEL analysis. 
Figure shows the data represent the mean (± SEM) of three independent experiments, 
each performed in triplicate. All showed significant difference between untreated cells 
and Phyllanthus-treated cells, p<0.05 (Tang et al., 2010). 
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3.4.2.2 DNA ladder formation 
The late detection of DNA fragmentation in cells treated with Phyllanthus 
extracts was studied using agarose gel electrophoresis. Analysis of DNA fragments in 
apoptotic cells by agarose gel electrophoresis will produce a characteristic DNA ladder 
which is described as biochemical hallmarks of apoptosis (Cohen, 1997; Nagata, 2000).  
DNA content from Phyllanthus treated cells was extracted and electrophoresed 
on agarose gel. The typical ladder DNA fragments were observed in Phyllanthus 
extracts-treated MeWo (Figure 3.7A) and PC-3 (Figure 3.7B) cells on agarose gel under 
a UV transiluminator. This similar pattern was seen with standard anticancer drugs, 
which possess apoptotic induction, indicating the ability of Phyllanthus extracts to 
induce apoptosis on MeWo and PC-3 cells. 
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Figure 3.7: Apoptotic DNA fragmentation was observable in Phyllanthus extracts-
treated (A) MeWo and (B) PC-3 cells.  
Figure shows Lane 1 -4: aqueous extracts and Lane 6 – 9: methanol extracts for 
P.amarus, P.niruri, P.urinaria and P.watsonii, orderly. Lane 5 and 10: 1kb DNA 
marker, Lane 11: standard drugs, where (A) 5’Fluorouracil for MeWo and (B) 
Doxorubicin for PC-3 cells. Lane 12: untreated cells (Tang et al., 2010).  
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3.4.3 Phyllanthus induced changes in membrane integrity by LDH release 
One of the biochemical changes during necrosis is leakage of lactate 
dehydrogenase (LDH) enzyme. The determination of necrotic-induction of Phyllanthus 
was performed by measuring LDH levels in treated cancer cells by using CytoTox-One 
Homogeneous Membrane Integrity Assay. This is a fluoremetric assay to allow 
measurement of the release of LDH from cells with damaged membrane which is 
associated with necrotic cell death (Loo & Rillema, 1998; Denecker et al., 2001). LDH 
released into the culture medium was measured based on the conversion of resazurin 
into resorufin through enzymatic activity.  
3.4.3.1 LDH Levels in MeWo cells 
In untreated cells, the LDH level was measured at 1.2% (p<0.05). However, 
LDH levels were noticed to increase in MeWo cells after treatment with Phyllanthus 
extracts (Figure 3.8). For aqueous extracts, the LDH levels in MeWo cells were induced 
by P.niruri, P.urinaria and P.watsonii in the range from 8.5 to 9.0% (p<0.05) and 5.1% 
by P.amarus (p<0.05). This indicates that the aqueous extracts of P.amarus possessed 
the lowest necrotic effect among aqueous extracts in MeWo cells. 
For methanolic extracts, the LDH leakage induced by P.amarus, P.urinaria and 
P.watsonii ranged from 7.3 to 7.8%, and 8.3% by P.niruri (p<0.05). The methanolic 
extract of P.niruri possessed strongest necrotic effect among the methanolic extracts on 
MeWo cells. However, the percentage of LDH levels induced by 5’FU was much 
stronger at 30.0% (p<0.05).  
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Figure 3.8: The percentage of LDH levels in treated and untreated MeWo cells.  
Figure shows the LDH levels in the treated group was higher than the untreated 
(control) group. Data represent the mean (± SEM) of three independent experiments, 
each performed in triplicate. All showed significant difference between untreated cells 
and Phyllanthus-treated cells, p<0.05 (Tang et al., 2010).  
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3.4.3.2 LDH Levels in PC-3 cells 
The LDH levels produced by untreated PC-3 cells were 2.1%. (p<0.05) (Figure 
3.9) This LDH level was increased in PC-3 cells upon treatment with Phyllanthus 
extracts. In both aqueous and methanolic extracts of Phyllanthus, the percentage of 
LDH levels in PC-3 cells induced by all four Phyllanthus species ranged from 10.0-
12.0% (p<0.05). For the standard drug, doxorubicin, the LDH levels induced was 26.0% 
(p<0.05). Hence, the necrotic effect of doxorubicin seems to be stronger than 
Phyllanthus extracts with a 10.0% difference (p<0.05).  
 
Figure 3.9: The percentage of LDH levels in the treated and untreated PC-3 cancer cells. 
Figure shows the LDH levels in the treated group were higher than that of the untreated 
(control) group. Data represent the mean (± SEM) of three independent experiments, 
each performed in triplicate. All showed significant difference between untreated cells 
and Phyllanthus-treated cells, p<0.05 (Tang et al., 2010). 
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3.5 Phyllanthus exerts Anti-Metastatic Effect 
Tumour metastasis is a multistep process which includes adhesion of tumour 
cells to the extracellular matrix (ECM) of basement membrane, degradation of ECM by 
secreted proteolytic enzymes, migration and invasion of cancer cells through the 
systemic and/or lymphatic system (Zetter, 1998). Therefore, the anti-metastatic effect of 
Phyllanthus was studied by assessing several assays; migration, invasion, cell-matrix 
adhesion, transendothelial migration and zymographies.  
3.5.1 Inhibition of Cancer and Endothelial Cells’ Migration 
The transwell assay was performed to quantify the migratory potential of cancer 
(MeWo and PC-3) and endothelial (HUVECs) cells after treatment with Phyllanthus at 
different concentrations. 31.3-500.0 µg/ml.  
3.5.1.1 Inhibition of MeWo Cells’ Migration 
The migration activity of MeWo cells was decreased after treatment with 
Phyllanthus extracts (p<0.05) (Figure 3.10). At 31.3 µg/ml of aqueous extracts of 
Phyllanthus, the migrated MeWo cells ranged from 81.3-88.9% and reduced to 12.0-
25.6% at 500.0 µg/ml (p<0.05). For methanolic extracts, the migrated MeWo cells 
ranged from 83.3-92.9% at 31.3 µg/ml and reduced to a range of 4.4-12.6% at 500.0 
µg/ml (p<0.05). Notably the anti-migration effect of methanolic extracts of Phyllanthus 
was greater than aqueous extracts. P.urinaria showed the strongest anti-migration 
activity in both aqueous and methanolic extracts, followed by P.watsonii, P.niruri and 
P.amarus.  
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Figure 3.10: Effect of Phyllanthus extracts on the migration ability of MeWo cells. 
Figure shows (Upper) MeWo cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Migration ability of treated MeWo cells was 
quantified and represented the mean ± SEM of three independent experiments, each 
performed in triplicate. The asterisk indicates a significant difference between untreated 
(control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.5.1.2 Inhibition of PC-3 Cells’ Migration 
The migration activity of PC-3 cells was decreased after treatment with 
Phyllanthus extracts (Figure 3.11). At 31.3 µg/ml of aqueous extracts of Phyllanthus, 
the migrated PC-3 cells ranged from 84.0-91.8% and reduced to 20.0-28.6% at 500.0 
µg/ml (p<0.05). For methanolic extracts, the migrated PC-3 cells ranged from 43.1-
66.0% at 31.3 µg/ml and reduced to 1.6-6.5% at 500.0 µg/ml (p<0.05). P.urinaria 
showed the strongest anti-migration activity in both aqueous and methanolic extracts, 
followed by P.watsonii, P.niruri and P.amarus. 
 
Figure 3.11: Effect of Phyllanthus extracts on the migration ability of PC-3 cells. 
Figure shows (Upper) PC-3 cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Migration ability of treated PC-3 cells was 
quantified and represented the mean ± SEM of three independent experiments, each 
performed in triplicate. The asterisk indicates a significant difference between untreated 
(control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.5.1.3 Inhibition of HUVECs’ Migration  
The migration activity of Phyllanthus against HUVECs was found to be dose-
dependent (Figure 3.12). At 31.3 µg/ml of Phyllanthus aqueous extracts, the migrated 
HUVECs were ranged from 93.3-97.2% and reduced to a range of 64.9-73.6% at 500.0 
µg/ml (p<0.05). For methanolic extracts of Phyllanthus, the migrated HUVECs ranged 
from 93.2-97.7% at 31.3 µg/ml and reduced to 69.8-70.0% at 500.0 µg/ml (p<0.05). As 
noted, P.amarus showed the strongest anti-migration activity in both aqueous and 
methanolic extracts, followed by P.urinaria, P.watsonii, and P.niruri.  
 
Figure 3.12: Effect of Phyllanthus extracts on the migration ability of HUVECs. 
Figure shows (Upper) HUVECs cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Migration ability of treated HUVECs was 
quantified and represented the mean ± SEM of three independent experiments each 
performed in triplicate.  The asterisk indicates a significant difference between 
untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.   
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3.5.2 Inhibition of Cancer Cell’s Motility  
The wound migration assay is a simple and inexpensive method which allows 
dual studies; cancer cell migration and cell-cell interactions. This assay was performed 
to confirm previous findings in transwell migration assay and allows investigation of 
cancer cell-cell interaction after Phyllanthus treatment. This assay was performed only 
on cancer (MeWo and PC-3) cells, as it requires to create a "wound" or “denuded zone”  
in a cell monolayer and not suitable for HUVECs which needs adhesion molecules on 
the flask for growth.  
3.5.2.1 Inhibition of MeWo Cells’ Motility 
The anti-migration effect of Phyllanthus extracts on MeWo cells by the wound 
migration assay is shown in Figure 3.13. The reduction in migration activity of MeWo 
cells was clearly observed after treatment with different concentrations of Phyllanthus 
extracts. The migrated MeWo cells ranged from 88.9-93.3% by aqueous extracts 
treatment at 31.3 µg/ml and further reduced to a range of 28.0-31.0% at 500.0 µg/ml 
(p<0.05). For methanolic extracts, the migrated MeWo cells ranged from 84.0-91.5% at 
31.3 µg/ml and further reduced to a range of 11.0-21.9% at 500.0 µg/ml (p<0.05). 
P.urinaria showed the strongest anti-migration activity in both aqueous and methanolic 
extracts, followed by P.watsonii, P.niruri and P.amarus. 
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Figure 3.13: Effect of Phyllanthus extracts on the motility of MeWo cells.  
Figure shows (Upper) MeWo cell monolayer was scraped, and the cells were treated 
with different concentrations of Phyllanthus extracts for 48 hours. (Lower) Quantitative 
assessments of migrated cells are expressed as mean ± SEM of three independent 
experiments, each performed in triplicate. The asterisk indicates a significant difference 
between untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
. 
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3.5.2.2 Inhibition of PC-3 Cells’ Motility 
For the PC-3, the anti-migration effect of Phyllanthus extracts was observed in 
wound migration assay (Figure 3.14). The migrated PC-3 cells were around 90.6-93.6% 
at 31.3 µg/ml for the the aqueous extracts treatment, and reduced to a range of 20.7-
35.0% at 500.0 µg/ml. For the methanolic extracts, the percentage of migrated PC-3 
cells was 74.6-85.9% at 31.3 µg/ml and further reduced to a range of 20.3-23.9% at 
500.0 µg/ml. As noted again, P.urinaria showed the strongest anti-migration activity in 
both aqueous and methanolic extracts, followed by P.watsonii, P.niruri and P.amarus. 
 
Figure 3.14: Effect of Phyllanthus extracts on the motility of PC-3 cells.  
Figure shows (Upper) PC-3 cell monolayer was scraped to create denuded zone and 
treated with different concentrations of Phyllanthus extracts for 24 hours. (Lower) 
Quantitative assessments of migrated cells are expressed as mean ± SEM of three 
independent experiments, each performed in triplicate.  The asterisk indicates a 
significant difference between untreated (control) and Phyllanthus-treated cells, 
*p<0.05 and **p <0.01.  
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3.5.3 Inhibition of Cancer and Endothelial Cells’ Invasion 
The invasion ability of cancer cells allows cancer cells to invade beyond the 
constraints of the normal tissue from which they originate and to enter the circulation 
that leads them to reach distant organs/tissues and eventually form secondary tumours, 
called metastases (Mareel & Leroy, 2003). Invasion also plays an important role during 
tumour angiogenesis as endothelial cells from pre-existing blood vessels need to invade 
surrounding tissues to form new blood vessels towards solid tumour (Carlevaro et al., 
1997).  
Thus, the anti-invasion activity of Phyllanthus extracts on MeWo and PC-3 cells 
as well as HUVECs was studied with transwell invasion assay after treatment with 
Phyllanthus at different concentrations (31.3-500.0 µg/ml).  
3.5.3.1 Inhibition of MeWo Cell’ Invasion 
The invasion activity of MeWo cells was noted to decrease after treatment with 
Phyllanthus extracts (Figure 3.15). The invasion ability of MeWo cells were 
significantly inhibited by both aqueous and methanolic extracts of Phyllanthus from 
31.3-500.0 µg/ml (p<0.05). At 31.3 µg/ml of aqueous extracts, the invaded MeWo cells 
were 83.9-91.9% and reduced to a range of 13.6-31.8% at 500.0 µg/ml (p<0.05). For 
methanolic extracts, the invaded MeWo cells ranged from 84.6-92.9% at 31.3 µg/ml 
and reduced to a range of 8.4-15.3% at 500.0 µg/ml (p<0.05). P.urinaria showed the 
strongest anti-invasion activity in both aqueous and methanolic extracts, followed by 
P.watsonii, P.niruri and P.amarus. 
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Figure 3.15: Effect of Phyllanthus extracts on the invasion ability of MeWo cells. 
Figure shows (Upper) MeWo cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Invasion ability of treated MeWo cells was 
quantified and represented the mean ± SEM of three independent experiments, each 
performed in triplicate.  The asterisk indicates a significant difference between 
untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.   
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3.5.3.2 Inhibition of PC-3 Cell’ Invasion 
The invasion activity of PC-3 cells was decreased after treatment with 
Phyllanthus extracts (Figure 3.16). At 31.3 µg/ml of aqueous extracts, the invaded PC-3 
cells ranged from 83.2-93.6% and reduced to 20.9-31.8% at 500.0 µg/ml (p<0.05), 
while for methanolic extracts, the invaded PC-3 cells ranged from 60.6-91.2% at 31.3 
µg/ml and reduced to 11.1-21.1% at 500.0 µg/ml (p<0.05). As noted before, P.urinaria 
showed the strongest anti-invasion activity in both aqueous and methanolic extracts, 
followed by P.watsonii, P.niruri and P.amarus. 
 
Figure 3.16: Effect of Phyllanthus extracts on the invasion ability of PC-3 cells. 
Figure shows (Upper) PC-3 cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Invasion ability of treated PC-3 cells was 
quantified and represented the mean ± SEM of three independent experiments, each 
performed in triplicate.  The asterisk indicates a significant difference between 
untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.5.3.3 Inhibition of HUVECs’ Invasion 
For HUVECs, the invasion activity reduced upon treatment with Phyllanthus 
extracts (Figure 3.17). At 31.3 µg/ml of aqueous extracts of Phyllanthus, the invaded 
HUVECs ranged from 93.6-98.9% and reduced to 51.2-52.6% at 500.0 µg/ml (p<0.05), 
while for methanolic extracts, the percentage of invaded HUVECs were 90.3-93.9% at 
31.3 µg/ml and reduced to a range of 48.3-55.9% at 500.0 µg/ml (p<0.05). The results 
showed that both aqueous and methanolic extracts of Phyllanthus showed similar extent 
of anti-invasion effects on HUVECs for all Phyllanthus species.  
 
Figure 3.17: Effect of Phyllanthus extracts on the invasion ability of HUVECs.  
Figure shows (Upper) HUVEC cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Invasion ability of treated HUVECs was 
quantified and represented the mean ± SEM of three independent experiments, each 
performed in triplicate. The asterisk indicates a significant difference between untreated 
(control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.   
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3.5.4 Cell-Extracellular Matrix Interactions in Cancer Cells 
The interaction of cancer cell with ECM proteins such as fibronectin, laminin 
and collagen is important to enable cancer cells to adhere, invade and metastasize. 
Disruption of these interactions could halt cancer progression. Cell-matrix adhesion 
assay was performed to study the interaction of PC-3 cells to type-IV collagen and 
MeWo cells to fibronectin after treatment with Phyllanthus extracts 
3.5.4.1 Inhibition on MeWo Cells-Extracellular Matrix Interactions 
Figure 3.18 shows the adhesion activity of MeWo cells to fibronectin was 
significantly reduced after treatment with Phyllanthus extracts. At 31.3 µg/ml of 
aqueous extracts, the adherent MeWo cells ranged from 64.7-71.6% and reduced to 3.6-
16.2% at 500.0 µg/ml (p<0.05), while for methanolic extracts, the adherent MeWo cells 
were 61.1-68.8% at 31.3 µg/ml and further reduced to 2.0-4.6% at 500.0 µg/ml 
(p<0.05). P.urinaria again showed the strongest inhibitory effect on adhesion activity of 
MeWo cells in both aqueous and methanolic extracts, followed by P.watsonii, P.amarus 
and P. niruri. 
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Figure 3.18: Effects of Phyllanthus on MeWo cells adhesion activity.  
Figure shows the adhesion ability of treated MeWo cells towards fibronectin were 
exhibited a dose-dependent manner of Phyllanthus concentrations. Data represent the 
mean (± SEM) of three independent experiments, each performed in triplicate. The 
asterisk indicates a significant difference between untreated (control) and Phyllanthus-
treated cells, *p<0.05 and **p <0.01.   
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3.5.4.2 Inhibition on PC-3 Cells-Extracellular Matrix Interactions 
The adhesion ability of PC-3 cells towards type-IV collagen was reduced after 
treatment with Phyllanthus extracts (Figure 3.19). In the aqueous extracts treatment, the 
adherent PC-3 cells were 82.6-90.6% at 31.3 µg/ml, and reduced to a range of 10.6-
11.7% at 500.0 µg/ml, while for methanolic extracts, the adherent PC-3 cells were 70.7-
81.2% at 31.3.0 µg/ml and reduced to 3.8-4.4% at 500.0 µg/ml. Again P.urinaria 
showed the strongest inhibitory effects in adhesion activity of PC-3 cells, followed by 
P.watsonii, P.amarus and P.niruri in both aqueous and methanolic extracts.  
 
Figure 3.19:  Effects of Phyllanthus on PC-3 cells’ adhesion activity.  
Figure shows the adhesion ability of treated PC-3 cells towards type-IV collagen were 
exhibited a dose-dependent manner to Phyllanthus concentrations. Data represent the 
mean (± SEM) of three independent experiments, each performed in triplicate. The 
asterisk indicates a significant difference between untreated (control) and Phyllanthus-
treated cells, *p<0.05 and **p <0.01.  
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3.5.5 Inhibition of Cancer Cells’ Transendothelial Migration 
During metastasis, cancer cells will transvasate into blood vessels, circulate in 
the blood stream and transmigrate out from the vessels into a new site of the body to 
form secondary tumours. In order to study cancer cells-endothelium interaction and 
transmigration, tumour transendothelial migration assay was performed. 
3.5.5.1 Inhibition of MeWo Cells’ Transendothelial Migration 
As shown in Figure 3.20, Phyllanthus extracts significantly inhibited 
transendothelial migration of MeWo in a dose-response manner at all concentration 
(p<0.05). At 31.3 µg/ml of aqueous extracts, the transendothelial migrated MeWo cells 
ranged from 73.8-81.3% and reduced to 4.2-21.6% at 500.0 µg/ml. For methanolic 
extracts, the transendothelial migrated MeWo cells were around 72.9-82.6% at 31.3 
µg/ml and reduced to 2.0-4.8% at 500.0 µg/ml. Again, P.urinaria showed the strongest 
inhibitory effects on transendothelial migration ability of MeWo cells, followed by 
P.watsonii, P.niruri and P.amarus in both aqueous and methanolic extracts. 
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Figure 3.20: Effects of Phyllanthus on transendothelial migration of MeWo cells. 
Figure shows (Upper) MeWo cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Transendothelial migration ability of treated 
MeWo cells was quantified and represented the mean ± SEM of three independent 
experiments each performed in triplicate.  The asterisk indicates a significant difference 
between untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.5.5.2 Inhibition of PC-3 Cells’ Transendothelial Migration 
Phyllanthus extracts also exhibits the inhibiton effect on transendothelial 
migration of PC-3 cells in a dose-response manner (Figure 3.21). At 31.3 µg/ml of 
aqueous extracts of Phyllathus, the transendothelial migrated PC-3 cells ranged from 
72.2-83.6% and reduced to 10.3-21.3% at 500.0 µg/ml, while for methanolic extracts, 
the transendothelial migrated PC-3 cells were 51.9-80.3% at 31.3 µg/ml and reduced to 
3.3-13.3% at 500.0 µg/ml. P.urinaria again showed the strongest inhibitory effects on 
transendothelial migration ability of PC-3 cells, followed by P.watsonii, P.niruri and 
P.amarus in both aqueous and methanolic extracts.  
 
Figure 3.21: Effects of Phyllanthus on transendothelial migration of PC-3 cells.  
Figure shows (Upper) PC-3 cells were treated with different concentrations of 
Phyllanthus extracts for 72 hours. (Lower) Transendothelial migration ability of treated 
PC-3 cells was quantified and represented the mean ± SEM of three independent 
experiments, each performed in triplicate.  The asterisk indicates a significant difference 
between untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.5.6 Inhibition on Matrix Metalloproteinase (MMP) Enzymes 
Matrix metalloproteinases (MMPs) are zinc-dependent matrix proteases which 
are involved in ECM destruction, cell growth, apoptosis, angiogenesis, invasion and 
migration. Inhibition of these enzymes is believed to prevent endothelial and cancer 
cells’ invasiveness, subsequently, decreasing the incidence of tumour metastasis and 
halts the formation of secondary tumours. Gelatinase (MMP-2 and -9) and matrilysins 
(MMP-7 and -26) metalloproteases were detected in MeWo, PC-3 and HUVECs by 
zymographies and their activities were noted to be altered upon Phyllanthus treatment.  
3.5.6.1 Inhibition of MMP-2 and MMP-7 in MeWo cells 
As shown in Figure 3.22, MMP-2 was detected at 64kDa in MeWo cells. At 
31.3 µg/ml of aqueous extracts of Phyllathus, the MMP-2 levels ranged from 89.2-
95.3% (p<0.05) and reduced to 21.4-33.3% at 500.0 µg/ml (p<0.01). For methanolic 
extracts, the MMP-2 levels were around 81.4-94.2% at 31.3 µg/ml (p<0.05) and 
reduced to a range of 13.3-21.4% at 500.0 µg/ml (p<0.01).  
Besides that, MMP-7 was also detected at 64kDa in MeWo cells (Figure 3.22). 
At 31.3 µg/ml of aqueous extracts of Phyllathus, the MMP-7 levels ranged from 89.4-
93.3% (p<0.05) and reduced to 26.3-34.2% at 500.0 µg/ml (p<0.01). For methanolic 
extracts, the MMP-2 levels ranged from 80.4-91.4% at 31.3 µg/ml (p<0.05) and reduced 
to 29.4-33.4% at 500.0 µg/ml (p<0.01). P.urinaria showed the strongest inhibitory 
effects on MMP-2 and -7 activities of MeWo cells, followed by P.watsonii, P.niruri and 
P.amarus in both aqueous and methanolic extracts.  
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Figure 3.22: Zymography analysis of MeWo cells. MMP-2 and -7 were detected at 
64KDa and 20kDa, respectively.  
Figure shows the MMPs activities were measured and expressed as mean ± SEM of 
three independent experiments, each performed in triplicate.  The asterisk indicates a 
significant difference between untreated (control) and Phyllanthus-treated cells, 
*p<0.05 and **p <0.01.  
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3.5.6.2 Inhibition of MMP- 7, -9 and -26 in PC-3 cells 
Four different MMPs were detected in PC-3 cells; MMP-7 at 20kDa, pro-MMP 
9 at 92kDa, active MMP-9 at 82kDa and MMP-26 at 18kDa (Figure 3.23). As shown in 
Figure 3.23, MMP-7 levels ranged from 80.3-91.4% (p<0.05) at 31.3 µg/ml and reduced 
to 20.3-31.3% at 500.0 µg/ml (p<0.01) of aqueous-treated cells. For methanolic 
extracts, the MMP-7 levels were around 79.3-81.3% at 31.3 µg/ml (p<0.05) and 
reduced to a range of 26.8-37.2% at 500.0 µg/ml (p<0.01).  
The MMP-26 activity was reduced by Phyllanthus extracts in treated PC-3 cells 
and its levels ranged from 71.3-81.4% (p<0.05) at 31.3 µg/ml and were reduced to 43.2-
60.2% at 500.0 µg/ml (p<0.01) in aqueous-treated PC-3 cell. For methanolic extracts, 
the MMP-26 levels were 65.3-71.4% at 31.3 µg/ml (p<0.05) and reduced to 34.3-49.2% 
at 500.0 µg/ml (p<0.01). As MMP-26 acts as an activator of pro-MMP-9 to activate 
MMP-9, reduction of MMP-26 activity is followed by increased levels of pro-MMP 9. 
The pro-MMP-9 levels ranged from 21.4-25.7% (p<0.05) at 31.3 µg/ml and increased to 
86.3-91.7% at 500.0 µg/ml (p<0.01) of aqueous-treated PC-3 cells. For methanolic 
extracts, the pro-MMP-9 levels ranged from 10.4-21.4% at 31.3 µg/ml (p<0.05) and 
increased to 83.2-91.5% at 500.0 µg/ml (p<0.01). As consequence from this, active 
MMP-9 activity in PC-3 cells was reduced after treatment with Phyllanthus. At 31.3 
µg/ml of aqueous extracts of Phyllathus, the active MMP-9 levels were 80.2-88.2% 
(p<0.05) and reduced to 17.3-23.8% at 500.0 µg/ml (p<0.01). For methanolic extracts, 
the MMP-9 levels ranged from 79.2-87.4% at 31.3 µg/ml (p<0.05) and reduced to a 
range of 9.4-14.2% at 500.0 µg/ml (p<0.01).  
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Figure 3.23: Zymography analysis of PC-3 cells.  
Figure shows four different MMPs; MMP-7, pro-MMP-9, active MMP-9 and MMP-2, 
were detected, measured and expressed as mean ± SEM of three independent 
experiments, each performed in triplicate.  The asterisk indicates a significant difference 
between untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.5.6.3 Inhibition of MMP- 2 in HUVECs 
As shown in Figure 3.24, MMP-2 is detected at 64kDa in HUVECs. At 31.3 
µg/ml of aqueous extracts of Phyllathus, the MMP-2 levels ranged from 88.2-93.3% 
(p<0.05) and this was reduced to 43.2-51.4% at 500.0 µg/ml (p<0.01). For methanolic 
extracts, the MMP-2 levels were around 79.3-89.3% at 31.3 µg/ml (p<0.05) and 
reduced to 40.3-45.3% at 500.0 µg/ml (p<0.01). P.urinaria showed the strongest 
inhibitory effects on MMP-2 activity on PC-3 cells, followed by P.watsonii, P.niruri 
and P.amarus in both aqueous and methanolic extracts.   
 
Figure 3.24: Zymography analysis of HUVECs. MMP-2 was detected at 64kDa.  
Figure shows the levels of MMP-2 activity was measured and expressed as mean ± 
SEM of three independent experiments, each performed in triplicate.  The asterisk 
indicates a significant difference between untreated (control) and Phyllanthus-treated 
cells, *p<0.05 and **p <0.01.  
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3.6 Phyllanthus exerts Anti-Angiogenic Effect 
The extracellular matrix (ECM) gel-induced capillary tube formation assay is 
one of the most widely used in vitro assays to mimic the reorganization phase of 
angiogenesis. This assay measures the ability of endothelial cells to form capillary-like 
tube structures with the the support of extracellular matrix. The resulting tubes will 
eventually form hollow lumen and become guidance pathways that facilitate tumour cell 
metastasis. Thus, ECM gel-induced capillary tube formation assay was used to assess 
the anti-angiogenic effects of Phyllanthus extracts 
Without any treatment, endothelial cells become elongated and form 
microcapillary-like tube structures, organized by larger number of HUVECs on ECM 
gel (Figure 3.25). The inhibition in gel-induced microcapillary-like tube structures by 
Phyllanthus extracts was noticed from 31.3-500.0 µg/ml. At 31.3 µg/ml of aqueous 
extracts of Phyllanthus, the percentage of tube formation ranged from 90.8-93.3% 
(p<0.05) and was further reduced to 31.3-37.4% at 500.0 µg/ml (p<0.05). For 
methanolic extracts, the percentage of tube formation was around 90.1-92.3% at 31.3 
µg/ml and reduced to 24.6-30.6% at 500.0 µg/ml (p<0.05). P.urinaria again showed the 
strongest inhibitory effect on microcapillary-like tube structures of HUVECs, followed 
by P.watsonii, P.amarus and P.niruri in both aqueous and methanolic extracts. 
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Figure 3.25: Effect of Phyllanthus extracts on microcapillary-like tube formation of 
HUVECs.  
Figure shows (Upper) Microcapillary-like tube formation of HUVECs at different 
concentrations of Phyllanthus extracts. (Lower) The completed microcappilary-like 
tube formation was calculated and expressed as mean ± SEM of three experiments, each 
performed in triplicate.  The asterisk indicates a significant difference between 
untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.7 Disruption of Cancer Cell Signalling Pathways by Phyllanthus 
From the results, Phyllanthus extracts have exhibited anti-proliferation, anti-
metastasis, anti-angiogenesis and induction of apoptosis on both melanoma (MeWo) 
and prostate (PC-3) cancer cell lines. Further investigations to study the underlying 
molecular mechanisms of these anticancer effects of Phyllanthus on MeWo and PC-3 
cells was carried out. The cancer ten-pathway reporter array was performed to profile 
the changes in the activities of ten different signalling pathways relevant to cancer that 
is influenced by Phyllanthus. The ten-related cancer pathways that were screened 
included Wnt, Notch, p53/DNA damage, TGFβ, cell cycl3/pRb-E2F, NFκB, Myc/Max, 
hypoxia, MAPK/ERK and MAPK/JNK.  
3.7.1 Alterations on Multiple Signalling Pathways in MeWo cells  
Figure 3.26 showed the differential expression of each cancer-related pathway in 
treated and untreated MeWo cells. It was noted that in the untreated MeWo cells, six 
(p53/DNA damage, NFκB, Myc/Max, Hypoxia, MAPK/ERK and MAPK/JNK) 
investigated pathways were expressed to regulate the cell growth and survival. It is 
observed that out of these six pathways, four pathways (NFκB, Myc/Max, Hypoxia and 
MAPK/ERK) showed significantly down-regulation in treated MeWo cells (p<0.05). 
Contrarily, the expression of p53/DNA damage and MAPK/JNK pathways showed 
significant up-regulation in the treated cells (p<0.05). Other pathways investigated were 
found to be not significantly affected by Phyllanthus extracts (p>0.05). 
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Figure 3.26: Alterations in ten cancer-related pathways upon Phyllanthus treatment in MeWo cells.  
Figure shows data represent the mean (± SEM) of three independent experiments, each performed in triplicate. The asterisk indicates a significant 
difference between untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
  
142 
 
3.7.2 Alterations on Multiple Signalling Pathways in PC-3 cells  
Figure 3.27 depicts the differential expression of Wnt, Notch, p53, TGF-β, cell 
cycle/pRB-E2F, NFκB, Myc/Max, Hypoxia, MAPK/ERK and MAPK/JNK pathways 
affected by Phyllanthus species on PC-3 cells. It was noted that in the untreated PC-3 
cells, all ten investigated pathways were expressed to regulate the cells growth and 
survival. Upon treatment with the different Phyllanthus species, the cells showed a 
significant down regulation of six pathways; Wnt, NFκB, Myc/Max, Hypoxia, 
MAPK/ERK and MAPK/JNK, suggesting that the plant extracts exerted its properties 
by targeting these pathways (p<0.05). The other pathways were not significantly 
affected by Phyllanthus extracts (p>0.05).  
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Figure 3.27: Alterations in ten cancer-related pathways upon Phyllanthus treatment in PC-3 cells.  
Figure shows data represent the mean (± SEM) of three independent experiments, each performed in triplicate. The asterisk indicates a significant 
difference between untreated (control) and Phyllanthus-treated cells, *p<0.05.  
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3.7.3 Phyllanthus disrupted anti-apoptotic/pro-apoptotic balance in cancer cells 
One of the hallmarks of cancer is the inhibition of apoptosis. This can be 
achieved by suppressing the expression of pro-apoptotic protein, Bax and stimulating 
the expression of anti-apoptotic protein, Bcl-2. As shown in Figure 3.28, Bax and Bcl-2 
proteins were detected at 23kDa and 26kDA, respectively.  
In Figure 3.28A, it is observed the levels of the pro-apoptotic Bax proteins in 
treated MeWo was significantly increased with a concurrent decreased in anti-apoptotic 
Bcl-2 protein in treated MeWo cells as compared to untreated MeWo cells (p<0.05).  
Besides that, another apoptosis related protein; p53, was also detected at 53kDa. The 
p53 levels were significantly up-regulated in MeWo cells after treatment with 
Phyllanthus extracts (p<0.05). These observations indicate that Phyllanthus was able to 
induce apoptosis through the activation of p53 pathway and disrupted the anti-
apoptotic/pro-apoptotic balance in MeWo cells.  
A similar phenomenon was observed in treated PC-3 cells (Figure 3.28B). The 
graph shows a significant increase of Bax protein in the Phyllanthus-treated cells 
(p<0.05) with a concurrent decrease in Bcl-2 (p<0.05). P53 protein was not found in 
both untreated and treated PC-3 cells, suggesting Phyllanthus induced apoptosis via 
p53-independent pathway.  
Among the species of Phyllanthus, both aqueous and methanolic extracts of 
P.watsonnii showed the most significant changes on Bax and Bcl expression (p<0.01), 
followed by P.urinaria, P.niruri and P.amarus.  
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(A)  
(B)  
Figure 3.28: Effects of Phyllanthus extracts on pro-apoptotic/anti-apoptotic balance in 
(A) MeWo and (B) PC-3 cells.  
Figure shows data represent the mean (± SEM) of three independent experiments, each 
performed in triplicate. The asterisk indicates a significant difference between untreated 
(control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.7.4 Alterations of MAPK Pathways by Phyllanthus extracts  
The high expressions of MAPK signalling in melanoma and prostate cancers 
impinges on most signalling pathways and plays a critical role in the progression of 
cancer such as tumour metastasis and angiogenesis. Three different major MAPK were 
studied; ERK, JNK and p38 MAPK pathways.   
3.7.4.1 Down-Regulation of MAPK/ERK, p38 MAPK and PI3K/Akt Pathways in 
MeWo cells 
Three up-stream activator molecules in MAPK and PI3K/Akt pathways; pan-
Ras, c-Raf and Akt were highly expressed in the untreated MeWo cells. The constitutive 
activations of these molecules can activate their downstream targets including 
MAPK/ERK (RSK, Elk1, c-Jun/AP-1), MAPK/JNK (JNK1/2) and p38 (p38 MAPK). 
As shown in Figure 3.29, the expressions of all these intracellular signalling molecules 
were detected in untreated MeWo cells indicating their involvement in regulating 
MeWo cells’ growth. However, the expression of all these intracellular signalling 
molecules had notably been down-regulated expression (p<0.05) except for JNK1/2 
protein which showed a slight increase in expression in treated MeWo cells.  
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Figure 3.29: Alterations in activities of intracellular signalling molecules of MAPK and PI3K/Akt pathways upon Phyllanthus treatment in MeWo 
cells.  
Figure shows data represent the mean (± SEM) of three independent experiments, each performed in triplicate. The asterisk indicates a significant 
difference between untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.7.4.2 Down-Regulation of MAPK and PI3K/Akt Pathways in PC-3 cells 
In untreated PC-3 cells, two upstream activators, pan-Ras and c-Raf were highly 
expressed to ensure constitutive activation of MAPK pathways (Figure 3.30). Another 
upstream activator of Akt was also found to be highly expressed in PC-3 cells. The 
constitutive activations of pan-Ras, c-Raf and Akt can activate their downstream targets 
in three different MAPK pathways; MAPK/ERK (RSK, Elk1, c-Jun/AP-1), MAPK/JNK 
(JNK1/2) and p38 (p38 MAPK). As shown in Figure 3.30, the detected expressions of 
all these intracellular signalling molecules in untreated PC-3 cells indicate their 
involvement in regulating PC-3 cells’ growth. Nevertheless, expression all these 
signalling molecules proteins had notably been down-regulated in PC-3 cells treated 
with the different species of Phyllanthus (p<0.05).  
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Figure 3.30: Alterations in activities of intracellular signalling molecules of MAPK and PI3K/Akt pathways upon Phyllanthus treatment in PC-3 cells. 
Figure shows data represent the mean (± SEM) of three independent experiments, each performed in triplicate. The asterisk indicates a significant 
difference between untreated (control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.7.5 Alterations of Myc/Max and Hypoxia Pathways by Phyllanthus extracts  
The high expression of Myc/Max and hypoxia pathways in melanoma and 
prostate cancers was observed in untreated MeWo and PC-3 cells (Figure 3.26 and 
3.27), suggesting their crosstalk activities to regulate tumour metastasis and 
angiogenesis. In these pathways, three intracellular signalling molecules were detected 
by western blot; c-myc, HIF-1α, VEGF and GSK3β. However, their expressions were 
altered after treatment with Phyllanthus.  
3.7.5.1 Down-Regulation of Myc/Max and Hypoxia Pathways in MeWo cells 
As shown in Figure 3.31, the expression of the c-myc was detected at 65kDa and 
its expression was noticed significantly decreased by aqueous- (p<0.05) and 
methanolic-Phyllanthus (p<0.01) treated MeWo cells as compared to untreated cells. 
The downstream target of c-myc; HIF-1α and VEGF were detected at 120kDa and 
50kD, respectively. Their expression was significantly down-regulated in treated MeWo 
cells as compared to untreated cells (p<0.05).  A negative regulator of c-myc, glycogen 
synthase kinase 3-beta (Gsk3β) was detected at 51kDa and its expression was 
significantly up-regulated in treated MeWo cells as compared to untreated MeWo cells 
(p<0.01).  
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Figure 3.31: Alterations in activities of intracellular signalling molecules of Myc/Max 
and Hypoxia pathways upon Phyllanthus treatment in MeWo cells.  
 
Figure shows data represent the mean (± SEM) of three independent experiments, each 
performed in triplicate. The asterisk indicates a significant difference between untreated 
(control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.7.5.2 Down-Regulation of Wnt, Myc/Max and Hypoxia Pathways in PC-3 cells 
The expression of Wnt signalling pathway was detected at increased levels in 
PC-3 cells (Figure 3.27) with high percentage down-regulation when treated with 
Phyllanthus. Investigation of the downstream molecules in this pathway, revealed 
expression of three intracellular signalling molecules; Dishevelled (DSH) at 95kDA, 
Gsk3β at 47kDA and β–catenin at 65kDA. After treatment with aqueous (p<0.05) and 
methanolic (p<0.01) extracts of Phyllanthus species as shown in Figure 3.32A, the 
expression of DSH and β–catenin were noted significantly down-regulated. Contrarily, 
the expression of Gsk3β was significantly up-regulated in treated PC-3 cells as 
compared to untreated PC-3 cells (p<0.01).  
In the Myc/Max and hypoxia pathways, three different intracellular signalling 
molecules were detected by western blot. As shown in Figure 3.32B, the expression of 
the c-myc was detected at 67kDA and its expression was noted to be down-regulated in 
aqueous- (p<0.05) and methanolic-treated (p<0.01) PC-3 cells. The downstream targets 
of c-myc; HIF-1α and VEGF were detected at 120kDa and 50kDa, respectively. The 
expression of HIF-1α and VEGF in PC-3 was significantly down-regulated by 
Phyllanthus extracts (p<0.05).  
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(A)  
(B)  
Figure 3.32: Alteration in intracellular signalling molecules of (A) Wnt and (B) 
Myc/Max and Hypoxia pathways in PC-3 cells after treatment with Phyllanthus 
extracts.  
 
Figure shows data represent the mean (± SEM) of three independent experiments, each 
performed in triplicate. The asterisk indicates a significant difference between untreated 
(control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.    
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3.7.6 Alterations of NFκB Pathway by Phyllanthus extracts in MeWo and PC-3 
cells 
Two members of NFκB signalling pathway proteins were detected in MeWo and 
PC-3 cells; NFκB p50 and NFκB p52. As shown in Figure 3.33, both proteins were 
significantly down-regulated in MeWo and PC-3 cells after treatment Phyllanthus 
extracts as compared to untreated cells. The level of both NFκB p50 and p52 
expressions were down-regulated to a range of 56.4-72.3% (p<0.05) by aqueous and 
44.5-57.9% by methanolic extracts in treated cells (p<0.01) in both cells.  
Among the Phyllanthus species, P.urinaria showed strongest inhibitory effects 
on these intracellular signalling molecules in NFκB pathways, followed by P.watsonii, 
P.amarus and P.niruri for both aqueous and methanolic extracts.   
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(A)   
(B)     
Figure 3.33: Alterations of activities intracellular signalling molecules in NFκB 
pathway in (A) MeWo and (B) PC-3 cells after treatment with Phyllanthus extracts. 
 
Figure shows data represent the mean (± SEM) of three independent experiments, each 
performed in triplicate. The asterisk indicates a significant difference between untreated 
(control) and Phyllanthus-treated cells, *p<0.05 and **p <0.01.  
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3.8  Proteomic profiling of the differentially expressed proteins in Phyllanthus 
treated MeWo and PC-3 cells 
The interaction of protein in a cell is complex and provides a comprehensive 
picture of cellular function and biological processes. In cancer, this interaction usually 
is tightly regulated to ensure malignancy of cancer. The dysregulation of some proteins 
and/or interactions may halt the growth of cancer. Therefore, studies of cancer-related 
proteins in cancer cells after treatment with Phyllanthus plant extracts could explain its 
anticancer properties via regulation in the protein and/or interaction networks of cancer. 
A 2D electrophoresis approach was performed to compare the proteomic 
profiles of an untreated cell with that treated cancer cells to identify differentially 
expressed proteins that may be involved in the anticancer activity of Phyllanthus plant 
extracts. The proteomic profiles of untreated and treated MeWo (Figure 3.34) and PC-3 
(Figure 3.35) cells were obtained from ImageMaster 2D scanner (GE Healthcare Life 
Sciences). A two-dimensional electrophoresis gel analytical software, PDQuest version 
7.1 (Bio-Rad, USA) was used to to evaluate and identify the differentially expressed 
proteins between untreated and treated groups.  
Differentially expressed proteins were statistically defined based on two criteria: 
1) degree of intensity >1.0 fold (Protein scores of greater than 70 are considered 
significant, p<0.05) and 2) reoccurrence of the same proteins in the three repeated 
experiments.   
3.8.1.1 Proteomic profiling of human melanoma, MeWo cells  
According to these criteria, 52 proteins in treated MeWo cells were identified by 
MS/MS and grouped in four biological processes; Group 1 (cell adhesion, migration, 
invasion and metastasis), Group II (proliferation, cell cycle and apoptosis), Group III 
(glycogenesis and glycolysis) and Group IV (protein synthesis and energy 
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metabolisms), based on their functions described in UniProtKB/Swiss-Prot protein 
database (Table 3.4).  
In Group I, 8 proteins were found to be differentially expressed in treated MeWo 
cells. Of these, type I cytoskeletal 13 keratin was found to be up-regulated (p<0.05). Its 
expression was significantly up-regulated about 1.4-1.8 folds higher than untreated 
cells. Proteins that were down-regulated in treated cells were identified as Ephrin-B1, 
alpha-centractin, bystin, superoxide dismutase, tubulin beta chain, F-actin-capping 
protein subunit alpha-2 and partitioning defective 3 homolog.  
In Group II, 21 proteins were significantly down-regulated in MeWo cells after 
treatment with Phyllanthus extracts. Among these down-regulated proteins, HCLS1-
associated protein X-1 and casein kinase II subunit alpha proteins showed the greatest 
reduction at 1.5-2.3 folds in their expression as compared to untreated cells (p<0.05).  
In Group III, 5 enzymes were down-regulated in treated MeWo cells. These 
identified enzymes were glucosamine--fructose-6-phosphate aminotransferase, protein 
phosphatase 1 regulatory subunit 3D, alpha-enolase, pyruvate kinase isozymes M1/M2 
and phosphoglycerate kinase 1. 
In Group IV, 15 proteins were found to be down-regulated at the range of 1.3-
1.9 in Phyllanthus treated MeWo cells as compared to untreated cells. Eight of these 
proteins; E3 ubiquitin-protein ligase ARIH2 and RNF115, aspartate aminotransferase, 
26S protease regulatory subunit 8, putative elongation factor 1-alpha-like 3, 
mitochondrial inner membrane organizing system protein 1 (MINOS), zinc finger 
protein, Sec1 and trimethyllysine dioxygenase have been known to be involved 
involved in regulation of mitochondrial integrity and stability of cellular proteisn.  
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Figure 3.34: The proteomic profiles of (A) untreated, aqueous- (B) and methanolic- (C) 
Phyllanthus treated MeWo cells. 
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Table 3:4: The differentially expressed proteins in treated MeWo cells.  
 Differentially expressed proteins in Phyllanthus-treated MeWo 
cells 
Group I 
(Cell 
adhesion, 
migration, 
invasion and 
metastasis) 
Down-regulated Up-regulated 
1.  
2.  
3.  
5.  
6.  
 
7.  
8.  
 
9.  
Ephrin –B1  
Alpha-centractin  
Bystin  
Vimentin  
Superoxide dismutase 
[Mn], mitochondrial 
Tubulin beta chain  
F-actin-capping protein 
subunit alpha-2 
Partitioning defective 3 
homolog 
 
 
4.  Keratin, type I 
cytoskeletal 13 
   
Group II 
(Proliferation, 
cell cycle and 
apoptosis) 
Down-regulated 
10. 
  
11. 
 
  
12. 
 
   
13. 
 
  
14. 
  
15.   
16.   
17. 
  
18.   
19. 
  
20.  
Casein kinase II subunit 
alpha  
Bis(5'-nucleosyl)-
tetraphosphatase 
[asymmetrical] 
Mitochondrial import 
inner membrane 
translocase subunit Tim8 
Structure-specific 
endonuclease subunit 
SLX1  
E3 ubiquitin-protein 
ligase TRAF7  
Humanin-like protein 9 
Galectin-3 
Heterogeneous nuclear 
ribonucleoprotein H 
Annexin A5 
Transcription elongation 
factor A protein-like 3 
Nuclear body protein 
SP140-like protein 
 
 
 
 
21.  
22. 
  
23.  
24. 
  
25. 
  
26.  
 
27. 
  
28. 
29.  
30. 
   
31. 
   
32.   
14-3-3 protein theta 
Peptidyl-prolyl cis-trans 
isomerase A  
Zinc finger protein 169 
GRB2-related adapter 
protein  
HCLS1-associated 
protein X-1  
Methyl-CpG-binding 
domain protein 4 
Glutathione transferase 
omega – 1 
Peroxiredoxin-1  
Serpin B9  
E3 ubiquitin-protein 
ligase ZNRF1  
E3 ubiquitin-protein 
ligase ARIH2  
E3 ubiquitin-protein 
ligase RNF115 
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Group III 
(Glycogenesis 
and 
glycolysis) 
Down-regulated 
33. 
 
 
  
34. 
  
35.  
 
Glucosamine--fructose-6-
phosphate 
aminotransferase 
[isomerizing] 2 
Protein phosphatase 1 
regulatory subunit 3D 
Alpha-enolase 
36. 
  
37.  
Pyruvate kinase 
isozymes M1/M2  
Phosphoglycerate kinase 
1 
  
Group IV 
(Protein 
synthesis and 
energy 
metabolisms) 
Down-regulated 
38. 
 
 
39. 
  
40. 
 
  
41.  
42.  
 
43. 
  
44.  
 
Aspartate 
aminotransferase, 
cytoplasmic  
Small proline-rich 
protein 3  
Patatin-like 
phospholipase domain-
containing protein 4 
Ethanolamine kinase 1 
26S protease regulatory 
subunit 8  
Putative elongation factor 
1-alpha-like 3 
Mitochondrial inner 
membrane organizing 
system protein 1 
45. 
46. 
  
47.  
48.  
49.  
50. 
 
  
51. 
  
52.  
Cathepsin D  
AP-4 complex subunit 
sigma-1  
Adenylate kinase 
Metallothionein-1H  
Zinc finger protein 534 
Mitochondrial inner 
membrane protease 
ATP23 homolog  
Sec1 family domain-
containing protein 1 
Trimethyllysine 
dioxygenase, 
mitochondrial 
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3.8.1.2 Proteomic profiling of human prostate adenocarcinoma, PC-3 cells  
There were 72 differentially expressed proteins identified in treated PC-3 cells 
(Table 3.5). In Group I, 10 proteins were found to be differentially expressed in 
Phyllanthus treated PC-3 cells. Of these, three keratin proteins (type II cytoskeletal 8, 
type I cytoskeletal 9, and keratin-associated protein 3-1) were observed to be up-
regulated. Notably, these up-regulated proteins were derived from same family, keratin 
and their expressions were about 1-2 folds higher than untreated cells. The 7 other 
proteins found to be down-regulated were Ephrin-B1, actin, EH domain-binding protein 
1, heat shock protein 1, vimentin, tubulin alpha-8 chain and MEMO1. 
In Group II, 28 proteins were significantly down-regulated in treated PC-3 cells. 
Among these altered proteins, five namely gluthathione S-transferease P, protein Wnt-
5a, proto-oncogene Wnt-3, putative Ras-related protein Rab-42 and GTPAse HRas 
precursor showed the greatest reduction in their expression with a range of 1.7-2.2 folds 
higher than untreated cells (p<0.05).  
In Group III, 7 down-regulated proteins were identified in the treated PC-3 cells 
and five of them were enzymes; phosphoglycerate kinase-1, alpha-enolase, 
glyceraldehyde-3-phosphate dehydrogenase (G3PD), fructose-biphosphate aldolase and 
triosephosphate isomerase.  
In Group IV, 27 proteins were differentially expressed with only one being 
significantly up-regulated in PC-3 after treatment with Phyllanthus extracts; voltage-
dependent anion-selective channel protein 1 in the range of 1.5-1.8 folds higher. Among 
the down-regulated proteins detected, four have been associated with calcium regulation 
were detected; 39S ribosomal protein L51, calumenin, calreticulin and 78 kDa glucose 
regulated protein.  
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Figure 3.35: Proteomic profiles of (A) untreated, aqueous- (B) and methanolic- (C) 
Phyllanthus treated PC-3 cells. 
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Table 3.5: The differentially expressed proteins in treated PC-3 cells.  
 Differential expressed proteins in Phyllanthus-treated PC-3 cells 
Group I 
(Cell adhesion, 
migration, 
invasion and 
metastasis) 
Down-regulated Up-regulated 
1.   
3.  
4. 
 
5.  
8.  
9. 
10.  
Ephrin –B1  
Actin, cytoplasmic 2 
EH domain-binding protein 
1  
Heat shock protein beta-1 
Vimentin  
Tubulin alpha-8 chain 
Protein MEMO1 
 
2.  
 
6. 
 
7. 
 
Keratin, type II 
cytoskeletal 8 
Keratin, type I cytoskeletal 
9 
Keratin-associated protein 
3-1 
   
Group II 
(Proliferation, 
cell cycle and 
apoptosis) 
Down-regulated 
11. 
 
12. 
13. 
 
14. 
 
15. 
16. 
17. 
18. 
19. 
 
20. 
 
21. 
 
22. 
23. 
 
24. 
 
DNA damage-binding 
protein 2 
Transcription factor 23 
Proliferation-associated 
protein 2G4 
Growth factor receptor-
bound protein 2 
Gremlin-1 
14-3-3 protein theta 
14-3-3 protein gamma 
Annexin A1 
Coiled-coil domain-
containing protein 74B 
Heterogeneous nuclear 
ribonucleoprotein H 
Glutathione S-transferase P 
Protein Wnt-5a 
Transmembrane protein 
222 
Sperm protein associated 
with the nucleus on the X 
chromosome N3 
 
25. 
 
26. 
27. 
 
 
28. 
29. 
30. 
 
31. 
32. 
33. 
 
34. 
 
35. 
36. 
 
37. 
 
38. 
 
ATP-dependent DNA 
helicase Q1 
Galectin-1 
Heat shock protein beta-1 
Glutathione transferase 
omega – 1 
Peroxiredoxin-1 
Thioredoxin-dependent 
peroxide reductase, 
mitochondrial 
RuvB-like 2 
Serpin B9 
E3 ubiquitin-protein ligase 
ZNRF1 
Probable G-protein coupled 
receptor 179 
Bcl-2-like protein 11 
Proto-oncogene Wnt-3 
precursor 
Putative Ras-related 
protein Rab-42 
GTPase HRas precursor 
   
Group III 
(Glycogenesis 
and glycolysis) 
Down-regulated 
39. 
40. 
 
41. 
42. 
 
 
Urocortin-3 
Phosphoglycerate kinase 1 
Alpha-enolase 
Glyceraldehyde-3-
phosphate dehydrogenase 
 
 
 
43. 
 
44. 
45 
Fructose-bisphosphate 
aldolase a 
Triosephosphate isomerase 
Neuroglobin 
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Group IV 
(Protein 
synthesis and 
energy 
metabolisms) 
Down-regulated 
45. 
 
46. 
 
47. 
 
 
48. 
 
49. 
 
 
50. 
51. 
 
52. 
53. 
 
54. 
55. 
 
 
56. 
 
57. 
 
58. 
 
 
 
39S ribosomal protein 
L51  
Betaine--homocysteine S-
methyltransferase 1 
Bis(5'-nucleosyl)-
tetraphosphatase 
[asymmetrical] 
Galactose-3-O-
sulfotransferase 3 
Type 2 lactosamine 
alpha-2,3-
sialyltransferase 
Calumenin 
Protein disulfide-
isomerase A4 
Calreticulin 
Heat shock protein HSP 
90-alpha 
ADP/ATP translocase 1 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 
5'-AMP-activated protein 
kinase subunit beta-1 
78kDa glucose-regulated 
protein 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 12 
 
59. 
 
60. 
 
61. 
 
 
62. 
 
 
63. 
 
64. 
 
65. 
 
66. 
67. 
 
68. 
 
69. 
 
71. 
 
72. 
  
Protein disulfide-isomerase 
A3 
Elongation factor Tu, 
mitochondrial 
Mitochondrial inner 
membrane organizing system 
protein 1 
NADH dehydrogenase 
[ubiquinone] flavoprotein 2, 
mitochondrial 
ADP-ribosylation factor-like 
protein 6 
Vacuolar protein sorting-
associated protein 26A 
BTB/POZ domain-containing 
protein KCTD5 
Dynamin-1-like protein 
Nicotinamide N-
methyltransferase 
Proteasome subunit beta 
type-3 
Speckle-type POZ protein-
like 
Adenylate kinase isoenzyme 
6  
Eukaryotic translation 
initiation factor 3 subunit 12 
Up-regulated 
70. Voltage-dependent anion-selective channel protein 1 
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CHAPTER 4: DISCUSSION 
The integration of human knowledge and intelligence in science and technology 
has improved the quality of human health with earlier diagnosis, different types of 
treatments and reductions in hospitalization. However, the global burden of cancer has 
not decreased but has seen a continuous rise (Ferlay et al., 2010). Modern cancer 
treatment therapies such as surgery, chemotherapy and immunotherapy are deemed 
relatively unsuccessful due to their ineffectiveness, side effects, safety issues and 
costliness. In addition, humankind is confronted with increasing implementation of 
cancer-associated lifestyle choices such as smoking and physical inactivity, contributing 
to an increase in the number of deaths caused by cancer annually (Hanahan & 
Weinberg, 2011). As not all cancer patients respond positively to current anticancer 
agents, mortality rates of certain cancers continue to rise, including melanoma and 
prostate cancer. 
Herbs and plants are the basic remedies in many traditional medicine systems 
and have been extensively used throughout the world for thousands of years and still 
continue to offer mankind with alternatives for disease treatment. The exploration of 
anticancer agents from plant sources began in the 1950s and is still active, with the 
successful discoveries of plant-derived anticancer drugs such as taxol, vinblastine and 
vincristine (Cragg & Newman, 2005; Shoeb, 2006). The “back to basics” approach is 
due to both its long history of usage in disease treatment and the 
pharmacological/nutritional value of these products which are believed to be able to 
halt/delay cancer progression (Deorukhkar et al., 2007).  
In this study, the anticancer properties of four Phyllanthus (P.amarus, P.niruri, 
P.urinaria and P.watsonii) were studied on human melanoma, MeWo and prostate 
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adenocarcinoma, PC-3 cells. The main aims of this study were to identify the various of 
ways by which Phyllanthus plant extracts exert their anti-cancer properties on these two 
cancer cell lines 
4.1 Bioactive Compounds in Phyllanthus 
Food is the main source of essential nutrients to support the nutritional needs of 
our body. Plant-based foods contain a wide range of non-nutrient bioactive compounds 
for vital biological functions including the defense system. These bioactive compounds 
are normally non-toxic in the human body and are important for health promotion. 
Several epidemiologic studies have shown that a plant-based diet provided protective 
effects on chronic diseases such as cancer (Duthie et al., 2000; Talalay & Fahey, 2001). 
In cancer treatment, approximately 74% of anticancer agents are naturally derived 
products (Tan et al., 2006). 
Phyllanthus extracts were subjected to high performance liquid chromatography 
(HPLC) coupled with electronspray ionization (ESI) and mass spectrometry (LCMS- 
MS) analysis to identify the presence of bioactive compounds. The results revealed that 
Phyllanthus extracts consists of twelve bioactive compounds; gallic acid, 
galloylglucopyronside, digalloylglucopyronside, trigalloylglucopyronside, 
tetragalloylglucopyronoside, corilagen, geraniin, rutin, quercetin glucoside, quercetin 
diglucoside, quercetin rhamnoside, and caffeolquinic acid. (Table 3.1) Some of these 
bioactive compounds such as geraniin, corilagen and gallic acid have been proven to 
possess anticancer effect on different cancers (Alía et al., 2006; Guruvayoorappan & 
Kuttan, 2007; Lee et al., 2008a; Chen et al., 2009).  
Geraniin is the main tannin in Euphorbiaceae and its hydrolysation produces 
corilagin (Okuda et al., 1980). Both of these compounds were identified in all four 
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Phyllanthus species. In addition, geraniin is the only bioactive compound that can be 
found in both aqueous and methanolic extracts of four Phyllanthus species. Geraniin 
and corilage have been shown to contribute to growth arrest and induction of apoptosis 
in several cancer cells (Pan et al., 2000; Huang et al., 2004b; Chu et al., 2007; Lee et 
al., 2008a; Wang & Jin, 2010; Xiong & Qing, 2010). Besides this, gallic acid has been 
shown to exhibit anti-proliferative effects on several cancer cell lines such as lung 
(Ohno et al., 1999; Choi et al., 2009), stomach, colon (Yoshioka et al., 2000), prostate 
(Chen et al., 2009) and cervical (Choi et al., 2009).  
As no individual class of components could be fully responsible for the 
activity/effect produced by a whole extract (Sun & Hai Liu, 2006), it was therefore 
more meaningful to assess the activity of Phyllanthus extracst as a whole mixture of 
bioactive compounds rather than as their individual compounds. Semi-purification of 
crude extract of Phyllanthus yielded two fractions (fraction 1 and 2). Both fractions 
were evaluated for their cytotoxicity as comparison to crude extracts of Phyllanthus 
species. 
4.2 Anti-Proliferative Effect of Phyllanthus 
Anti-proliferative effect or cytotoxicity screening was conducted on human skin 
melanoma (MeWo) and prostate (PC-3) cancer cell lines. The half-maximal inhibitory 
concentration (IC50) value is a parameter used to assess dose/concentration of anticancer 
drug, which has an impact on the proliferation of cancer cells. In the present study, 
crude (aqueous and methanolic) extracts of four plant species of Phyllanthus displayed 
different IC50 values on human skin melanoma (MeWo) (Table 3.2) and prostate (PC-3) 
(Table 3.3) cell lines. The variations in the IC50 values of Phyllanthus extracts against 
melanoma and prostate cancer cells might be due to the differing levels of bioactive 
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compounds present in each Phyllanthus species. Among the four Phyllanthus species, 
P. urinaria showed the strongest anti-proliferative effect with the lowest IC50 values 
compared to other species. This could be associated to the presence of higher content of 
bioactive compounds in both extracts.  
As noted, the methanolic extracts of Phyllanthus seemed to have more 
pronounced anti-proliferative effects compared to the aqueous extracts as their effect 
was exhibited at a relatively low dose. Geraniin can be found in both aqueous and 
methanolic extracts. However, geraniin is present together with other bioactive 
compounds in aqueous extracts. This mixture might have reduced the killing effect of 
geraniin on cancer cells, thus resulting in the aqueous extracts exerting the same anti-
proliferative effect at a higher dose as compared to methanolic exracts. Several studies 
reported that the organic-soluble compounds are likely to inhibit or are lethal to 
cancerous cells than water-soluble compounds based solely on its toxicity effect (Cai et 
al., 2004; Saetung et al., 2005). 
 Phyllanthus extracts have exhibited low cytotoxic effects on normal human skin 
(CCD- 1127Sk) and prostate (RWPE-1) cell lines as well as the human umbilical vein 
endothelial cells (HUVECs). These findings correlate with studies carried out by Huang 
et al. in which Phyllanthus plants likely displayed selective killing against cancer cells 
(Huang et al., 2004a). This selective anti-proliferative or cytotoxic effect of Phyllanthus 
is important because currently available anticancer drugs can target normal cells and 
cancer cells, resulting in serious side effects. Thus, Phyllanthus may be applied in 
cancer treatments as it has much lower undesirable side effects.   
The anti-proliferative effect of Phyllanthus species could be due to the presence 
of different bioactive compounds in aqueous extract including galic acid, rutin, and 
quercetin, as well as geraniin in both aqueous and methanolic extracts (Table 1). These 
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bioactive compounds have been reported to possess anti-proliferative effects associated 
with their natural antioxidant activity (Aruoma et al., 1993; Lamson & Brignall, 2000; 
Yen et al., 2002; Alía et al., 2006; Lin et al., 2008; Ito, 2011). The roles of these 
bioactive compounds against cancer have been well documented as they can reduce the 
chance of cancer development by preventing mutation caused by free radicals in normal 
cells (Rao & Agarwal, 2000; Hayes & McMahon, 2001). Therefore, the low anti-
proliferative effect of Phyllanthus extracts on normal cells (CCD- 1127Sk, RWPE-1 
and HUVECs) is believed due to presence of these naturally occurring bioactive 
compounds with antioxidative properties in Phyllanthus plant extracts.  
Phyllanthus plant extracts exhibited selective cytotoxicity against MeWo and 
PC-3 human cancer cells. In comparison, the plant extracts did not show any significant 
cytotoxicity on normal human skin (CCD-1127Sk) and prostate (RWPE-1) cells. In 
contrast, semi-purification of all Phyllanthus’ aqueous crude extract; fraction 1 and 2 
have displayed cytotoxicity to both normal and cancer cell lines. As mentioned earlier, 
no any individual class of components in an extract could be entirely held accountable 
for the activity produced by the whole extract itself (Sun & Hai Liu, 2006). Therefore, it 
was more meaningful to assess the anticancer activity of Phyllanthus as a complete 
mixture of bioactive compounds in crude extracts rather than fractionation of 
Phyllanthus species.  
4.3 Regulation of Cancer Cells Proliferation by Phyllanthus 
Cell cycle is the main regulator in cell proliferation and growth. Deregulation of 
this process will drive cancer cells into uncontrolled proliferation, which has been 
described as one of the hallmark traits of cancer (Evan and Vousden, 2001). This 
deregulation of cell cycle in human cancer appears to be the ultimate targets for possible 
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therapeutic interventions. Several studies have showed that the anti-proliferative effects 
of cytotoxic agents are attributed to cell cycle arrest at different phases (G0/G1, S or 
G2/M) and lead to apoptosis induction (Hsieh & Wu, 1999; Evan & Vousden, 2001). 
Phyllanthus extracts induced cell cycle arrest at S-phase in MeWo cell (Figure 
3.2) indicating that DNA synthesis was interupted, halting the progression of cell cycle 
at S-phase and leading to apoptosis induction with evidence of apoptotic cell 
accumulation of Sub-G1 phase. The induction of apoptosis in MeWo cells was further 
implicated with caspases-3/7 activation, TUNEL-positive cells and DNA fragmentation 
(Figure 3.4-3.7). The S-phase arrest in Phyllanthus treated MeWo cells were due to an 
alteration in MAPK/JNK and PI3K/Akt (Figure 3.29). Shishodia et al. has shown the 
the suppression of PI3K/Akt and activation of JNK/c-Jun  would lead to activation of 
cyclin-dependent kinase inhibitor (CKI), p21 to induce S-phase arrest (Shishodia et al., 
2007). In addition, the cell cycle arrest at S-phase was further imposed with the 
activation of p53 in treated MeWo cells (Figure 3.28A).The involvement of p53 to 
induce cell cycle arrest at S-phase was observed as p21 is a major target for 
transactivation by p53 (Radhakrishnan et al., 2004). The activation of p21 will induce 
cell cycle arrest at S-phase through two mechanisms; (1) interaction of p21 with the 
proliferating cell nuclear antigen (PCNA) (Waga et al., 1994; LaBaer et al., 1997; 
Levine, 1997) and/or (2) p21 directly inhibiting the activity of cyclin E/CDK2 
complexes (Harper et al., 1995; Kuwajerwala et al., 2002; Shishodia et al., 2007). 
Beyond its involvement with cyclin/CDKs, p21 also involved in regulation of various 
DNA-binding proteins that contribute to growth arrest including NFκB, Myc, E2F, 
STAT3, and estrogen receptor (Perkins, 2002; Coqueret, 2003; Fritah et al., 2005). 
Therefore, the down-regulations of c-myc (Figure 3.31) and NFκB (Figure 3.33A) 
proteins were observed in MeWo cells after treatment with Phyllanthus extracts (Figure 
4.1C and 4.1D).  
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Phyllanthus extracts have exerted their growth arrest on treated-PC-3 cells by 
accumulating the cells at Go/G1-phase (Figure 3.3), indicating that Phyllanthus extracts 
may interfere with protein synthesis in PC-3 cells. The induction of apoptosis by 
Phyllanthus was observed with accumulation of apoptotic cells at Sub-G1 phase, and 
further implicated with caspases-3/7 activation, TUNEL-positive cells and DNA 
fragmentation (Figure 3.4-3.7). The G1-phase arrest in Phyllanthus treated PC-3 cells 
was believed due to the down-regulation of MAPKs, Wnt, NFκB and Myc/Max 
pathways (Figure 3.30, 3.32 and 3.33). The down-regulation of these pathways could 
lead to the activation of cyclin-dependent kinase inhibitor (CKI), p27, which in turn, the 
activated p27 proteins could inhibit the activation of cyclin E/CDK2 and/or cyclin 
D/CDK4 complexes that halted cell cycle progression at G1 phase (Collins et al., 2005; 
Ollinger et al., 2007). In addition, down-regulation of Wnt and Myc/Max pathways by 
Phyllanthus in PC-3 cells caused activation of GSK3β to degrade c-myc and β-catenin 
proteins (Figure 4.2C), which in turn, reduce production of cyclin D, which is an 
important initiator of cell cycle. Several studies have shown the involvement of Wnt 
and Myc/Max pathways in regulation of cyclin D to induce cell growth arrest 
(Massagué, 2004; Dolcet et al., 2005; Tang et al., 2009).  
4.4 Induction of Apoptosis by Phyllanthus 
Evasiveness of apoptosis is one of the hallmarks of cancer. This can be achieved 
by suppressing the expression of pro-apoptotic protein, Bax and stimulating the 
expression of anti-apoptotic protein, Bcl-2. However, the expression of Bcl-2 was 
greatly suppressed, accompanied by the up-regulation of Bax expression in Phyllanthus-
treated MeWo and PC-3 cells (Figure 3.28). The reduction in Bcl-2 expression was due 
to the inhibitions in MAPK pathway by Phyllanthus extracts (Milella et al., 2002; Xiao 
et al., 2004) (Figure 3.29 and 3.30). The highly expressed Bax could induce cytochrome 
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c release from the mitochondria which can then induce proteolytic activation of 
procaspse-9. This in turn activates caspase-3 and -7 (Kirsch et al., 1999; Fan et al., 
2005) as detected (Figure 3.4) and finally leads to apoptosis induction in MeWo and 
PC-3 cancer cells (Figure 4.1E and 4.2E). 
Other pro-apoptotic factors, caspase-3 and -7 were also found to be up-regulated 
in treated MeWo and PC-3 cells (Figure 3.4). The actived caspase-3 and -7 can induce 
apoptosis via (1) cleaving and releasing of caspase-activated DNase (CAD) from its 
inhibitor in CAD/ICAD complex, which in turn, translocates into the nucleus to cause 
internucleosomal DNA fragmentation (Cohen, 1997; Fan et al., 2005) and (2)  
inactivation of enzyme poly (ADP-ribose) polymerase (PARP) (Los et al., 2002). 
Therefore, elevation of these caspases after Phyllanthus treatment produces the 
appearance of the morphological characteristics of apoptosis, allowing for DNA 
fragments to be seen on an agarose gel (Figure 3.7) and is further confirmed with the 
presence of TUNEL-positive cells (Figure 3.5). Hence, the anti-proliferative effect of 
Phyllanthus extracts on MeWo and PC-3 cancer cell lines was accompanied with 
apoptosis by triggering the activation of caspase-3 and -7. Several studies have reported 
the involvement of geraniin, rutin, quercetin and gallic acid that presence in Phyllanthus 
extracts to induce apoptosis via caspases activation (Serrano et al., 1998; Ohno et al., 
1999; Shen et al., 2003; Lee et al., 2008a; Wang & Jin, 2010).  
The PI3K/Akt pathway is an overactive intracellular signalling pathway that can 
be found in different cancers that involves in the regulation of apoptosis, cell cycle 
progression and cellular growth (Figure 4.1A and 4.2A) (Luo et al., 2003; Osaki et al., 
2004; Vara et al., 2004). However, supression of Akt protein by Phyllanthus was 
observed in both MeWo and PC-3 cells (Figure 3.29 and 3.30) and this suppression 
could induce apoptosis through activation of pro-apoptotic factors such as Bax, GSK3β, 
procaspase-9 and TRAIL/APO-2L (TNF-Related Apoptosis-Inducing Ligand) (Cross et 
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al., 1995; Datta et al., 1997; Testa & Bellacosa, 2001). The activation of Bax and 
GSK3β were both detected in the treated cancer cells (Figure 3.28, 3.31 and 3.32). 
Induction of apoptosis by Phyllanthus will be further implemented when the 
transcription factor cyclic AMP response element-binding protein (CREB) and IκB 
kinase (IKK), a positive regulator of NFκB are dephosphorylated by Akt protein, thus 
possibly leading to a reduction in the expression of genes with anti-apoptotic activity 
(Kane et al., 1999; Vara et al., 2004).  
Ras proteins are membrane bound GTPases responsible for transmitting 
extracellular signals into the nucleus to regulate gene-driven malignancy of cancer 
including proliferation, apoptosis, evasion, metastasis and angiogenesis (Figure 4.1B 
and 4.2B) (Roberts & Der, 2007). The observed down-regulation of pan-Ras proteins by 
Phyllanthus will then leads to suppression of its downstream target; c-Raf (Figure 3.29 
and 3.30). The major downstream targets of c-Raf can be subdivided into three mitogen-
activated protein kinase (MAPK) pathways; ERK1/2, JNK1/2 and p38 MAPK (Figure 
4.1B and 4.2B). In cancer cells, the activate ERK1/2 molecules will activate RSK and 
Elk1 proteins that subsequently activate c-Jun and c-Fos proteins. Both c-Jun and c-Fos 
will then combine to form an activator protein (AP-1) which is a transcription factor 
that regulates survival genes (Figure 4.1B and 4.2B). Besides that, JNK1/2 and p38 
MAPK pathways are also involved in enhancing AP-1 formation by also producing c-
Jun and c-Fos (Roberts & Der, 2007). However, all these intracellular signalling 
molecules involved in the MAPK signalling were noted to be down-regulated in MeWo 
and PC-3 cells after treatment with Phyllanthus extracts (Figure 3.29 and 3.30). These 
observations could be due to presence of quercetin and gallic acid in Phyllanthus 
extracts that induce apoptosis via suppression of MAPK pathway as observed (Ishikawa 
& Kitamura, 2000; Nguyen et al., 2004; Granado-Serrano et al., 2006; Ho et al., 2010).   
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Tumour necrosis factor-alpha (TNF-α) is a cytokine that and is capable of 
activating multiple downstream signalling pathways, including caspases, IκB kinase 
(IKK) and JNK (Baud & Karin, 2001; Lin, 2002). TNF-α does not usually induce 
apoptosis unless NFκB has been inactivated (Baud & Karin, 2001; Karin & Lin, 2002). 
During TNF-α induced apoptosis, caspases will be activated and IKK will be 
inactivated. The inactivation of IKK causes NFκB to bind to its inhibitor and is then 
unable to translocate into nucleus to regulate its target genes, which include inhibitors 
of apoptosis (IAPs) family (Baldwin, 2001; Karin & Lin, 2002). Therefore, Phyllanthus 
probably causes apoptosis in MeWo cells by regulating TNF-α induced apoptosis 
through activation of the JNK pathway (Figure 3.29) and inhibition of NFκB pathway 
(Figure 3.33A).  
In different types of cancer, NFκB is constitutively active and is believed to play 
an anti-apoptotic role (Ahn et al., 2007). The inhibition of NFκB was observed in 
MeWo and PC-3 cells after treatment with Phyllanthus extracts (Figure 3.33). The 
inhibitory effect of Phyllanthus extracts on NFkB pathway was conducted by measuring 
the activities of NFkB-1 (p50) and NFkB -2 (p52). Both p50 and p52 lack a 
transactivation domain, thus are required to form homodimers or heterodimers with 
other Rel subunits, in order to regulate its target genes (Figure 4.1D and 4.2D). The 
anti-apoptotic effects of active NFκB have been proposed as NFκB induces the 
expression of the Inhibitors of Apoptosis (IAPs) and some anti-apoptotic proteins. The 
IAPs can suppress the activation of effector caspases (caspases-3, -6, -7, and 9), 
whereas anti-apoptotic proteins (e.g. Bcl-2) can antagonize the function of the pro-
apoptotic proteins (e.g. Bax). Therefore, the observed down-regulation of NFκB 
pathways in treated cancer cells (Figure 3.33) is believed to inhibit proliferation and by 
suppressing anti-apoptotic proteins (Bcl-xl and cIAP) as well as by inducing 
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programmed cell death in MeWo and PC-3 cells (Figure 4.1D and 4.2D) (Levine et al., 
2003; Aggarwal, 2004).  
The highly conserved cellular processes of apoptosis cannot be regulated by a 
single protein; instead they are usually controlled by a group of tightly regulated 
proteins. Uncontrolled proliferation of cancer cells can cause many of these proteins to 
be differentially expressed to pace with the tumour growth. With the treatment of 
Phyllanthus, many of these proteins were found to be altered in MeWo (Table 3.4) and 
PC-3 cells (Table 3.5) such as keratin, Ephrin-B1, alpha-centractin, bystin, tubulin, 
actin, vimentin and protein MEMO1 (Figure 4.1G and 4.2G).  
Two differentially expressed proteins showed greatest reduction in their 
expression in treated cells after treatment with Phyllanthus; HCLS1-associated protein 
X-1 (HAX1) and casein kinase II subunit alpha (CK2). HAX-1 is a 35kDa protein that 
interacts with HS1 and the α-subunit of G13 heterotrimeric G protein for cell migration 
(Suzuki et al., 1997; Radhika et al., 2004). HAX-1 is highly expressed in hypoxic 
tumour progression, metastatic pancreatic cancer and oral squamous cell carcinoma, 
liver, lung, and breast cancer (Velculescu et al., 1995; Jiang et al., 2003; Ramsay et al., 
2007). The down-regulation of HAX-1 is believed to inhibit cell migration and induce 
apoptosis as it shares partial sequence similarity with pro-apoptotic proteins in Bcl-2 
family (Suzuki et al., 1997; Klein et al., 2006). CK2 is a highly conserved protein 
serine/threonine kinase and is highly expressed in different cancers (Landesman-Bollag 
et al., 2001; Litchfield, 2003; Izeradjene et al., 2005). Several studies showed that the 
involvement of CK2 has anti-apoptotic function through (1) inhibition on Max which is 
a transcriptional partner of the c-myc, from caspase-mediated degradation (Krippner-
Heidenreich et al., 2001), (2) deactivation of Bid, a pro-apoptotic protein (Desagher et 
al., 2001), and (3) through protection from Fas- and drug-triggered apoptosis (Desagher 
et al., 2001; Guo et al., 2001). Therefore, down-regulation of CK2 in treated MeWo 
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cells could elicit apoptosis induction and could increase the susceptibility of MeWo 
cells to apoptotic inducer chemotherapeutic agents (Faust & Montenarh, 2000; Ravi & 
Bedi, 2002; Ruzzene et al., 2002).   
Another differentially expressed protein that showed reduction in its expression 
in treated cells after treatment with Phyllanthus was galectin. Galectin is a 
multifunctional protein, which can act as (1) an apoptosis inhibitor (Yang & Liu, 2003; 
Hoyer et al., 2004), (2) mRNA splicing promoter (Dagher et al., 1995; Vyakarnam et 
al., 1997), and (3) as an adhesion molecule (Glinsky et al., 2001) to promote cancer 
progression and metastasis (Takenaka et al., 2002; Liu & Rabinovich, 2005). Therefore, 
the down-regulation of galectins in treated MeWo and PC-3 cells is believed to inhibit 
metastasis and trigger programmed cell death.  
Besides this, Phyllanthus extracts also disrupted cancer-related proteins involved 
in cell cycle to halt the growth of MeWo and PC-3 cells. These altered proteins include 
DNA damage-binding protein 2, transcription factor 23, gremlin-1, proliferation-
associated protein 2G4, growth factor receptor-bound protein 2, 14-3-3 proteins, 
annexin A1, glutathione, galectin-1, heat shock proteins, peroxiredoxin, RuvB-like 2 
and Serpin B9, in treated cancer cells  (Table 3.4 and 3.5). Among these proteins, the 
expressions of glutathione S-transferases showed the greatest reduction compared to 
other proteins. Glutathione S-transferases (GSTs) are a family of enzymes that play an 
important role in redox homeostasis. These enzymes are highly expressed in cancer 
cells and are believed to limit the efficacy of chemotherapeutic agents (Tew, 1994; 
Townsend et al., 2003). This occurs via detoxification whereby the agents are 
conjugated with reduced gluthathione, causing them to be more water-soluble and 
enhancing the elimination of the agents (Hayes & McMahon, 2001; Michael & Doherty, 
2005). Therefore, the suppression of GSTs in treated PC-3 cells could possibly bypass 
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detoxification of Phyllanthus extracts, allowing them to be circulated to target cancer 
areas.  
Another down-regulated protein by Phyllanthus was Damaged DNA Binding 
protein 2 (DDB2). It is a 48kDa subunit protein of the damage-specific DNA-binding 
heterodimeric complex (DDB) and is involved DNA repair mechanism, transcription 
and cell cycle regulation in normal cells (Datta et al., 2001; Martinez et al., 2001; 
Takimoto et al., 2002; Stoyanova et al., 2009). During cell cycle, high levels of DDB2 
in G1-phase are observed (Stoyanova et al., 2009). It has been proposed that DDB2 
plays an important role in regulation of cell cycle and apoptosis induction rather than in 
the DNA repair mechanism (Kulaksız et al., 2005). Therefore, the low level of DDB2 
proteins in treated cells is believed to attribute to cell cycle arrest and the triggering 
apoptosis induction.   
Lactate dehydrogenase (LDH) is a cytoplasmic enzyme that is produced by the 
mitochondria and present in all tissues. It plays an important role in oxidation of lactate 
while reducing pyruvate in carbohydrate metabolism during anaerobic glycolysis 
(Nathan et al., 2006). LDH has been widely used as a general indicator and monitors for 
acute or chronic tissue damage, heart attack, kidney and liver disease as well as cancer. 
(Goldberg et al., 1989; Ribeiro et al., 1999; Danpure, 2004). The potential of LDH as a 
tumour biomarker was identified in several cancers such as melanoma (Ugurel et al., 
2009), lung (Jørgensen et al., 1989; Molina et al., 2004), breast (Seth et al., 2003; Duffy 
& Crown, 2008) and prostate cancers (Albers et al., 2008; Scher et al., 2009). During 
necrosis, LDH enzyme will be secreted due to damaged cell membrane of necrotic cells 
and causes an inflammatory reaction (Drent et al., 1996). However, the changes in the 
cytoplasmic membrane integrity during late apoptosis also resulting secretion of LDH 
(Rauen et al., 1999; Jiang et al., 2007). Measurements of LDH enzyme as an indicator 
of necrosis, demonstrated that Phyllanthus extracts besides having apoptotic activity, 
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also possess minimal capacity for inducing necrotic cell death on both MeWo and PC-3 
cells (Figure 3.8 and 3.9). Taken together, the results indicate that the Phyllanthus plant 
possesses a dual-capability for cell death.   
4.5 Anti-Metastatic Effect of Phyllanthus 
Typically, tumour metastasis is the main cause for high morbidity and mortality 
rates in cancer patients. Most melanoma and prostate cancer patients’ exhibits clinical 
evidence of tumour metastases such as lung, breast and bone metastases (Jemal et al., 
2011). The mortality associated with metastasized tumours, accounting for 90% of all 
cancer deaths (Gupta & Massagué, 2006). Metastases has caused poor prognosis in 
these cancer patients and is a major clinical challenge in cancer treatment.  
Cancer cell interaction with the basement membrane is an important step in the 
initiation of the metastatic cascade (Poste & Fidler, 1980; Gupta & Massagué, 2006). 
The basement membrane is a thin layer that underlies the epithelium of vessels, 
capillaries, cavities and organs. It is composed of glycoproteins such as collagen and 
laminin (Okegawa et al., 2004). However, adhesion activity of MeWo and PC-3 cells 
after treatment with Phyllanthus extracts to fibronectin and type-IV collagen 
respectively, was disrupted (Figure 3.18 and 3.19). In addition, Phyllanthus extracts 
have significantly inhibited MeWo and PC-3 cells’ migration and invasion ability in a 
dose-dependent manner (Figure 3.10-3.17). Migration of cancer cells across the 
endothelium is important for secondary tumour development and Phyllanthus extracts 
significantly inhibited the transendothelial migration of MeWo (Figure 3.20) and PC-3 
cells (Figure 3.21). All these findings indicate that Phyllanthus exhibits its anti-
metastatic activity through inhibition of several crucial steps of tumour-invasion which 
include attachment of tumour cell to the membrane, migration, invasion and 
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transendothelial migration of MeWo and PC-3 cells and could possibly lessen the 
chances of secondary tumour formation. Epithelial-mesenchymal transition (EMT) is a 
cellular process that allows immotile epithelial cells to become motile mesenchymal 
cells, promoting carcinoma invasion and metatstasis as well as resistance to apoptosis 
(Voulgari & Pintzas, 2009). Several signalling networks including PI3K/Akt- (Figure 
4.1A and 4.2A), Ras/MAPK- (Figure 4.1B and 4.2B), Wnt- (Figure 4.1C and 4.2C) and 
NFκB-dependent (Figure 4.1D and 4.2D) pathways in EMT were found to be down-
regulated in treated MeWo and PC-3 cells, and are thus believed to inhibit metastasis of 
cancer cells (Klymkowsky & Savagner, 2009). The inhibition on metastasis was further 
imposed with the up-regulation of keratin and concurrent down-regulation of vimentin 
in MeWo and PC-3 cells after treatment with Phyllanthus. The exact mechanism of up-
regulation of keratin during EMT is unclear but its down-regulation in treated cells can 
restrict the motility of cells, thus halting metastasis (Paccione et al., 2008).   
In cell cytosol, Akt protein protects vimentin from caspase-induced proteolysis, 
and in Phyllanthus-treated cells, Akt was down-regulated and thus down-regulates 
production of vimentin. The overexpression of vimentin is always correlated with 
tumour growth and invasion, where vimetin is believed to regulate various intracellular 
signalling pathways and cell surivial (Zhu et al., 2010). This is done by (1) stabilization 
of the ERK protein, allowing it to be translocated into the nucleus (Perlson et al., 2006; 
Satelli & Li, 2011) and (2) preventing assembly of the Raf-14-3-3 complex, allowing 
Ras protein to be continuously expressed and thus regulate signalling pathways in cells 
(Tzivion & Avruch, 2002). Therefore, down-regulation of vimentin could decrease 
melanoma and prostate cancer growth, adhesion and invasion as well as apoptosis 
induction via suppression on ERK- and Ras-dependent pathways as observed. 
A phosphoserine/phosphothreonine binding protein, 14-3-3 is involved in 
protein kinase signalling that regulates several vital biological processes in cancer 
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including cell cycle, DNA damage checkpoint, activation of MAPK, prevention of 
apoptosis, and coordination of integrin signalling and cytoskeletal dynamics 
(Hermeking, 2003a; Tzivion et al., 2006). This can all be achieved by association of 14-
3-3 with (1) oncogenic proteins (Ras, Bcr and Bcr-Abl), (2) cell survival factors (Bad, 
Bax, ASK-1), (3) tumour suppressors (p53, TSC2, p27) and (4) cell cycle regulators 
(Cdc25 A, B and C, Wee1, Chk1) as well as (5) proteins involved motility (p130 Cas, 
integrins β1, β2, β3 and Ron) (Hermeking, 2003a; Wilker & Yaffe, 2004; Tzivion et al., 
2006). However, all these vital biological processes in MeWo and PC-3 cells are 
believed to be interrupted due to the down-regulation of the 14-3-3 protein.  
4.6 Anti-Angiogenesis Effect of Phyllanthus 
Tumour-induced angiogenesis is the growth of new blood capillaries from pre-
existing blood vessels and involves multiple steps including endothelial cell (EC) 
activation, disruption of vascular basement membranes, and migration and proliferation 
of ECs (Delgado et al., 2011). Tumour-induced metastasis and angiogenesis are 
intrinsically connected as highly vascular tumours may have a higher metastatic 
potential than angiogenic tumours (Zetter, 1998). Besides providing oxygen and 
nutrients for tumour growth, angiogenesis also provides a path to allow the tumour cells 
to metastasize (Weidner et al., 1991).  
Tumour-induced angiogenesis has similar cytophysiological changes in 
endothelial cells as in metastatic cells. The activated endothelial cells will migrate out 
from parental vessels, invade basement membrane, proliferate and assemble into new 
capillaries to supply oxygen and nutrients to tumours (Zetter, 1998). Therefore, the anti-
angiogenesis activity of Phyllanthus was studied by assessing cell viability, migration, 
invasion and microcapillary-like tube structure formation using HUVECs.  
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The migration and invasion capabilities of endothelial cells are the basis in 
angiogenesis. Their motility capability is initiated by pro-angiogenic factors including 
VEGF, secreted by the tumour (Carmeliet & Jain, 2000). In addition, this factor can 
increase proliferation and differentiation of endothelial cells into capillaries to form new 
blood vessels for tumour growth and metastasis. Results show that Phyllanthus extracts 
have effectively inhibited the migration and invasion ability of HUVECs (Figure 3.12 
and 3.17). In addition, the low expression of VEGF and its regulator, HIF-1α in MeWo 
and PC-3 cells were detected after treatment with Phyllanthus extracts (Figure 3.31 and 
3.32) and further explaines that Phyllanthus extracts have reduced the expression and/or 
secretion of VEGF of cancer cells via suppression on HIF-1α to inhibit angiogenesis 
(Figure 4.1C and 4.2C). Therefore, these findings suggested that Phyllanthus extracts 
can significantly reduce migration and invasion of endothelial cells, indicating the 
plants potential as an anti-angiogenic agents and was shown previously by Huang et al 
(Huang et al., 2006). On the ECM gel, HUVECs assembled into microcapillary–like 
tube structures or lumen and this formation was inhibited when treated with Phyllanthus 
extracts (Figure 3.25).  
Besides that, suppression on Wnt and Myc/Max pathways in MeWo (Figure 
4.1C) and PC-3 (Figure 4.2C) cells by Phyllanthus extracts can be attributed to down-
regulation of VEGF and HIF-1α. This can achieve by activate GSK3β protein to 
degrade β-catenin and c-myc proteins, thus down-regulating the expression of VEGF 
and HIF-1α (Figure 3.31 and 3.32). In addition, suppression on MAPK and PI3K/Akt 
pathways in MeWo (Figure 4.1A and 4.2B) and PC-3 (Figure 4.2A and 4.2B) cells by 
Phyllanthus extracts could also lead to inactivation of VEGF, thus inhibiting tumour-
induced angiogenesis (Adya et al., 2008).  
Besides VEGF, the Ephrin-B1 protein also plays an important role in tumour-
induced angiogenesis. Ephrin-B1 can act as a ligand to bind and activate Eph receptor 
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tyrosine kinases that induce migration and integrin-mediated αvβ3 and α5β1 attachment  
(Huynh-Do et al., 2002; Sawai et al., 2003; Surawska et al., 2004; Kuijper et al., 2007; 
Tanaka et al., 2007). High expression of Ephrin-B1 is found in different types of 
advanced cancer such as studies gastric, colorectal, breast, ovarian, neuroblastoma, and 
lung cancers (Sawai et al., 2003; Herath et al., 2006; Cortina et al., 2007; Tanaka et al., 
2007; Vaught et al., 2008). Therefore, down-regulation of of Ephrin-B1 by Phyllanthus 
extracts could inhibit cancer progression via inhibition on modulation integrin-mediated 
cell attachment, migration and angiogenesis (Huynh-Do et al., 2002).  
Several plant-derived compounds identified to possess anti-angiogenesis activity 
includes sanguinarine isolated from Sanguinaria canadensis, vinca alkaloids from 
Catharanthus roseus and pterogynidine from Alchornea glandulos (Eun & Koh, 2004; 
Kruczynski et al., 2006; Flávia et al., 2009). The anti-angiogenic effect of Phyllanthus 
against endothelial cells could be due to the presence of bioactive compounds in the 
plant such as gallic acid, rutin and quercetin (Donnini et al., 2006; Guruvayoorappan & 
Kuttan, 2007; Chen et al., 2009). These compounds have been reported to reduce the 
sensitivity of endothelial cells towards VEGF via inhibitions on several signalling 
pathways including PI3k/Akt, NFκB and Ras/MAPK pathways (Figure 3.29, 3.30 and 
3.33) (Shiojima & Walsh, 2002; Donnini et al., 2006; Liu et al., 2006b; Adya et al., 
2008; Kitamura et al., 2008; Lu et al., 2010). All these findings indicate that 
Phyllanthus can inhibit tumour growth through the suppression of blood vessel 
development and has a high potential to be developed as an anti-angiogenesis agent. 
Furthermore, Phyllanthus could also possibly prevent other angiogenesis-mediated 
disorders such as diabetic blindness, age-related macular degeneration, rheumatoid 
arthritis and stroke. 
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4.7 Activation of Matrix Metalloproteinases by Phyllanthus 
In metastasis, matrix proteolytic enzymes such as matrix metalloproteinases 
(MMPs) are known to be crucial for degradation of extracellular matrix components and 
promoting both endothelial and tumour cellular invasion in vitro and in vivo (Huang et 
al., 2006; Bourboulia & Stetler-Stevenson, 2010). Overexpression of MMP enzymes is 
always associated with poor prognosis (Sier et al., 1996; Yoshizaki et al., 2001; 
Pellikainen et al., 2004; Liu et al., 2005). MMP-2 and MMP-9 are always found highly 
expressed in various cancers malignancies, including cervical, melanoma, breast, colon 
and prostate cancers (Stearns & Stearns, 1996; Luca et al., 1997; Kondapaka et al., 
1998; Nielsen et al., 1998).  
In this study, different MMP enzymes including MMP-2, -7, -9 and -26 were 
detected in HUVECs, MeWo and PC-3 cell lines (Figure 3.22-3.24). Phyllanthus 
extracts showed inhibitory effects on expression of MMP-2 in HUVECs and MeWo 
cells. Human matrilysin-2, also known as MMP-26 is an activator for pro-MMP-9 (Uría 
& López-Otín, 2000; Marchenko et al., 2001). MMP-9 and MMP-26 are commonly 
found in the human prostate carcinoma tissue samples than in prostatitis, benign 
prostate hyperplasia (BSH), and normal prostate tissue (Lee et al., 2006b). However, 
PC-3 cells showed reduction of both active MMP-26 and MMP-9 after treatment with 
Phyllanthus extracts; in conjuction with increasing levels of pro MMP-9 level (Figure 
3.23). Another down-regulated MMP enzyme in treated MeWo and PC-3 cells was 
MMP-7 which has a broad proteolytic activity against a variety of extracellular matrix 
substrates, including collagens, proteoglycans, elastin, laminin, fibronectin, and casein 
(Wilson & Matrisian, 1996; Adachi et al., 1999). The reduction of active MMP-2, -7 
and -9 after treatments with Phyllanthus extracts partially explain the inhibition of 
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migration and invasion of endothelial cell as well as melanoma and prostate cancer 
cells.   
In Phyllanthus, several bioactive compounds have been identified (Tang et al., 
2010). Some of these bioactive compounds have been suggested to inhibit activities of 
MMPs including gallic acid and 5-caffeoylquinic acid. Gallic acid has been shown to 
inhibit migration and invasion of several cancer cells through the reduction of MMP 
activities (Ho et al., 2010; Lu et al., 2010) and 5-caffeoylquinic acid has also been 
shown to be a strong inhibitor on MMP-9 (Jin et al., 2005). In addition, these reduced 
activities of MMPs upon treatment with Phyllanthus could be due to alteration in signal 
transduction in PI3K/AKT, Ras-Raf-MAP kinase, Wnt, NFκB pathways in the 
regulation of MMP expression (Figure 4.1 and 4.2) (Montague et al., 2004; Ho et al., 
2010). In addition, both Wnt5a and Wnt-3 proteins are involved in Wnt signalling 
pathway and regulation of MMPs, were found to be down-regulated by Phyllanthus 
extracts (Masckauchán et al., 2006; Pukrop et al., 2006).  
There are several proteins involved in regulations of MMPs that were found to 
be altered in treated cancer cells such as superoxide dismutase and heat shock protein. 
The down-regulated mitochondrial superoxide dismutase protein could suppress MMP 
action and alters intracellular ROS and nitric oxide levels via inhibition on the 
MAPK/ERK pathway (Ranganathan et al., 2001; Zhang et al., 2002). In addition, 
down-regulation of heat shock protein beta-1 Hsp27 protein could affect MMP-9 
activity, thus inhibits metastasis and angiogenesis (Hansen et al., 2001; Aldrian et al., 
2002; Lee et al., 2008b).  
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4.8 Alteration in Energy Metabolism of Cancer cells 
The rapid uncontrolled proliferation of cancer cells usually outpaces new blood 
vessels generation, hence resulting in insufficient bloods supply/oxygen to tumour 
tissues. In this hypoxic condition, the cancer cells are forced to up-regulate the 
expression of genes and enzymes which are involved an anaerobic glycolytic pathway 
as the main route of energy production, and this phenomenon is known as Wasburg 
effect (Warburg, 1956; Hsu & Sabatini, 2008) (Vander Heiden et al., 2009). The 
expression of hyoxia-inducible factor (HIF) is activated during low oxygen level 
(Guppy, 2002; Xu et al., 2005). The active HIF will mediate activation genes involved 
in angiogenesis (e.g. VEGF), cell survival (e.g. IGF-1) and metastasis (e.g. LOX, PAI-
1) and drives tumour progression (Poon et al., 2009). This metabolic adaptation in 
response to these alterations is believed to be associated with resistance to therapeutic 
agents (Carmeliet et al., 1998).    
Phyllanthus extracts were noted to inhibit the glycolytic pathway and energy 
production in MeWo and PC-3 by down-regulating HIF-1α protein. The deactivated 
HIF-1α protein will reduce the production VEGF and thus inhibit tumour angiogenesis, 
glycolytic pathway and energy production and thereby decrease cancer progression 
(Figure 3.31 and 3.32). The synthesis of HIF-1α protein in the Wasburg effect is 
regulated by activation of the PI3K/Akt and Ras-MAPK (Poon et al., 2009). Therefore, 
both PI3K/Akt and Ras-MAPK pathways were also noted to be suppressed by 
Phyllanthus plant extracts (Figure 3.29 and 3.30). In addition, several glycolytic 
enzymes were significantly down-regulated in MeWo and PC-3 cells after treatment 
with Phyllanthus extracts (Table 3.4 and 3.5, Group III) such as glucosamine-fructose-
6-phosphate aminotransferase, fructose-bisphosphate aldolase protein phosphatase 1 
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regulatory subunit 3D, alpha-enolases, pyruvate kinase isozymes M1/M2, urocortin-3, 
alpha-enolase, GAPDH and phosphoglycerate kinases.  
The mitochondrion is involved in protein synthesis and energy metabolism for 
cancer cell survival, transformation, invasion and metastasis (Wallace, 1999). Thirteen 
mitochondria-related components (E3 ubiquitin-protein ligase ARIH2 and RNF115, 
aspartate aminotransferase, 26S protease regulatory subunit 8, putative elongation factor 
1-alpha-like 3, mitochondrial inner membrane organizing system protein 1 (MINOS), 
zinc finger protein, Sec1, trimethyllysine dioxygenase, 39S ribosomal protein L51, 
calumenin, calreticulin and 78 kDa glucose regulated protein) were found to be down-
regulated in Phyllanthus-treated MeWo (Table 3.4, Group IV) and PC-3 (Table 3.4, 
Group IV) cells. This down-regulation is believed to be attributed to alteration in 
intracellular calcium, energy production (e.g. ATP) and stability of cellular proteins in 
treated (MeWo and PC-3 cells, thus triggering apoptotic cell death and halting cancer 
growth (Henderson et al., 1982; Franklin et al., 1997; Yabe et al., 1997; Ferrell et al., 
2000; Sreedhar & Csermely, 2004; Zhang et al., 2004; Thornburg et al., 2008; Alkhaja 
et al., 2012; Sun et al., 2012) .   
Among the affected mitochondria-related components in Phyllanthus-treated 
cells, only one protein was significantly up-regulated; voltage-dependent anion-
selective channel protein 1. Voltage-dependent anion-selective channel protein 1 
(VDAC) is a mitochondrial outer membrane protein that regulates ATP/ADP exchange 
and respiratory control (Hiller et al., 2008). VDAC has been shown to be pro-apoptotic 
by regulation of Bak and Bax (Tsujimoto & Shimizu, 2002; Rostovtseva et al., 2005) as 
well as activation of caspase-8 to induce extrinsic apoptosis pathway (Madesh & 
Hajnóczky, 2001; Roucou et al., 2002). Therefore, the up-regulation of VDAC by 
Phyllanthus extracts was able to initiate apoptotic cell death in cancer cells (Figure 
4.2F). 
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Figure 4.1: Schematic diagram illustrating Phyllanthus regulates multiple signalling 
[MAPKs (A), PI3K/Akt (B), Myc/Max and Hypoxia (C), NFκB (D) and p53 (E)] 
pathways and protein activities (G) in MeWo cells. 
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Figure 4.2: Schematic diagram illustrating Phyllanthus regulates multiple signalling 
[(MAPKs (A), PI3K/Akt (B), Wnt, Myc/Max and Hypoxia (C), NFκB (D), and 
apoptosis (E)] pathways and protein activities (G) in PC-3 cells. 
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CHAPTER 5: CONCLUSION 
Modern therapies for cancer treatment such as surgery, chemotherapy and 
immunotherapy are deemed relatively unsuccessful due to their ineffectiveness, safety 
issues (side effects) and costliness. Although chemotherapy was advocated at one time, 
but recent studies have implied that these agents are no longer effective as they used to 
be, mainly these agents being cytotoxic to both normal and cancer cells. These 
treatments are often elicited undesirable side effects such as vomiting, nausea and 
alopecia. As not all cancer patients respond positively to current anticancer agents, the 
mortality rates are on a continuous rise including melanoma and prostate cancer.  
Natural product-based traditional medicine, is often overshadowed by modern 
medicine, has returned to be a holistic approach for health care in many societies. This 
“back to basic” approach is due to its long history of usage in disease treatment and the 
pharmacological/nutritional value of these products which are believed to be able to 
halt/delay cancer progression. Therefore, the anticancer properties of Phyllanthus plant 
extracts were studied against human melanoma, MeWo and prostate adenocarcinoma, 
PC-3 cells.  
In summary, the findings of the study suggested that Phyllanthus extracts 
possesses the ability to suppress the proliferation of MeWo and PC-3 directly without 
affecting the growth of normal cells; CCD-1127Sk, RWPE-1 and HUVECs. P.urinaria 
showed the strongest anti-proliferative effect on both cancer cell lines with an IC50 
value ranged 54.2-56.2 µg/ml and 155.7-193.3 µg/ml for methanolic and aqueous 
extracts, respectively. The selective killing on cancer cells by Phyllanthus extracts was 
observed. However, the anti-proliferative effect of Phyllanthus extracts should be 
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further investigated on the other types of normal cells to further imposed its selective 
killing properties on cancer cells only.   
The anti-proliferative effect of Phyllanthus extracts against MeWo and PC-3 
cells is likely to be due to the induction of growth arrest and apoptosis. Treatment with 
Phyllanthus extracts induced significant different cell cycle arrest in treated MeWo (S-
phase arrest) and PC-3 (G1-phase arrest). Phyllanthus extracts induces cell cycle arrest 
at S-phase in MeWo cell was due to an alteration in MAPK/JNK, PI3K/Akt and p53 
pathways to interfere activities of the PCNA and/or cyclin E/CDK2 complexes. On the 
other hand, the G1-phase arrest in Phyllanthus treated PC-3 cells was due to 
suppression on MAPK, PI3K/Akt, Wnt and Myc/Max pathways to inhibit cyclin 
E/CDK2 and/or cyclin D/CDK4 complexes, halting cell cycle progression. However, a 
detailed investigation on the G1- and S-phases related proteins such as cyclin D, cyclin 
E, cyclin A, p21, and p27 as well as other cell cycle regulatory molecules are required 
to shed light on the actual molecular mechanisms of Phyllanthus extracts induced cell 
cycle arrest.  
Phyllanthus extracts were capable to induce apoptosis in PC-3 and MeWo cells 
via activation of caspases-3/7 to induce DNA fragmentation. Caspase activation 
represents one of the earliest known markers for the onset of apoptosis while DNA 
fragmentation which occurs downstream of caspase cascade activation represents a late, 
dispensable step in the apoptotic process. Other pro-apoptotic factor, Bax was also 
found to be up-regulated in treated cancer cells. The activated Bax could induce 
cytochrome c release from mitochondria to initiate caspases-induce apoptosis. However, 
a detailed exploration of other pro-apoptotic and anti-apoptotic proteins as well as the 
regulatory molecules such as cytochrome c and PUMA needs to be carried out to 
explicate the exact molecular mechanism of Phyllanthus-induced apoptosis. Besides 
inducing apoptosis, Phyllanthus extracts were also showed to capable induce minimal 
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necrotic cell death. The induction of necrosis by Phyllanthus extracts was observed 
through the leakage of LDH enzymes from the treated cancer cells. All these findings 
were based on biochemical changes during apoptotic and necrotic mechanisms. 
Therefore, further investigation is necessary to investigate Phyllanthus-induce apoptosis 
or necrosis in the term of morphological changes. The typical apoptotic cells’ 
morphology including chromatin condensation, cell shrinkage, membrane blebbing, and 
formation of apoptotic bodies can be investigated by staining methods includes Hoescht 
33258, Acridine orange/ethidium bromide (AO/EtBr), and Annexin-V. Besides that, 
transmission electron microscopy (TEM) may provide a better and clear view of the 
morphological changes during apoptosis/necrosis.  
Typically, tumour-induced metastasis and angiogenesis are the main cause for 
high morbidity and mortality rates in cancer patients. Both are intrinsically connected. 
Besides providing oxygen and nutrients for tumour growth, angiogenesis also provides 
a path to allow the tumour cells to metastasize. The anti-metastatic and anti-angiogenic 
effects of Phyllanthusextracts were observed when Phyllanthus extracts inhibited 
several essential steps during metastasis and angiogenesis; (i) adhesion, (ii) migration, 
(iii) invasion, (iv) transendothelial migration and (v) microcapillary-like tube 
formations. These observations were most likely due to reduction in activities of matrix 
metalloproteinase-2, -7, -9 and VEGF in Phyllanthus-treated cells. In addition, 
Phyllanthus extracts have impaired energy production and mitochondria integrity of 
MeWo and PC-3 cells via inhibition on hypoxia pathway and glycolytic enzymes. 
These observed anticancer properties ofPhyllanthus extracts are believed to be 
due to the plants inhibitory effects on multiple signalling pathways; MAPKs, Wnt, 
Myc/Max, Hypoxia and NFκB, via alteration on their intracellular signalling activities 
including c-Ras, pan-Raf, RSK, Akt, Elk1, RSK, c-Jun, JNK1/2, β-catenin, GSK3β, c-
myc, HIF-1α, VEGF, NFκB p50 and p52.  
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The highly conserved cellular processes of invasion, metastasis and apoptosis 
cannot be regulated by a single protein; instead they are usually controlled by a group of 
tightly regulated proteins. Uncontrolled proliferation of cancer cells can cause many of 
these proteins to be differentially expressed to pace with the tumour growth. With the 
treatment of Phyllanthus, many of these vital proteins were found to be altered in 
MeWo and PC-3 cells and this may affects cellular functions and biological processes in 
MeWo and PC-3 cells, thus halts their progression.  
In summary, this study revealed a comprehensive perspective of the possible 
mechanism behind the anticancer activity of Phyllanthus extracts by inspection of their 
regulation in multiple signalling pathways and protein-protein interaction in melanoma 
(MeWo) and prostate adenocarcinoma (PC-3) cells. This study not only shows that 
Phyllanthus could be developed as an alternative anticancer agent; the identified 
diffentially expressed proteins could become potential targets for development of new 
anticancer agents. Besides, Phyllanthus also possibly be part of plant-based diet to 
prevent cancer development. Further in vivo studies with Phyllanthus alone or in 
conjunction with existing chemotherapeutic drugs are needed to demonstrate the overall 
effect in a living subject (e.g. mice) in term of toxicity and efficacy as an 
anticancer/antitumour agent.  
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APPENDICES  
APPENDIX I: Reagent and media preparation 
(1) Equipment used 
 
- Vertical laminar flow cabinet (Microflow, Birmingham, UK) 
- Water bath (SASTEC) 
- Electronic balance (SASTEC) 
- Analytical balance (SATEC) 
- Ultracentrifuge (Eppendorf) 
- GloMax®-Multi Detection Reader (Promega, USA) 
- Inverted microscope (Olympus CK-40) 
- Inverted microscope (Olympus BX41)  
- Olympus µ-1040 camera 
- UV transilluminator (Vilbert loumat, France) 
 
(2) Preparation of EMEM, DMEM and RPMI-1640  
 
- EMEM supplemented with L-glutamine stock (powder form), (Flowlab, Australia) 
- DMEM supplemented with L-glutamine stock (powder form), (Flowlab, Australia) 
- RPMI-1640 supplemented with L-glutamine stock (powder form), (Flowlab, 
Australia) 
- Sterile Fetal Bovine Serum, FBS (Flowlab, Australia) 
- Penicillin-Stretomycin, (Gibco-BRL, USA) 
- HEPES buffer (Sigma-Aldrich, Ireland Ltd) 
- Sodium bicarbonate (NaHCO3) (Sigma-Aldrich, Ireland Ltd)  
- Filter unit with 0.2µm membrane filter, (Nalgene, USA) 
- Autoclaved double-distilled water 
 
Growth medium (GM) – 1000 ml  
 
Stock media  13.39g  
HEPES buffer  4.7g  
Sodium bicarbonate  3.7g 
Fetal Bovine Serum  (inactivated) 50ml 
Penicillin-streptomycin  0.2ml  
Distilled water  Top up to 1000ml  
 
- Mix all the chemicals into a 1000ml reagent bottle and then filter through a 0.2 
µm of membrane filter.   
- Store at 4°C.   
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(3) Preparation of freezing medium  
 
- Prepared serum free EMEM/RPMI-1640  
- Fetal Bovine Serum (Flowlab, Australia)  
- DMSO (Sigma-Aldrich, Ireland Ltd) 
- Autoclaved double distilled water 
- Sterile 50ml falcon bottle (Corning Inc, USA) 
 
 
Freezing medium – 10ml  
 
Prepared serum free EMEM/RPMI-1640  6ml  
Fetal Bovine Serum  (inactivated) 3ml 
DMSO 1ml  
 
- Mix all the chemicals into a 10ml falcon bottle.  
- Store at 4°C.  
 
 
(4) Preparation of 1X PBS (100ml) 
 
- 1 PBS tablet (Amresco, USA) 
- Double distilled water (100ml)  
 
- Dissolve the PBS tablet in the double distilled water  
- Autoclave the 1X PBS buffer  
 
 
(5) Reagents for MTS assay  
 
CellTiter 96® Aqueous Non-Radioactive Cell Proliferation assay kit (Promega, 
Madison, WI) 
 
Kit components  
- 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphonyl)-2H   
  tetrazolium, inner salt (MTS) solution 
- Phenazine methosulphate (PMS) solution  
- Store at -20°C 
 
  
(6) Reagents for DNA staining for cell cycle analysis  
 
- Ice cold 70% ethanol  
- PBS  
- RNase (1 mg/ml)  
- Propidium iodide (PI) (1 mg/ml)  
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(7) Reagents for DNA extraction  
  
- PBS  
- Lysis buffer  
- Phenol/chloroform/isoamyl alcohol (24:25:1) 
- 3M Sodium acetate (pH 5.2)  
- Isopropanol   
- Deionized water-RNase solution (10 mg/ml) 
 
 
(8) Preparation of lysis buffer for DNA Fragmentation assay 
 
0.5 M EDTA, pH7.0 40 ml  
1 M Tris-Cl buffer, pH 8.0  5 ml  
100 % Triton X-100  5 ml  
Distilled water  50 ml 
 
 
(9) Preparation of 0.5 M EDTA, pH7.0  
 
- Disodium EDTA.2H2O (18.61 g)  
- Double distilled water (100 ml)  
- Fine adjust to the desired pH (7.0) with 1 M NaOH 
 
 
(10) Preparation of 1 M NaOH  
 
- NaOH (4 g)  
- Double distilled water (100 ml) 
 
 
(11) Preparation of 1M Tris-Cl, pH 8.0 
 
- Tris base (12.11 g) 
- Double distilled water (80 ml) 
- Fine adjust to the desired pH (8.0) with concentrated HCI  
- Distilled water (final volume 100  ml)  
 
 
(12) Preparation of 3 M sodium acetate, pH 5.2  
 
- Hydrated sodium acetate (20.4 g) 
- Double distilled water (40 ml) 
- Fine adjust to the desired pH (5.2)  
- Distilled water (final volume 50 ml)  
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(13) Reagents for Capsase-3/7 assay  
 
Caspase-Glo 3/7 Assay kit (Promega, Madison, WI) 
 
Kit components  
- Caspase-Glo 3/7 substrate  
- Caspase-Glo 3/7 buffer  
 
 
(14) Reagents for TUNEL Assay  
 
ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (S7101), (Chemical 
International, USA).   
 
Kit components  
- Equilibration buffer  
- Reaction buffer 
- TdT enzyme  
- Stop/Wash buffer 
- Anti-digoxigenin-peroxidase 
- DAB substrate 
- DAB dilution buffer  
 
Materials required but not supplied in the kit  
- Deionized water (dH2O) 
- Xylene  
- Ethanol:absolute, 90 %, 70 % (diluted in dH2O) 
- 100% n-butanol (1-butanol)  
- Ethanol:acetic acid 2:1 (v:v)  
- 1% paraformaldehyde in PBS (pH 7.4)  
- PBS 
- Hydrogen peroxide 
- 0.5% methyl green  
- Triton X-100 
- Slide mounting medium  
- Silanized glass slides 
- Plastic coverslips  
- Humidified chamber 
- Microcentrifuge tubes  
- 37 °C covered water bath  
- Light microscope  
- Filter through 0.2 m filter unit  
- Reagent bottles 
 
 
(15) Preparation of 0.5% methyl green 
 
- 0.1 M sodium acetate, pH 4.0  
- 0.85% methyl green stock (0.425 g)  
- Filter through 0.2 m filter unit  
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(16) Reagents for LDH release assay  
 
CytoTox-One Homogeneous Membrane Integrity Assay kit (Promega, Madison, WI) 
 
Kit components  
- Substrate mix 
- Assay buffer  
 
 
(17) Preparation of Adhesion Molecules 
 
Fibronectin and Type-IV Collagen 
 
- Mix the lypholized with sterile double distilled water  
- Store at -20 °C 
 
ECM (Extracellular Matrix) 
 
- Store at -20°C 
- Thaw overnight before use 
 
 
(18) Preparation of Gels and Buffers for Western Blot Analysis 
 
Preparation of Separting gel (12%) – 2 gels (10.0 ml) 
 
30% Bis/Acrylamide Mix   
(29.2% acrylamide and 0.8% N,N’-
methylene-bis-acrylamide) 
 
 
4.0 ml  
1.5M Tris buffer, pH 8.8  2.5 ml  
10 % SDS (Sodium Dodecyl Sulfate) 100.0 µl  
10% APS (Ammonium Persulfate) 50.0 µl 
TEMED (N,N,N’,N’-
tetramethylethylenediamine) 
5.0 µl 
Double distilled water  3.4 ml 
 
 
Preparation of Stacking gel – 2 gels (8.0 ml) 
 
30% Bis/Acrylamide Mix   
(29.2% acrylamide and 0.8% N,N’-
methylene-bis-acrylamide) 
1.32 ml  
1M Tris buffer, pH 6.8  2.52 ml  
10 % SDS (Sodium Dodecyl Sulfate) 100.0 µl  
10% APS (Ammonium Persulfate) 50.0 µl 
TEMED (N,N,N’,N’-
tetramethylethylenediamine) 
10.0 µl 
Double distilled water  6.0 ml 
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Dilution of primary antibodies (All antibodies purchased from Merck, Millipore) 
 
Anti-Pan-Ras (Ab-3) Mouse mAb 1:1000 
PhosphoDetect™ Anti-c-Raf (pSer 6 2 ¹) 
Mouse mAb 
1:1000 
PhosphoDetect™ Anti-Elk1 (pSer383) 
Rabbit pAb 
1:1000 
Anti-p90RSK 1:500 
Anti-c-Jun/AP-1 (Ab-3) Mouse mAb 1:2000 
PhosphoDetect™ Anti-JNK1/2 
(pThr¹83/Tyr¹85) Rabbit pAb 
1:1000 
Anti-Akt1 (88-100) Rabbit pAb 1:2500 
PhosphoDetect™ Anti-p38 MAP Kinase 
(pThr¹80, pTyr¹82) Rabbit pAb 
1:1000 
PhosphoDetect™ Anti-GSK3β (pSer9) 
Mouse mAb 
1:2000 
Anti-β-Catenin Mouse mAb (9G10) 1:500 
Anti-Dishevelled-3 Antibody (Rabbit) 1:1000 
PhosphoDetect™ Anti-c-Myc (pThr58, 
Ser62) Rabbit pAb 
1:1000 
Anti-HIF-1α Antibody (Rabbit) 1:200 
Anti-VEGF (Rabbit) 1:500 
Anti-NFκB p50 Antibody (Rabbit) 1:1000 
Anti-NFκB p52 Antibody (Mouse) 1:1000 
 
 
Dilution of secondary antibodies (Purchased from Merck, Millipore) 
 
Rabbit Anti-mouse IgG 1:10,000 
Goat Anti-rabbit IgG 1:10,000 
 
 
Lysis buffer 
- 50 mM Tric, pH 8.0 SDS 
- 150.0 mM NaCI  
- 1.0% Triton X®-100 
- Protease inhibitor cocktail (P9599, Sigma-Aldrich, Ireland Ltd) 
 
Laemmli 2X sample Buffer 
- 4% SDS 
- 20% Glycerol 
- 125.0 mM Tris, pH 6.8 
- 0.02% Bromophenol blue 
- 10%βME, β-mercaptoethanol (Add freshly, just before use) 
 
10% SDS solution 
-5.0 g SDS 
- 50.0 ml of distilled water 
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10% APS (Ammonium Persulfate) 
- 1.0 g APS 
- 10.0 ml of double distilled water 
 
 
Gel Electrophoresis Running Buffer 
- 25.0 mM Tris base 
- 190.0 mM Glycine 
- 0.1% SDS 
 
 
Transfer Buffer 
-50.0 mM Tris base 
- 380.0 mM Glycine 
- 0.1% SDS 
- 20% Methanol 
 
 
TBS buffer 
- 8.0 g NaCI 
- 0.2 g KCI 
- 3.0 g Tris base 
 
 - Dissolve in 800 ml double distilled water 
 - Adjust pH to 8.0 with 1 M HCI 
 - Top up to final volume of 1 liter 
 - Sterilize by autoclaving and store at room temperature 
 
 
Washing buffer (TBST) 
- TBS with 0.1% Tween® 20 
 
 
Blocking buffer (5% Nonfat Dried Milk in TBST) 
- 5.0 g nonfat dried milk powder 
- 100.0 ml of TBST 
 
 
 
(19) Preparation of Buffers in 2D Gel Dimentional   
 
Sample preparation solution (with urea and thiourea) 
 
 Final concentration Amount 
Urea 7.0 M 10.5 g 
Thiourea 2.0 M 3.8 g 
CHAPS 2.0% (w/v) 1.0 g 
IPG buffer 2.0% (w/v) 500.0 µl 
DTT 40.0 mM 154.0 mg 
Double distilled water - to 25.0 ml  
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Thiourea rehydration stock solution  
 
 Final concentration Amount 
Urea 7.0 M 10.5 g 
Thiourea 2.0 M 3.8 g 
CHAPS 2.0% (w/v) 0.5 g 
IPG buffer 2.0% (w/v) 500.0 µl 
1% bromophenol blue  0.002% 50.0 µl 
Double distilled water - to 25.0 ml  
 - DTT is added prior to use; 7 mg DTT for 2.5 ml of rehydration stock solution  
SDS equilibration buffer solution  
 
 Final concentration Amount 
Urea 6.0 M 72.1 g 
This-HCI, pH 8.8 75.0 mM 10.0 ml 
Glycerol (87% w/w) 29.3% (v/v) 69.0 ml 
SDS 2.0% (w/v) 4.0 g 
1% bromophenol blue  0.002% 400.0 µl 
Double distilled water - to 200.0 ml  
 
- First equilibration: Add 100 mg of DTT in 10 ml of SDS equilibration buffer 
- Second equilibration: Add 250 mg of Iodoacetamide 10 ml of SDS equilibration 
buffer 
 
 
1X Laemmli SDS electrophoresis buffer 
 
 Final concentration Amount 
Tris base 25 mM 30.3 g 
Glycine 192 mM 144.0 g 
SDS 0.1% (w/v) 10.0 g 
Double distilled water - to 10.0 liter 
 
 
30% T, 2.6% C monomer stock solution 
 
 Final concentration Amount 
Acrylamide 30.0% 300.0 g 
N,N’-methylenebisacrylamide 0.8% 8.0 g 
Double distilled water - to 1 liter 
 
 - Filter solution through a 0.45 µm filter 
 - Store at 4°C in the dark 
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4X Resolvng gel buffer solution 
 
 Final concentration Amount 
Tris base 1.5 M 181.7 g 
Double distilled water - 750.0 ml 
HCI - Adjust to pH 8.8 
Double distilled water - to 1 liter  
 
Agarose sealing solution 
 Final concentration Amount 
Laemmli SDS 
electrophoresis buffer 
  
100.0 ml 
Agarose 0.5% 0.5 g 
1% Bromophenol blue 0.002% (w/v) 200.0 µl 
 
Fixation solution 
Ethanol 200.0 ml  
Acetic acid, glacial  50.0 ml  
Double distilled water  250.0 ml 
 
5% Coomassie blue  
Coomassie Blue G-250  0.5 g  
Double distilled water  10.0 ml 
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APPENDIX II: The fold changes of differentially expressed proteins in treated MeWo cells.  
No 
UniProtKB/Swiss-
Prot (Accession 
number) 
Protein 
Phyllanthus 
PA(H) PN(H) PU(H) PW(H) PA(M) PN(M) PU(M) PW(M) 
 I Cell Adhesion, Migration, Invasion and Metastasis and Angiogenesis 
1 P98172 Ephrin-B1 -1.46 -1.47 -1.53 -1.48 -1.59 -1.58 -1.57 -1.65 
2 P61163 Alpha-centractin -1.42 -1.33 -1.57 -1.45 -1.58 -1.75 -1.58 -1.74 
3 Q13895 Bystin -1.43 -1.57 -1.34 -1.45 -1.46 -1.59 -1.48 -1.65 
4 P13646 Keratin, type I cytoskeletal 13 1.42 1.47 1.46 1.57 1.74 1.58 1.57 1.64 
5 P08670 Vimentin -1.73 -1.92 -1.72 -2.01 -1.85 -1.73 -1.72 -1.92 
6 
P04179 
Superoxide dismutase [Mn], 
mitochondrial 
-1.29 -1.54 -1.57 -1.39 -1.58 -1.85 -1.65 -1.48 
7 P07437 Tubulin beta chain -1.42 -1.48 -1.67 -1.97 -1.57 -1.58 -1.59 -1.54 
8 
P47755 
F-actin-capping protein subunit 
alpha-2 
-1.34 -1.33 -1.63 -1.58 -1.68 -1.58 -1.53 -1.63 
9 Q8TEW0 Partitioning defective 3 homolog -1.32 -1.49 -1.32 -1.68 -1.50 -1.56 -1.68 -1.58 
 II Proliferation, Cell Cycle, and Apoptosis 
10 P68400 Casein kinase II subunit alpha -2.28 -1.97 -1.83 -2.08 -2.18 -2.08 -1.95 -2.07 
11 P50583 
Bis(5'-nucleosyl)-tetraphosphatase 
[asymmetrical] -1.47 -1.53 -1.48 -1.37 -1.58 -1.74 -1.63 -1.75 
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12 O60220 
Mitochondrial import inner 
membrane translocase subunit 
Tim8 -1.56 -1.35 -1.64 -1.62 -1.63 -1.65 -1.68 -1.58 
13 Q9BQ83 
Structure-specific endonuclease 
subunit SLX1 -1.37 -1.49 -1.57 -1.48 -1.93 -1.57 -1.74 -1.63 
14 Q6Q0C0 
E3 ubiquitin-protein ligase TRAF7 
1.48 1.57 1.65 1.57 1.45 1.78 -1.69 -1.549 
15 P0CJ76 
Humanin-like protein 9  
-1.56 -1.68 -1.58 -1.58 -1.62 1.67 1.73 1.78 
16 P17931 Galectin-3 -1.58 -1.75 -1.63 -1.69 -1.68 -1.68 -1.64 -1.78 
17 P31943 
Heterogeneous nuclear 
ribonucleoprotein H -1.49 -1.57 -1.34 -1.63 -1.56 -1.68 -1.58 -1.84 
18 P08758 Annexin A5 -1.42 -1.57 -1.73 -1.57 -1.57 -1.47 -1.59 -1.47 
19 Q969E4 
Transcription elongation factor A 
protein-like 3 -1.32 -1.47 -1.57 -1.74 -1.62 -1.48 -1.68 -1.57 
20 Q9H930 
Nuclear body protein SP140-like 
protein -1.32 -1.38 -1.55 -1.57 -1.58 -1.58 -1.57 -1.58 
21 P27348 14-3-3 protein theta -1.42 -1.47 -1.29 -1.58 -1.57 -1.67 -1.45 -1.34 
22 P62937 
Peptidyl-prolyl cis-trans isomerase 
A -1.54 -1.23 -1.47 -1.54 -1.58 -1.62 -1.57 -1.46 
23 Q14929 Zinc finger protein 169 -1.69 -1.57 -1.33 -1.84 -1.75 -1.55 -1.47 -1.56 
24 O75791 GRB2-related adapter protein -1.59 -1.43 -1.4 -1.83 -1.56 -1.48 -1.53 -1.28 
25 O00165 HCLS1-associated protein X-1 -1.69 -1.72 -1.97 -1.66 -1.84 -1.86 -1.67 -1.78 
26 O95243 
Methyl-CpG-binding domain 
protein 4 -1.49 -1.63 -1.56 -1.57 -1.66 -1.54 -1.63 -1.64 
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27 P78417 
Glutathione transferase omega - 1 
-1.45 -1.53 -1.46 -1.57 -1.64 -1.53 -1.48 -1.58 
28 Q06830 Peroxiredoxin-1 -1.45 -1.42 -1.46 -1.47 -1.64 -1.74 -1.53 -1.48 
29 P50453 Serpin B9 -1.32 -1.31 -1.53 -1.56 -1.57 -1.45 -1.55 -1.63 
30 Q8ND25 
E3 ubiquitin-protein ligase ZNRF1 
-1.48 -1.64 -1.67 -1.57 -1.56 -1.46 -1.53 -1.58 
31 Q06210 E3 ubiquitin-protein ligase ARIH2 -1.48 -1.58 -1.64 -1.6 -1.57 -1.65 -1.45 -1.64 
32 Q9Y4L5 
E3 ubiquitin-protein ligase 
RNF115 -1.56 -1.43 -1.66 -1.73 -1.69 -1.58 -1.58 -1.56 
 III Glycogenesis and glycolysis 
33 Q969E3 
Glucosamine--fructose-6-
phosphate aminotransferase 
[isomerizing] 2 -1.57 -1.58 -1.58 -1.53 -1.65 -1.73 1.67 -1.48 
34 P00558 
Protein phosphatase 1 regulatory 
subunit 3D -1.33 -1.58 -1.53 -1.64 -1.56 -1.37 -1.57 -1.74 
35 P06733 Alpha-enolase -1.42 -1.57 -1.74 -1.73 -1.58 -1.57 -1.65 -1.69 
36 P04406 
Pyruvate kinase isozymes M1/M2 
-1.45 -1.67 -1.47 -1.63 -1.78 -1.36 -1.36 -1.75 
37 
 
 
P04075 
 
Phosphoglycerate kinase 1 
-1.57 -1.58 -1.61 -1.64 -1.48 -1.53 -1.52 -1.58 
 IV Protein Synthesis and Energy Metabolism 
38 P17174 
Aspartate aminotransferase, 
cytoplasmic -1.26 -1.67 -1.68 -1.56 -1.57 -1.58 -1.53 -1.58 
39 Q9UBC9 Small proline-rich protein 3 -1.63 -1.75 -1.74 -1.56 -1.67 -1.68 -1.73 -1.57 
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40 P41247 
Patatin-like phospholipase 
domain-containing protein 4 -1.63 -1.32 -1.49 -1.66 -1.53 -1.53 -1.58 -1.64 
41 Q9HBU6 Ethanolamine kinase 1 -1.39 -1.75 -1.57 -1.83 -1.48 -1.75 -1.68 -1.74 
42 P62195 26S protease regulatory subunit 8 -1.53 -1.64 -1.57 -1.74 -1.75 -1.56 -1.64 -1.54 
43 Q5VTE0 
Putative elongation factor 1-alpha-
like 3 -1.48 -1.64 -1.64 -1.57 -1.57 -1.64 -1.58 -1.85 
44 Q5TGZ0 
Mitochondrial inner membrane 
organizing system protein 1 -1.53 -1.63 -1.74 -1.56 -1.67 -1.68 -1.64 -1.75 
45 P07339 Cathepsin D -1.54 -1.54 -1.65 -1.46 -1.68 -1.68 -1.47 -1.58 
46 Q9Y587 AP-4 complex subunit sigma-1 -1.33 -1.57 -1.56 -1.36 -1.68 -1.74 -1.58 -1.67 
47 P00568 Adenylate kinase -1.58 -1.39 -1.53 -1.57 -1.56 -1.63 -1.68 -1.58 
48 P80294 Metallothionein-1H -1.29 -1.74 -1.73 -1.45 -1.59 -1.58 -1.76 -1.68 
49 Q76KX8 Zinc finger protein 534 -1.59 -1.46 -1.57 -1.64 -1.54 -1.63 -1.58 -1.58 
50 Q9Y6H3 
Mitochondrial inner membrane 
protease ATP23 homolog -1.59 -1.56 -1.57 -1.67 -1.68 -1.67 -1.68 -1.63 
51 Q8WVM8 
Sec1 family domain-containing 
protein 1 -1.44 -1.56 -1.64 -1.54 -1.76 -1.65 -1.75 -1.64 
52 Q9NVH6 
Trimethyllysine dioxygenase, 
mitochondrial -1.58 -1.48 -1.58 -1.54 -1.79 -1.68 -1.53 -1.66 
(Up-regulation indicated with “+” symbol and down-regulation indicated with “-” symbol) 
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APPENDIX III: The fold changes of differentially expressed proteins in treated PC-3 cells.  
No. 
UniProtKB/Swiss-
Prot (Accession 
number) 
Protein 
Phyllanthus 
PA(H) PN(H) PU(H) PW(H) PA(M) PN(M) PU(M) PW(M) 
 I Cell Adhesion, Migration, Invasion and Metastasis and Angiogenesis 
1 P98172 Ephrin-B1 -1.53 -1.45 -1.21 -1.41 -2.14 -2.21 -2.01 -2.31 
2 P05787 Keratin, type II cytoskeletal 8 1.45 1.32 1.38 1.21 1.86 1.74 1.92 1.62 
3 P63261 Actin, cytoplasmic 2 -1.43 -1.53 -1.21 -1.53 -1.74 -1.79 -1.72 -1.53 
4 Q8NDI1 EH domain-binding protein 1 -1.32 -1.32 -1.21 -1.13 -1.42 -1.32 -1.43 -1.43 
5 P04792 Heat shock protein beta-1 -1.43 -1.32 -1.54 -1.54 -1.42 -1.43 -1.32 -1.25 
6 P35527 Keratin, type I cytoskeletal 9 1.38 1.32 1.53 1.42 1.64 1.34 1.35 1.37 
7 Q9BYR8 Keratin-associated protein 3-1 1.53 1.32 1.47 1.64 1.47 1.53 1.42 1.46 
8 P08670 Vimentin -1.43 -1.32 -1.32 -1.11 -1.25 -1.43 -1.32 -1.42 
9 Q9NY65 Tubulin alpha-8 chain -1.53 -1.43 -1.48 -1.35 -1.40 -1.43 -1.42 -1.73 
10 Q9Y316 Protein MEMO1 -1.43 -1.42 -1.24 -1.32 -1.63 -1.32 -1.42 -1.43 
 II Proliferation, Cell Cycle, and Apoptosis                 
11 Q92466 DNA damage-binding protein 2 -1.42 -1.32 -1.43 -1.41 -1.42 -1.37 -1.43 -1.32 
12 Q7RTU1 Transcription factor 23 -1.39 -1.33 -1.42 -1.43 -1.53 -1.63 -1.58 -1.42 
13 Q9UQ80 
Proliferation-associated protein 
2G4 -1.37 -1.57 -1.42 -1.47 -1.63 -1.45 -1.53 -1.43 
14 P62993 
Growth factor receptor-bound 
protein 2 -1.42 -1.52 -1.43 -1.32 -1.42 -1.42 -1.43 -1.64 
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15 O60565 Gremlin-1 -1.43 -1.43 -1.33 -1.43 -1.56 -1.43 -1.54 -1.44 
16 P27348 14-3-3 protein theta -1.32 -1.43 -1.53 -1.42 -1.42 -1.21 -1.32 -1.42 
17 P61981 14-3-3 protein gamma -1.32 -1.32 -1.43 -1.35 -1.32 -1.42 -1.22 -1.32 
18 P04083 Annexin A1 -1.52 -1.54 -1.42 -1.43 -1.64 -1.43 -1.43 -1.43 
19 Q96LY2 
Coiled-coil domain-containing 
protein 74B -1.47 -1.34 -1.47 -1.46 -1.33 -1.33 -1.36 -1.57 
20 P31943 
Heterogeneous nuclear 
ribonucleoprotein H -1.47 -1.33 -1.35 -1.21 -1.44 -1.56 -1.43 -1.53 
21 P09211 Glutathione S-transferase P -1.96 -1.84 -1.77 -2.05 -1.89 -1.87 -2.01 -1.97 
22 P41221 Protein Wnt-5a -1.75 -1.87 -1.87 -1.92 -1.74 -1.84 -1.85 -2.01 
23 Q9H0R3 Transmembrane protein 222 -1.57 -1.52 -1.57 -1.42 -1.47 -1.62 -1.57 -1.46 
24 Q5MJ09 
Sperm protein associated with the 
nucleus on the X chromosome N3 -1.45 -1.57 -1.57 -1.57 -1.34 -1.45 -1.32 -1.46 
25 P46063 
ATP-dependent DNA helicase Q1 
-1.57 -1.57 -1.36 -1.46 -1.56 -1.47 -1.46 -1.57 
26 P09382 Galectin-1 -1.25 -1.46 -1.57 -1.47 -1.46 -1.33 -1.46 -1.46 
27 P04792 Heat shock protein beta-1 -1.37 -1.47 -1.47 -1.46 -1.56 -1.46 -1.34 -1.47 
28  P78417 
Glutathione transferase omega - 1 
-1.46 -1.46 -1.47 -1.47 -1.57 -1.54 -1.68 -1.57 
29 Q06830 Peroxiredoxin-1 -1.57 -1.42 -1.29 -1.33 -1.48 -1.62 -1.54 -1.67 
30 P30048 
Thioredoxin-dependent peroxide 
reductase, mitochondrial -1.45 -1.52 -1.12 -1.64 -1.58 -1.44 -1.57 -1.57 
31 Q9Y230 RuvB-like 2 -1.46 -1.47 -1.38 -1.32 -1.75 -1.57 -1.64 -1.57 
32 P50453 Serpin B9 -1.46 -1.50 -1.36 -1.38 -1.58 -1.67 -1.76 -1.63 
33 Q8ND25 
E3 ubiquitin-protein ligase 
ZNRF1 -1.56 -1.43 -1.47 -1.47 -1.58 -1.67 -1.82 -1.54 
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34 Q6PRD1 
Probable G-protein coupled 
receptor 179 -1.45 -1.43 -1.47 -1.56 -1.36 -1.37 -1.54 -1.58 
35 O43521 Bcl-2-like protein 11 -1.66 -1.52 -1.42 -1.56 -1.57 -1.73 -1.65 1.56 
36 P56703 Proto-oncogene Wnt-3 precursor -2.18 -1.92 -2.06 -2.34 -1.79 -1.97 1.83 -2.11 
37 Q8N4Z0 
Putative Ras-related protein Rab-
42 -2.11 -2.03 -1.79 -1.98 -1.96 -2.1 -2.15 -1.94 
38  P01112 GTPase HRas precursor -2.12 -1.99 -1.83 -1.74 -1.85 -2.03 -2.05 -1.92 
 III Glycogenesis and glycolysis                 
39 Q969E3 Urocortin-3 -1.37 -1.42 -1.37 -1.46 -1.65 -1.73 1.67 -1.47 
40 P00558 Phosphoglycerate kinase 1 -2.01 -2.12 -2.22 -1.93 -1.56 -1.37 -1.57 -1.36 
41 P06733 Alpha-enolase -1.42 -1.38 -1.37 -1.36 -1.58 -1.57 -1.65 -1.57 
42 P04406 
Glyceraldehyde-3-phosphate 
dehydrogenase -1.92 -1.88 -1.92 -1.83 -1.78 -1.36 -1.36 -1.56 
43 P04075 Fructose-bisphosphate aldolase a -1.63 -1.42 -1.39 -1.36 -1.48 -1.53 -1.52 -1.57 
43 P60174 Triosephosphate isomerase -1.47 -1.46 -1.47 -1.76 -1.48 -1.53 -1.49 -1.49 
44 Q9NPG2 Neuroglobin -1.47 -1.47 -1.58 -1.47 -1.56 -1.63 -1.74 -1.74 
 IV Protein Synthesis and Energy Metabolism                 
45 Q4U2R6 39S ribosomal protein L51 -1.37 -1.47 -1.36 -1.53 -1.64 -1.74 -1.65 -1.67 
46 Q93088 
Betaine--homocysteine S-
methyltransferase 1    -1.46 -1.47 -1.46 -1.48 -1.67 -1.48 -1.58 -1.57 
47  P50583 
Bis(5'-nucleosyl)-
tetraphosphatase [asymmetrical] -1.45 -1.57 -1.30 -1.42 -1.39 -1.47 -1.67 -1.87 
48 Q96A11 Galactose-3-O-sulfotransferase 3 -1.69 -1.74 -1.67 -1.85 -1.93 -1.74 -1.82 -1.89 
49 Q9Y274 
Type 2 lactosamine alpha-2,3-
sialyltransferase -1.28 -1.52 -1.58 -1.44 -1.68 -1.64 -1.58 -1.57 
50 O43852 Calumenin -1.53 -1.47 -1.47 -1.42 -1.57 -1.65 -1.56 -1.53 
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51 P13667 Protein disulfide-isomerase A4 -1.47 -1.41 -1.44 -1.45 -1.58 -1.64 -1.45 -1.57 
52 P27797 Calreticulin -1.54 -1.32 -1.47 -1.48 -1.45 -1.53 -1.57 -1.64 
53 P07900 
Heat shock protein HSP 90-alpha 
-1.64 -1.32 -1.34 -1.43 -1.55 -1.42 -1.32 -1.53 
54 P12235 ADP/ATP translocase 1 -1.46 -1.38 -1.45 -1.35 -1.58 -1.68 -1.67 -1.47 
55 P52209 
6-phosphogluconate 
dehydrogenase, decarboxylating -1.46 -1.49 -1.54 -1.45 -1.57 -1.52 -1.48 -1.56 
56 Q9Y478 
5'-AMP-activated protein kinase 
subunit beta-1 -1.38 -1.46 -1.47 -1.47 -1.67 -1.75 -1.47 -1.57 
57 P11021 78kDa glucose-regulated protein -1.46 -1.46 -1.47 -1.57 -1.57 -1.54 -1.57 -1.84 
58 Q9UI09 
NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 12 -1.42 -1.36 -1.33 -1.33 -1.57 -1.73 -1.57 -1.46 
59 P30101 Protein disulfide-isomerase A3 -1.20 -1.47 -1.37 -1.21 -1.57 -1.63 -1.56 -1.57 
60 P49411 
Elongation factor Tu, 
mitochondrial -1.48 -1.45 -1.57 -1.33 -1.38 -1.54 -1.68 -1.47 
61 Q5TGZ0 
Mitochondrial inner membrane 
organizing system protein 1 -1.47 -1.46 -1.47 -1.49 -1.57 -1.47 -1.67 -1.65 
62 P19404 
NADH dehydrogenase 
[ubiquinone] flavoprotein 2, 
mitochondrial -1.21 -1.32 -1.33 -1.43 -1.57 -1.57 -1.57 -1.74 
63 Q9H0F7 
ADP-ribosylation factor-like 
protein 6 -1.76 -1.50 -1.57 -1.54 -1.56 -1.54 -1.49 -1.70 
64 O75436 
Vacuolar protein sorting-
associated protein 26A -1.46 -1.54 -1.63 -1.76 -1.47 -1.38 -1.57 -1.57 
65 Q9NXV2 
BTB/POZ domain-containing 
protein KCTD5 -1.47 -1.47 -1.33 -1.50 -1.58 -1.65 -1.67 -1.66 
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66 O00429 Dynamin-1-like protein -1.47 -1.63 -1.47 -1.57 -1.56 -1.57 -1.67 -1.73 
67 P40261 
Nicotinamide N-
methyltransferase -1.29 -1.22 -1.34 -1.28 -1.45 -1.48 -1.83 -1.42 
68 P49720 Proteasome subunit beta type-3 -1.53 -1.22 -1.34 -1.47 -1.58 -1.53 -1.67 -1.57 
69  Q6IQ16 Speckle-type POZ protein-like -1.42 -1.67 -1.47 -1.47 -1.63 -1.64 -1.68 -1.47 
70 P21796 
Voltage-dependent anion-
selective channel protein 1 1.57 1.63 1.52 1.79 1.67 1.84 1.77 1.76 
71 Q9Y3D8 Adenylate kinase isoenzyme 6 -1.51 -1.33 -1.43 -1.49 -1.46 -1.64 -1.74 -1.76 
72 Q14152 
Eukaryotic translation initiation 
factor 3 subunit 12 -1.40 -1.37 -1.39 -1.49 -1.53 -1.67 -1.63 -1.53 
(Up-regulations indicated with “+” symbol and down-regulation indicated with “-” symbol). 
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APPENDIX IV: Additional Outputs of the PHD Project. 
Scientific Publications 
Tang Y-Q, Jaganath IB, Sekaran SD (2013). Phyllanthus spp. Exerts Anti-Angiogenic 
and Anti-Metastatic Effects through Inhibition on Matrix Metalloproteinase 
Enzymes. Manuscript submitted to “PLoS ONE”. 
 
Tang Y-Q, Jaganath IB, Sekaran SD (2013). Phyllanthus Suppresses MeWo Cell 
Proliferation and Induces Apoptosis through Modulation Multiple Signalling 
Pathways. Submitted to “Cellular Signalling”. 
 
Tang Y-Q, Jaganath IB, Sekaran SD (2013). Phyllanthus Suppresses Prostate Cancer 
Cell, PC-3 Proliferation and Induces Apoptosis through Multiple Signalling 
Pathways (MAPKs, PI3K/Akt, NFκB and Hypoxia). Evidence-Based 
Complementary and Alternative Medicine, 609581.  
 
Yin-Quan Tang and Shamala Devi Sekaran. (2011). Evaluation of Phyllanthus, for Its 
Anti-Cancer Properties. Prostate Cancer - From Bench to Bedside, ISBN: 978-
953-307-331-6 
 
Tang Y-Q, Jaganath IB, Sekaran SD (2010) Phyllanthus spp. Induces Selective Growth 
Inhibition of PC-3 and MeWo Human Cancer Cells through Modulation of Cell 
Cycle and Induction of Apoptosis. PLoS ONE 5(9): e12644. 
doi:10.1371/journal.pone.0012644 
 
 
Oral presentations 
Tang Y-Q, Jaganath IB, Sekaran SD. Anticarcinogenic and antitumour properties of 
phyllanthus spp. against human cancer. Oral presentation by Tang YQ at the 
PhD Candidature Defense at Department of Medical Microbiology, Faculty of 
Medicine, University of Malaya, Malaysia (2011, June 02).  
 
Tang Y-Q, Jaganath IB, Sekaran SD. The anticancer properties of phyllanthus spp. on 
human cancer cell lines. Oral presentation by Tang YQ at the PhD Conversion 
Seminar at Department of Medical Microbiology, Faculty of Medicine, 
University of Malaya, Malaysia (2010, September 07).  
 
 
 
Poster presentations 
Lee SH, Tang YQ, Komarasamy TV, Wang SM, Ong KC, Payne BJ, Jaganath and 
Sekaran SD. Inhibitory Potential of Malaaysian Medicinal Plant (Phyllanthus) 
against Dengue Virus Type 2 (DENV2). Presented at 1
st
 National Postgraduate 
Seminar 2012, University of Malaya. (11
th
 July 2012). 
 
Y.Q.Tang, S.H. Lee, T.V. Komarasamy, A. Rathakrishnan, S.M. Wang, I.B. Jaganath 
and S.D Sekaran. Effects of Malaysia Medicinal plant (Phyllanthus) against 
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Dengue Virus Type 2 (DENV2) .Presented at 9
th
 Asia-Pacific Congress Medical 
Virology (APCMV), Adelaide, Australia (6
th
 – 8th June 2012) 
 
Yin Quan Tang, Indu Bala Jaganath and Shamala Devi Sekaran. The Anti-Metastasis 
and Anti-Angiogenesis Properties of Phyllanthus Species. Presented at 18th 
International Student Congress of Medical Sciences (ISCOMS), The Netherlands 
(7
th
 -10
th
 June 2011). 
 
Tang Yin Quan, Indu Bala Jaganath and Shamala Devi Sekaran. Potential Anticancer 
Properties of Phyllanthus against Skin Melanoma and Prostate Cancer Cells. 
Presented at Creativity and Innovation Expo University of Malaya 2010, 
Malaysia (April, 2010) 
 
Yin-Quan Tang, Indu Bala Jaganath and Shamala Devi Sekaran. Anticarcinogenic 
properties of extracts derived from medicinal plant, Phyllanthus on human skin 
and prostate cancer cells. Presented at the UK-Malaysia Symposium on Drug 
Discovery and Development for Cancer, Kuala Lumpur, Malaysia (24-25
 
February 2010).  
 
Wee-Chee Tan, Sau-Har Lee, Yin-Quan Tang, Indu-Bala Jaganath, Shamala-Devi 
Sekaran. Phyllanthus spp. as potent antiviral agent against Dengue viruses. 
Presented at 4th Asian Regional Dengue Research Network Meeting; DUKE-
NUS Emerging Infectious Diseases Inauguration Symposium Meeting in 
Singapore (08 Dec 2009 to 11 Dec 2009).  
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 National Science Fellowships (NSF) from Ministry of Science, Technology and 
Innovation, Malaysia (2009 – 2013) 
 
 
 Postgraduate Research Funds from University of Malaya (2009-2010) 
 
 
 Best Poster Presentation (Cell Biology & Medical Biochemistry), 18th ISCOMS, 
The Netherland (2011).   
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